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ABSTRACT
Vogt Geisse, Katia P. Ph.D., Purdue University, December 2014. Structured deter-
ministic models applied to malaria and other endemic diseases. Major Professor:
Zhilan Feng.
This thesis includes modeling studies on three structured deterministic models.
These models are used to study the disease dynamics of malaria or the joint dis-
ease dynamics of HIV and HSV-2. Each of the models includes multiple components
containing individuals in various epidemiological classes for the purpose of addressing
questions that are of interests to biologists and epidemiologists. Some of the compart-
ments have a continuous age-structure, which is necessary for studying the specific
biological questions under investigation.
In Chapter 2 a chronological-age structured deterministic model for malaria is
presented. The model includes the human and mosquito populations with the hu-
man population structured by chronological age. The model consists of both PDEs
and ODEs. The infected human population is divided into symptomatic infectious,
asymptomatic infectious and asymptomatic chronic infected individuals. The original
PDE model is reduced to an ODE model with aging. The basic reproduction number
R0 is derived for both settings of the model. A novel assumption of the model based
on biological evidence is that the infectiousness of chronic infected individuals can be
triggered by bites from even susceptible mosquitoes. The model analysis indicates
that this assumption contributes greatly to the R0 value and therefore needs to be
further studied and understood. Numerical simulations for n = 2 age groups and a
sensitivity/uncertainty analysis show that it is important to consider both, asymp-
tomatic infectious individuals and asymptomatic chronic infections. Age-targeted
control strategies are also discussed.
xix
In Chapter 3 a deterministic malaria model is presented to study the effects of
a pre-erythrocytic vaccine on malaria dynamics. The model includes two vaccinated
classes, the first for initial vaccination dose(s) and the second for a booster dose. Vac-
cinated individuals in both compartments are structured by vaccine-age. A vaccine-
age dependent transition between vaccinated classes makes it possible to model a
minimum vaccine-age required for receiving the booster vaccination, feature which is
extensively discussed. The control reproduction number R is derived and shown to
determine the local stability of the disease free equilibrium. Global stability of the
disease free equilibrium is shown analytically under certain assumptions and condi-
tions for the existence of endemic equilibria are identified. Numerical results suggest
that the incorporation of two vaccination classes, as opposed to only one, allows for
a greater accuracy in predicting threshold vaccination coverages for disease eradi-
cation. The model also exhibits a backward bifurcation, indicating that R = 1 is
no longer the threshold value for disease eradication. The effect of waning vaccine
efficacy (vaccine-age dependent) on disease prevalence is also investigated.
Chapter 4 presents a deterministic model for the joint dynamics of HIV and HSV-
2 to study the effect that the presence of HSV-2 may have on the prevalence of HIV.
Infection-age is used to incorporate the epidemiological characteristic of HSV-2; i.e.
that infected individuals change between the acute and the latent stages. Treatment
may affect the lengths of these stages. The model is also structured by gender and
includes one male and two female populations with different activity levels. The basic
reproduction number for each disease, as well as the invasion reproduction numbers
are derived. Due to the model complexity, the derivation of these reproduction num-
bers and their biological interpretations are very challenging, which is one of the novel
aspects of this study. Numerical simulations are performed to confirm and extend the
analytical results. A sensitivity analysis is also conducted. Model results demonstrate
that control strategies for reducing co-infections with HIV and HSV-2, particularly
treating the high-risk group of females may have an important impact on the HIV
disease dynamics.
11. INTRODUCTION
Mathematical modeling of infectious diseases was first introduced in 1760 by the
physician and mathematician Daniel Bernoulli, son of Johann Bernoulli and nephew
of Jakob Bernoulli, both famous mathematicians. His work was about demonstrating
the advantages of inoculation of less virulent smallpox to prevent the disease, weighing
the risks. From then on physicians started to use mathematical models to explain the
underlying mechanisms that influence the transmission of infectious diseases. One of
the important applications of mathematical models is to help identify control strate-
gies either for eradicating a disease or reducing its endemicity. To understand how a
population may react to a particular pathogen, it is important to carry out experi-
ments to obtain information on the disease behavior and test hypotheses. Often these
experiments are difficult or impossible to conduct due to financial, organizational or
ethical reasons. Also data obtained from experiments is often incomplete, inaccurate
or limited. Hence, mathematical models can help explain the disease dynamics when
considering different epidemiological, demographic and/or social behaviors. Diseases
can produce an epidemic or an endemic situation in a population. An epidemic is
referred to as a disease that makes its appearance in a population as a sudden out-
break and remains in the population for a short period of time before disappearing.
An epidemic of a specific pathogen can be a recurring process, leaving each time a
portion of the population untouched. Diseases that cause epidemics are for example
the Influenza and the Ebola virus. An endemic disease on the other hand is a disease
that can be present in a population for long time. For instance HIV, HSV-2 and
Malaria are endemic diseases in many parts of the world. In cases of epidemics, pub-
lic health professionals and policymakers are interested in determining the severity
of the epidemics in terms of its length, final epidemic size (cumulative number of
people infected during the course of the epidemic), epidemic peak (highest possible
2number of people infected at a moment in time) and timing of the peak, and how
control strategies such as vaccination, treatment, quarantine and isolation may affect
these severity measures. In case of an endemic situation it is of great importance
to determine how different control measures will affect the prevalence. Considering
that millions of people die from endemic diseases each year, many in underdeveloped
countries, a reduction in prevalence can prevent a huge amount of cases and alleviate
the tremendous burden many endemic diseases cause in these parts of the world. Of
great interest is also to determine if to achieve disease extinction as an ultimate goal
and herewith revert the endemic nature of the disease is at all possible. Mathematical
models can also help identify the importance of characteristics, intrinsic of the disease
or peculiar to the host, that affect disease spread, in order to give advice on what kind
of experiments need to be designed or what hypotheses need to be rigorously tested
to achieve a better understanding of the disease dynamics in a particular population.
Models should be as simple as possible but not simpler. Many simple models have
generated useful insights into the disease transmission dynamics. For example, in the
standard SIR compartment model for infectious diseases, the population is divided
into three epidemiological classes: Susceptible (S), Infectious (I) and Recovered (R,
or immune). A simple deterministic model for continuous time consist of a system
of ordinary differential equations (ODEs). There are also SIS, SIRS, SEIR (E for
exposed) models that have been used to study various biological questions associ-
ated with different diseases. However, the simplicity of thees models are achieved by
making many simplifying assumptions, and some of these assumptions may not be
appropriate for the study of specific questions. In these cases, models need to include
additional complexities such as heterogeneities in age, gender, spatial location, etc. It
has also be demonstrated that in some cases the results produced by a simpler model
and a model with more realistic model assumptions may produce inconsistent out-
comes. In this thesis, based on biological motivations, we focus on models structured
by age, which include chronological-age, infection-age, or vaccine-age. The incorpora-
3tion of an age-structure will lead to models that include partial differential equations
(PDEs) and/or integro-differential equations.
In a deterministic model, the state variables at any moment in time are assumed
to depend uniquely on the parameter values chosen and on the history of the state
variables. In contrast, stochastic models usually allow the behavior of the model to
follow a probability distribution. The first contributions to mathematical epidemiol-
ogy using compartmental models were developed in the early 20th century by public
health physicians such as J. Brownlee, also a statistician, A.G. McKendrick, W.O.
Kermack and Sir Ronald Ross [1, 2]. According to [3], the first in establishing the
mass action law for compartmental models in epidemiology (contacts per infective per
unit time is proportional to the population size) were J. Brownlee [4] and Sir Ross [5].
Kermack and McKendrick’s famous work consists of a sequence of three papers [6–8].
The commonly used SIR model (Susceptible, Infected, Recovered) is derived from a
more general model in [6]. Sir Ronald Ross received the Nobel Prize in Medicine in
1902 due to his important work on malaria. His discovery that malaria is transmit-
ted by mosquitoes laid the foundation to all subsequent work on malaria dynamics.
In his work in [5] he showed that in order to control malaria it is not necessary to
eliminate all mosquitoes but to control the mosquito population to not exceed a given
threshold. A threshold as such can be found when analyzing most deterministic mod-
els, and is called the basic reproduction number, R0. This quantity is biologically
defined as the expected number of secondary infected cases a “typical” infected indi-
vidual produces in a totally susceptible population during its infectious period [9,10].
Usually, determining if R0 < 1 or if R0 > 1 describes the behavior of a disease.
In an epidemic situation the bounds on R0 determine if there will be an outbreak
(R0 > 1) of the disease after introduction of a small amount of infected individuals
into a susceptible population, or will determine if the number of infected people will
decrease (R0 < 1) as soon as the disease gets introduced into the population. In
case of an endemic disease, the value of the threshold usually determines if a disease
will persist (R0 > 1) or if it will eventually disappear (R0 < 1) after introducing it
4into a susceptible population. When R0 is found analytically one can determine the
importance that elements of the model, which can be affected by control measures,
play on the threshold.
Our consideration for incorporating age-structure in the models is motivated by
the need to study specific biological questions. For instance, if vaccination is planned
to be introduced into a population and if immunity from vaccination may wane with
time and/or the timing for an additional dose depends on when the previous dose(s)
was(were) received (as it is for a malaria vaccine), then differentiating vaccinated indi-
viduals by their vaccine-age is necessary to consider. In addition, in malaria endemic
countries children carry the biggest burden of the disease (e.g., 86% of the malaria
deaths occur in children under 5 years of age [11]), whereas adults may develop im-
munity over time and hence are better protected against clinical malaria. Therefore,
dividing the population by chronological-age including additional immunity classes
can be important in order to model their different susceptibility and/or infectivity.
Another example involves HSV-2 infection, which is characterized by alternating pe-
riods between low or no infectivity (latency) and periods of high infectivity (viral
shedding). Hence, to include variability in infectivity, we need to structure the model
by infection-age (time-since-infection). Details about mathematical modeling of these
diseases and age-structured models are discussed in the following sections.
1.1 Structured Models
Simple ODE models usually assume that the population is homogeneous. How-
ever, pathogens often do not affect individuals in the same way, e.g., infectivity,
susceptibility or recovery might be very different between individuals. In many cases
more details in population heterogeneities need to be included in order to accurately
describe the disease characteristics for the purpose of addressing specific biological
questions.
51.1.1 Chronological-age structured models
Continuous chronological-age structured models have been widely used and stud-
ied since 1926 when A.G. McKendrick presented a chronological-age structured model
to study the growth of a population [12–14]. It was not until the 1970s that the
first models for epidemics including chronological-age structure (but also infection-
age structure) were studied [15, 16]. For example, in 1974 Hoppensteadt presented a
model that follows individuals by their chronological age as well as “class-age” (time-
since-infection or infection-age) [15] to study the spread of diseases. In 1985 Dietz and
Schenzle [17] studied a model structured by chronological-age and infection-age where
contact rates and vaccination rates depend on chronological-age and the infectivity
and recovery rate depend on infection-age. In 1985 Anderson and May [18] analyzed a
chronological-age structured model to study implications for the design of vaccination
programs. More theoretical approaches from the late 1980s can be found for example
in [19,20]. Recent work includes for example [21–24]. In [24] Castillo-Chavez and Feng
studied global stability of a chronological-age structured model for Tuberculosis and
applied it to find an optimal vaccination strategy. The problem of optimal vaccina-
tion for chronological-age structured models was first studied by Hadeler and Mu¨ller
in [21, 22]. The first appearance of a chronological-age structured model for vector-
borne diseases was in 1976 by Adler [25], where the human population was structured
by infection-age and vectors by chronological-age. Later on, in 1991, Anderson and
May presented in [26] a model for malaria with the human population structured by
chronological-age, attempting to study immunity related questions. Recently, in 2004,
Park studied in detail a vector-host model with additional complexities, in which the
human population was structured by chronological-age [27]. In [28] and [29] a method
to reduce the partial differential equations system to an ordinary differential equa-
tions system is presented. The reduced system of ODEs can in many cases capture
the behavior of the partial differential equation model accurately while facilitating
the analysis of the model, analytically as well as numerically.
61.1.2 Vaccine-age structured models
Continuous vaccine-age structured models have been less studied than infection-
age or chronological-age structured models. They have been mainly developed for
diseases transmitted directly from human to human. Mathematical models struc-
tured by vaccine-age have appeared in the literature for example in [30–33]. Iannelli
et al. in [30] present an SIS type two strain epidemic model at population level
with super-infection, where the susceptible population is subjected to a vaccination
campaign. In their work, vaccinated individuals lose their immunity with time and
eventually become susceptible again. A similar, but somewhat simpler one strain SIS
and SIRS model subjected to waning vaccination is considered in [31] and [32, 33]
respectively, where the authors in [31–33] also show the existence of backward bifur-
cation (persistence of the disease in cases when R0 < 1) for the model upon vaccine
introduction and in [32] global stability analysis is conducted.
1.1.3 Infection-age (time-since-infection) structured models
Models structured by infection-age (age of infection as opposed to chronological-
age) first appeared in the famous work by Kermack and McKendrick [6]. In the
general model they presented, the infectivity, probability of recovery and death due
to the disease are dependent on infection-age (time-since-infection). The SIR (Suscep-
tible, Infected, Recovered) epidemiological model with ordinary differential equations,
without vital dynamics, is a special case of the general model presented in [6] and
is the main reason for the citations of the paper. Kermack and McKendrick incor-
porated time-since-infection dependent infectivity also in their subsequent endemic
models [7, 8], where they incorporated vital dynamics. Time-since-infection models
were neglected since then, until the 1970s, where these models were rediscovered for
example in [15, 16, 34, 35]. Subsequently the interests for infection-age structured
models were greatly increased due the appearance of HIV/AIDS. The infectivity of
HIV-positive individuals varies greatly during the course of the HIV infection until
7shortly before developing AIDS. Hence the time-since-infection model developed by
Kermack and McKendrick for epidemics became very useful also for endemic diseases.
In the 1990s interesting studies have included the effects of variable infectivity on the
dynamics of infectious diseases, worth mentioning are [36–39]. In the latter, the
authors have found that oscillations may occur (destabilization of the endemic equi-
librium) if variable infectivity is assumed, i.e., instability is possible if the infectivity
is concentrated early in the infected period. Such dynamics are not observed when
constant infectivity assumptions are used. More recent work including infection-age
dependence can be found in [40] for a model with vaccination, [41] for a model with
two strains of Tuberculosis, and [42, 43] for a general model with several infected
classes, each of which is structured by time-since entering that class.
The mathematics of structured models have been extensively studied. For example
see [1,2,44–49] for excellent overviews on mathematical epidemiology and/or detailed
mathematical analyses on structured models.
1.2 Malaria
1.2.1 Malaria overview
Malaria is a vector-borne infectious disease caused by parasites of the genus Plas-
modium and a major international health problem, especially in the tropical and
subtropical regions of the world including much of sub-Saharan Africa, Asia and the
Americas [50]. Globally 3.4 billion people live in areas at risk of malaria disease, which
is the 5th leading cause of death from infectious diseases worldwide [51]. It is esti-
mated that yearly around 207 million cases occur and that malaria kills approximately
667, 000 humans per year [52]. 80% of the cases and 90% of the deaths occurred in
Africa [52]. Malaria is a huge health and economic burden for many countries, with
direct costs estimated to be at least US$12 billion per year worldwide [51].
Five Plasmodium species are known to cause malaria in humans: P. falciparum,
P. vivax, P. ovale, P. malariae and P. knowlesi. Of these, P. falciparum is the
8most aggressive for humans and the one responsible for most of the deaths, in fact,
P.falciparum is responsible for over 1 million deaths annually and 75% of the malaria
cases worldwide [53]. The parasite is transmitted to humans by bites of female
Anopheles mosquitoes. There are different mosquitoes of the genus Anopheles re-
sponsible for spreading malaria, which differ on breeding habits, lifespan and human-
biting habits, depending on the geographical region and on the species [54, 55]. An.
gambiae, one of the highly anthropophilic species (i.e. feeds almost exclusively on
humans) is found in Africa where the malaria burden is highest [54].
The parasites causing malaria disease need humans and mosquitoes to complete
their life cycle. When an infected female Anopheles mosquito takes a blood meal it
inoculates sporozoites released from the salivary glands into the human host. These
sporozoites migrate to the liver within around 30 minutes and maturate in the liver
cells (hepatocytes) into schizonts. The liver-stage parasites differentiate and repro-
duce asexually to produce merozoites that are released into the bloodstream where the
erythrocytic cycle of the parasite begins. Merozoites invade red blood cells (erythro-
cytes) and reproduce asexually. Eventually these burst and release more merozoites,
which again invade erythrocytes or differentiate into sexual forms (male and female
gametocytes). The blood stage of the parasite is responsible for the clinical symptoms
on humans and the sexual form of the parasite in the human blood stage is responsible
for mosquito infection. Gametocytes are ingested during a blood meal by a mosquito
and the life cycle of the parasite continuous in the mosquito, which is known as the
sporogonic cycle, until it reaches the sporozoites stage that infect humans, and a new
cycle continues.
Most vulnerable to severe malaria when exposed to the parasite are people with
little or no immunity to the disease, such as young children, pregnant women, or
travelers coming from regions with no malaria infections [51]. In malaria endemic
countries children carry the biggest burden of the disease, in fact 86% of the malaria
deaths occur in children under 5 years of age [11] and they experience clinical symp-
toms most of the time when infected with P.falciparum [56, 57]. On the other hand,
9in regions where malaria is endemic, infected adults rarely experience clinical symp-
toms, even though they test positive for parasitemia and often carry a high load of
malaria parasites in their blood that may be lethal to a malaria-naive person [58,59].
Malaria symptoms vary from absent and very light to severe and may include high
fevers, shivering, headaches, shaking skills, body aches, etc. Because of the broad
range of symptoms that occur when infected with malaria, the disease can often be
mistaken with Influenza, Pneumonia, a Cold and other common diseases [60]. If
treated carefully and promptly following the recommended interventions correctly,
malaria is a mostly preventable and curable disease [52,60].
Current malaria control measures recommended include vector-control with the
goal to prevent mosquito bites and eliminate mosquitoes, such as the use of long-
lasting insecticidal nets and indoor residual spraying; the use of prophylactic drugs to
prevent malaria infection, like intermittent preventive treatment for the most vulner-
able (such as pregnant women and infants); early and confirmed diagnosis (through
microscopy or rapid diagnostic tests) and timely treatment with anti-malarial drugs,
etc. [52]. These interventions have proven to be effective in reducing malaria preva-
lence in endemic areas over the past decade [52], but are still incapable in fully con-
taining malaria for several reasons. These include among others the great adaptability
of parasites and mosquitoes, which lead to the development of antimalarial drugs re-
sistance and insecticide resistance. Drug resistance is aggravated by poor adherence
to the required course of treatment and limited access to proper treatment due to
under-performing health services in some malaria endemic regions. Also a careful and
timely monitoring of the development of insecticide resistance is required and hence
there is an urgent need for human capacity building in entomology and vector control
on site, which can be difficult to achieve due to often insufficient financial, human and
social resources available [52,61–63]. Hence other tools are needed to supplement the
current efforts, among which introducing a safe and effective malaria vaccine could
be a cost-effective and efficacious way that is being seriously considered [61, 64, 65].
Malaria vaccines that have been considered are for example pre-erythrocytic vaccines,
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which aim to generate antibodies responsible to neutralize sporozoites before humans
develop symptoms and can transmit the disease. Transmission-blocking vaccines on
the other hand are based on antigens expressed on the surface of the sexual and
mosquito mid-gut stages of the malaria parasite and hence reduce human infectious-
ness directly but without reducing symptoms. Efforts for development of a malaria
vaccine have been pursued since the 1960s but as of today there is no licensed vaccine
yet. Nevertheless, efforts continue and there are over 20 vaccine candidates in phase
1, phase 2 clinical trials or in pre-clinical development [66]. At present, the only
promising vaccine for malaria is RTS,S/AS01, which is currently undergoing phase 3
clinical trials (the last stage of testing before licensing).
1.2.2 Mathematical models of malaria
Compartmental deterministic models for vector-borne diseases, in particular for
malaria, increase in difficulty compared to models for directly transmitted (from hu-
man to human) diseases. When formulating compartmental vector-host models, gen-
erally, additional to the compartments for the host, compartments for the vector
have to be included which are coupled with the host compartments via transmission
rates. When modeling malaria, many times it is enough to include only two mosquito
compartments (susceptible and infectious mosquitoes) due to the short lifespan of
mosquitoes compared to humans. Nevertheless, the number of differential equations
of the deterministic model increases to at least two more equations, which raises
the complexity of the system. If an additional structure needs to be included (e.g.
chronological-age for humans) the difficulty of analysis of the model increases even
more.
When defining the transmission rate from vector to host and vice versa one can
use a “mass action” approach, i.e. assuming that the biting rate is limited by the
number of humans and mosquitoes as opposed to using “frequency dependent” trans-
mission, that assumes that the biting rate is saturated and not limited by the number
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of humans, i.e. the number of bites one individual mosquito can give is constant and
independent of the number of humans and the number of bites a human can get in-
creases with the number of mosquitoes. In other words, mass action assumes that the
larger the human population is, the more blood meals a mosquito is capable of taking.
On the contrary, frequency dependent transmission assumes that the number of blood
meals a mosquito is capable of taking only is limited by the biological capability of
meal intake of a mosquito and not by the availability of meals. It is important to
decide which modeling approach is best when formulating a model for a vector-borne
disease since theses two approaches affect for example the basic reproduction number
(R0) in different ways. If mass action is used to define the transmission term, then
reducing either the number of humans or the number of mosquitoes reduces R0. On
the other hand, if the model uses frequency dependent transmission, then reducing
the number of mosquitoes will reduce R0 but reducing the number of humans in-
creases the basic reproduction number. More careful discussions about the model
formulation of transmissions between human hosts and mosquitoes (particularly the
dependence on the ratio between the host and vector) can be found in Chitnis et
al [67] and in Chapter 14 in [1].
In the first malaria model developed by Sir Ronald Ross in 1911 [5], Ross captured
the basic features of malaria and concluded that malaria can be eradicated if the
mosquito population can be reduced below a certain threshold. More then 40 years
later, 1957, Macdonald in [68] presented a compartmental malaria model based on
Ross’ work in [5] and in [69–71]. In his model, following biological new findings
at the time about the life cycle of the parasite in the mosquito, Macdonald was
the first to include an exposed compartment for mosquitoes. His model lead to
better understanding of the implications these findings had on malaria transmission
and eventually was the basis of the usage of control measures that target mosquito
elimination. Almost other 40 years had to pass until Anderson and May in 1991,
based on Macdonald’s work, presented a malaria model in [26] that included an
exposed compartment for humans, which lead to more realistic disease dynamics
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than the previous existing models at the time. Since then, with the availability of
new data and increased knowledge about the parasites, many extensions of the Ross,
Macdonald and Anderson & May models have been developed to better understand
the disease dynamics of malaria [72].
More detailed biological and epidemiological factors have been included in these
extended models including the effects of human age [26,73–75], acquired immunity to
malaria [73,74,76,77], and genetic and spatial heterogeneity of parasite and host [78],
among others. In [73,74] Aron presents a compartmental differential-delay equations
model to study acquired immunity booster by re-exposure to the disease and waning
otherwise. He also includes age structure formulating the model as an age-prevalence
model in which the only temporal variable is age and omits mosquito equations in-
troducing the effect of mosquitoes only by a constant infection rate. In [26] Anderson
and May present a partial differential equations model structured by chronological-
age of humans. Their attempt was to capture the infected age-prevalence observed in
malaria endemic countries, but the model lacked on age-dependent parameters and
hence did not fit well with age-dependent prevalence observations [79]. It was then
suggested that host immunity should be considered with age [72]. There are exist-
ing models which model immunity by including an immunity function, for example
in [77] Filipe et al. introduced a chronological-age structured model and included
immunity by introducing complex immunity functions for different immunity classes
that depend on age and disease transmission level. He omitted mosquito equations
incorporating their effect in the transmission rate. Due to the complexity of the im-
munity functions, mathematical analysis of these models is many times not possible
and hence a numerical simulations approach has to be used to obtain results. Immu-
nity can be included also by considering separate immune classes (e.g., see [67,80,81]
and 82), but most of these models do not include an age-structure of the human host.
Models incorporating immunity loss as well as effects of climate, socio-econonomic
factors and their relationship to disease transmission have also been studied for ex-
ample in [83,84] Models analyzing the implementation of control measures for malaria
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have been of great interest as well. For example Agusto et al. in [85] present and
analyze a mathematical model that investigates the role of bed-nets and their impact
on malaria control. Ngonghala et al. investigate among other things in [86] how the
decrease in effectiveness of insecticide treated bed-nets affects malaria prevalence and
state that not considering this decay may lead to an overestimation on the impact of
insecticide treated bed-net use in malaria control.
Malaria vaccination models, with constant vaccination rates and constant lost
of immunity rates have been studied. For instance in [87] the authors present and
analyze a mathematical model to study the impact of personal protection of humans,
vaccination and treatment in controlling malaria. [88] develops ordinary differential
equations models for potential malaria vaccines that attack different stages of the
malaria parasite in the human body. The authors explore numerically the effects
that theses vaccination campaigns may have on the prevalence of the disease under
different types of immunization programs and levels of coverage. In [89] Okosun
et al. present and analyze analytically a deterministic model for malaria including
treatment and vaccination and investigate optimal conditions for eradication, and
Koella et al. review in [90] several mathematical models of malaria and their key
conclusions relevant for control.
1.3 HIV/HSV-2
1.3.1 Human Immunodeficiency Virus (HIV)
Human Immunodeficiency Virus (HIV) is an incurable sexually transmitted dis-
ease (STD). Studies believe that HIV originated in Africa and jumped from apes
to humans in the late 1800s. From then on the virus slowly spread out of Africa,
reached the United States in the mid-late 1970s and was first identified in the United
States in 1983. HIV affects cells of the immune system (T-cells) and, if not treated,
HIV ultimately develops to Acquired Immunodeficiency Syndrome (AIDS). HIV can
be controlled if treated in its early stages and treatment can lower the infectivity of
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infected individuals as well as significantly prolong lives of those affected [91]. AIDS
allows for gradual failure of the immune system, leaving humans vulnerable to a va-
riety of pathogen-caused infections. While many advancements have been made in
preventing and treating HIV/AIDS, with close to 50,000 new cases every year in the
United States [92], and 2.5 million worldwide [93] more education and development
of strategies are necessary for further reducing the numbers.
The importance of HIV has gathered attention from mathematical epidemiologists
throughout the years. Different aspects have been studied: antiviral therapy - strategy
and drug resistance at the population level [94,95], at the individual level (cell-to-cell
viral transmission) [96–98], or sexual behavior in [99]. In [96], Roy et al. consider
a time delay in the disease infection term, relating their results to a model without
delay. In [94], Granich et al. make a prediction of reduction of incidence based
on strategies of early detection and widely available antiviral therapy, through both
deterministic and stochastic models. In [95], Chibaya et al. explore a model of vertical
HIV transmission (mother-to-offspring), including treatment and drug-resistance. In
[98], Rong et al. construct two age-of-infection models of HIV at the cellular level,
exploring two strategies of treatment. In [99], Johnson et al. explore a model of
sexual behavior (extramarital relationships, condom use, concurrent relationships,
etc.) and its effect on the spread of HIV in South Africa. In [97], Kirschner et al.
present a system of ordinary differential equations that explores drug sensitive and
drug resistant viral cells dynamics.
1.3.2 Herpes Simplex Virus- 2 (HSV-2)
Herpes Simplex Virus- 2 (HSV-2), is a viral STD which is characterized by periods
of latency (low or no infectivity) and viral shedding (high infectivity) and is one of
the two viruses causing genital herpes. An outbreak of HSV-2 can be either symp-
tomatic or asymptomatic. The main symptoms are genital ulcers [100–102]. HSV-2
is a lifelong, incurable disease but antiviral medications can prevent outbreaks or
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shorten their duration while taking the medicine. Also, suppressive antiviral therapy
can reduce the probability of transmission to sexual partners. Currently there is no
licensed vaccine against genital herpes infection [103].
Several mathematical models have studied HSV-2 infection, [104–106] to name a
few. In [104], Foss et al. give a nice review of the mathematical models of HSV-2 up to
2009 and are critical of the models that exclude some of the important aspects of the
disease: latency, symptomatic and asymptomatic infectivity, reduction of shedding
since initial infection, type of initial infection (symptomatic or asymptomatic), and
the possibility for the disease to develop differently from the way it started (asymp-
tomatic initial outbreak can turn into symptomatic recurrent outbreaks and vice
versa). The system of ordinary differential equations proposed in [104] incorporates
all these aspects, and explores the differences between an initial, complex system, and
a simplified version. In [105], Schiffer et al. present a stochastic model of mucosal
HSV-2 pathogenesis to mimic the pattern of HSV-2 genital shedding frequency, recur-
rences, peak copy number during episodes, duration of shedding episodes, and lesion
diameter in particular patients. They conclude, corroborating their results with data,
that HSV-2 expression has a high variability among patients, and even within a single
patient as time progresses.
1.3.3 HIV/HSV-2 co-infection
There is mounting evidence of the correlation between HSV-2 and the transmis-
sion and acquisition of HIV. Studies show that the risk of HIV infection in HSV-2
seropositive individuals is significantly higher. Genital ulcers increase the number
of target cells available for HIV attachment and entry into the genital tract. Some
HSV-2 proteins increase the expression of HIV, hence HIV can be found in the gen-
ital ulcers themselves. HSV-2 reactivation has also been shown to stimulate HIV
replication, however even latent HSV-2 has been associated with higher risk of HIV
acquisition. Further, HIV-positive individuals have a higher probability to acquire
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HSV-2 and, in fact, a large portion of the HIV-positive individuals (40% − 80% in
the United States, e.g.) are co-infected with HSV-2 [107–114].
There have been only a few studies modeling the interaction between HIV and
HSV-2 [106, 115, 116] (and references therein). The model presented in Chapter 4 is
based on [106] where Feng et al. present a model to better understand the epidemio-
logical synergy between the two diseases and to study the potential impact of HSV-2
treatment on HIV prevalence. This model contains gender and heterogeneous mixing
between groups, a feature that previous models did not include.
1.4 Motivation and outline of the dissertation
This dissertation contains the study of three different kind of structured models
applied to either malaria or to HIV/HSV-2 co-infection.
My motivation to use mathematical models applied to malaria has two different
origins. First, from the applications point of view, the severity of malaria disease with
its public health implications, the complex parasite stages of the parasite’s life cycle
within human hosts, the adaptability of the parasite under various conditions, and
the difficulties in controlling the disease in underdeveloped countries, were aspects
that caught my attention and drove me to further understand malaria transmission.
Also, many aspects of malaria transmission, such as the indirect interactions between
mosquitoes and parasites at various stages within human hosts, are not well under-
stood. Hence it is for me of great interest to use mathematical models to generate
insights on how important these uncertain aspects really are for malaria transmission.
With respect to control efforts for malaria, it is exciting to study a vector-borne disease
that is imminently about to be the first parasitic disease for which a vaccine will be
licensed (expected in 2015 [66]) and to get insight using mathematical models on how
a malaria vaccine will affect the disease prevalence. Second, from the mathematical
point of view, it is challenging to study analytically vector-borne disease models due
to the multiple hosts used by the pathogen, which usually leads to higher-dimensional
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systems of differential equations. Incorporation of the complexity of malaria infec-
tion and the human immune system response to the disease may require a malaria
model to include chronological-age of the human host, in which case makes the model
will involve a system of partial differential equations coupled with ordinary differen-
tial equations. Models considering other types of structures, such as vaccine-age or
infection-age structure present similar mathematical challenges. Examples of these
types of models will be discussed in this dissertation.
My interest on HIV and HSV-2 has been let by the fact that these diseases exist
in many countries where malaria is endemic and hence there are interactions between
these diseases. Further examinations of these two diseases suggested an interesting
modeling problem to study the effect that treatment of HSV-2 may have on HIV
prevalence, as was done in [106]. Mathematically, modeling of sexually transmitted
disease with heterosexual transmissions is similar to that of vector-borne diseases, in
the sense that the transmission is passed between two subpopulations.
This dissertation is organized as follows. In Chapter 2 we develop a continuous
malaria model structured by chronological-age of humans. The model consists of a
system of first order partial differential equations (PDEs) for humans coupled with or-
dinary differential equations (ODEs) for mosquitoes. The infected human population
is divided into symptomatic infectious, asymptomatic infectious and asymptomatic
chronic infected individuals. Based on the information about how the presence of
mosquitoes may affect the parasite stages within the human host, we assume that
infectiousness of chronic infected individuals can be triggered by bites from even sus-
ceptible mosquitoes. Hence our model exhibits a “loop” between the asymptomatic
infectious stage and the asymptomatic chronic infected stage, which adds difficulty to
the model analysis. Most of the disease parameters are assumed to be chronological-
age dependent, hence our model can be used to study factors representing various
age-dependent immune responses. The questions our model can help address include
the following: First, how does age-dependent host immunity, asymptomatic chronic
infections and parasite adaptation to a variable number of mosquito bites may im-
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pact malaria dynamics? Second, which disease control strategy might be the most
effective? Third, which age-groups are best to be targeted for a a vaccination or
treatment/diagnosis strategy in order to reduce the reproduction number and/or the
prevalence more effectively?
In order to answer these questions we derive and interpret an analytic expression
for R0 for the PDE model as well as for an ODE model derived from the original
PDE model and we produce numerical results. R0 determines the local stability of the
disease free equilibrium and depends on chronological-age dependent parameters and
factors representing the key biological assumptions we made. Our model is capable
of generating important insight into the observed patterns of malaria dynamics and
can be useful for evaluating the effectiveness of various control measures. Numerical
results using sensitivity and uncertainty analyses help identify the most influential
factors for reducing the reproduction number R0 and the disease prevalence. The
age structure of the model makes it possible to determine specific age group(s) to be
targeted for vaccination or other control programs.
In Chapter 3 we present a vaccination model for a pre-erythrocytic vaccine for
endemic malaria. The model includes two vaccinated classes for humans, which are
structured by continuous vaccine-age. The rate of going from the first vaccinated
class (initial dose(s)) to the second vaccinated class (booster dose) is vaccine-age
dependent and hence allows the model to consider a minimum vaccine-age required
to obtain a booster vaccination. The efficacy of each vaccine dose is also allowed to be
vaccine-age dependent. The questions we answered with our model are several: First,
how does the conclusion of our model compare to that of a model which includes only
one vaccinated class? Second, how does the minimum vaccine-age requirement for
administration of the booster dose affect malaria prevalence, the reproduction number
and the vaccination coverage needed for eradication, if at all possible? Third, how
can the control reproduction number be used to determine vaccination coverage to
achieve the goals for disease control and can a backward bifurcation occur? Fourth,
what implications could waning efficacy have for malaria prevalence?
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The analysis of our model starts with deriving the control reproduction number
R and determining the local stability of the disease free equilibrium (DFE). We
show global stability of the DFE analytically under certain assumptions and identify
conditions for the existence of endemic equilibria. Numerical results explain the
importance of including two vaccination classes as opposed to only one. They also
show that when a minimum vaccine-age for a booster dose is considered, there may
be cases for which no added protection is obtained from the booster dose. The model
also exhibits backward bifurcation under several vaccination scenarios, indicating that
R = 1 is no longer the threshold value for disease eradication. We also observe that
without considering waning efficacy, the model may underestimate or overestimate
disease prevalence.
Finally, in Chapter 4 we study a mathematical model for the co-infection of HIV
and HSV-2. We incorporate an infection-age (time-since-infection) continuous vari-
able to track the alternating periods of infectiousness of HSV-2, hence we model
HSV-2 by partial differential equations coupled with integro-differential equations for
HIV. The model considers only heterosexual relationships and distinguishes three
population groups: males, general population females, and female sex workers. We
focus our attention on the effect of HSV-2 on HIV prevalence. The questions we ad-
dressed with this model are: First, what are the key aspects of the coupled dynamics
of the two sexually transmitted diseases, or more precisely, what are the parameters
associated with HSV-2 that may affect HIV prevalence the most? Second, what ef-
fect do female sex workers have on disease dynamics? Third, is it possible to derive
analytic expressions for the invasion reproduction numbers, considering the model
complexities due to structures in gender and infection-age?
In our model analysis of Chapter 4, in addition to the basic reproduction number
for each disease, we derive and interpret the invasion reproduction numbers (IRNs).
The infection-age dependency of parameters and the many possibilities of interaction
between classes add great complexity to the model and to the IRNs derivation and
interpretation. This is one of the novel aspects this study provides. We perform
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numerical simulations including a sensitivity analysis for a reduced ODE system,
which helps confirm the analytical results and helps to examine the effect of model
parameters on epidemiological outcomes. We observe that co-infection is a key aspect
to be considered. In general we conclude that HSV-2 treatment may be much more
effective in lowering HIV prevalence than HIV control measures may be in lowering
HSV-2 prevalence. Also, strategies for reducing HSV-2 in female sex workers may
help reducing the HIV prevalence in an HSV-2 endemic population.
Detailed discussion to answer the questions stated above can be found in each of
the chapters, and a summary containing the answers can be found in Chapter 5.
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2. IMPACT OF CHRONOLOGICAL-AGE-DEPENDENT
RELAPSE AND IMMUNITY ON MALARIA DYNAMICS
The work presented in this chapter is in collaboration with Christina (Lorenzo) Alvey
and has been published in the Journal of Biological Systems [117]. My main contribu-
tions to this work were in the model formulation and analysis, and in the discussion
and interpretation of results.
2.1 Introduction
Across Sub-Saharan Africa, humans have shown to develop immunity against the
malaria parasite. In regions where people are almost continuously exposed to the
parasite, different types of immunity have been observed: anti-disease immunity (i.e.,
gives protection against clinical disease), anti-parasite immunity (i.e., gives protec-
tion against mainly the asexual stage of the parasite in the body, which controls
parasite density) and transmission-reducing immunity (i.e., reduces the transmission
from human to mosquito) [58, 118]. In regions where malaria is endemic, infected
adults rarely experience clinical symptoms, even though they test positive for par-
asitemia and often carry a high load of malaria parasites in their blood that may
be lethal to a malaria-naive person [58, 59]. On the other hand, children, especially
young children, experience clinical symptoms most of the time when infected with
P.falciparum [56, 57]. The general belief is that an age-dependent anti-parasite and
anti-disease immunity can be observed in populations exposed almost continuously
to the parasite [58]. Studies have shown that this age-dependent immunity is either
due to repetitive exposure (for the human to be able to gain an effective immune re-
sponse to the parasite) or due to immune responses that depend on host development
and maturation, or a combination of both [119, 120]. Because of the human host’s
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ability to acquire clinical immunity against the infection, it is important to deter-
mine how and to what extent asymptomatic parasite carriers may influence malaria
transmission. The methods used to measure parasite presence in the body are often
not sensitive enough to detect low parasitemia [121]. This suggests that individuals
with low parasitemia represent a parasite reservoir for the subsequent transmission
season that could have been underestimated. In most malaria regions in Africa, the
endemicity of the disease is stable, which is probably because the infectiousness of the
human host is very insensitive to anti-malaria interventions [122]. Therefore, human
infectiousness to mosquitoes, especially of asymptomatic carriers, is an important
aspect to consider when modeling malaria transmission.
An infected human host is able to infect mosquitoes only when the parasites within
the human body have evolved into the sexual stage, i.e., when gametocytes are present
in the bloodstream. Thus, to determine the infectiousness of a human host, it is
important to consider the duration of gametocytemia and the effect of transmission-
reducing immunity, which prevents the parasite from developing inside the mosquito
mid-gut and stops the cycle [118]. However, it can be difficult to determine, for
asymptomatic carriers, how long gametocytes are present in their bloodstream. Nev-
ertheless, it has been observed that the duration of asymptomatic gametocyte car-
riage decreases with age [123]. It has also been argued that transmission-reducing
immunity is expected to be higher in children, since the anti-parasite immunity pre-
vents adults from developing high gametocytemia, whereas children develop enough
gametocytemia to acquire transmission-reducing immunity [118]. The factors which
stimulate gamecytogenesis are not very clearly understood [58, 123]. Therefore it is
important, for the guidance of future studies, to get some insight on how different
hypotheses on creation of gametocytes may affect malaria transmission. It has been
suggested that environmental factors may be associated with gametocyte produc-
tion [124, 125]. Seasons in the tropics are based on rainfall and are therefore linked
to mosquito bionomics. Mosquitoes can be found throughout the year; and thus,
seasonal mosquito activity is referred to increased number of mosquitoes in the rainy
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season [125]. During the dry season, it is expected that the parasite in the body of
asymptomatic carriers would be reduced to a minimum amount, but not disappear-
ing completely, leaving them with a chronic infection which is not enough to infect
mosquitoes. Evidence has been provided that mosquito saliva has an impact on the
parasite during the chronic asymptomatic stage of infection [126, 127]. It has been
hypothesized that in tropical regions, where the seasons are defined by mosquito
bionomics, the parasite has evolved to respond to the mosquitoes, specifically to
the mosquito bites [124, 125]. This hypothesis leads to the belief that reappearance
of gametocytemia, and so reappearance of infectious asymptomatic carriers may be
triggered by susceptible, not yet infectious, mosquito bites [125] on asymptomatic
chronic infected individuals. This has been recently shown for avian malaria in [127],
where chronic infected birds exposed to non-infected mosquitoes showed a signifi-
cantly higher blood stage parasitemia which lead to a significantly higher infection
prevalence for mosquitoes. A similar phenomenon has been demonstrated for other
vector-borne parasites [124] as well. This, together with the assumption that par-
tially immune children develop a better transmission-reducing immunity than adults,
as well as the knowledge that most adults do not show clinical symptoms, suggests
that it is important to study a model that incorporates several aspects: age depen-
dent immunity, factors responsible to stimulate gametocytogenesis and not only an
asymptomatic class, but divide the asymptomatic population into an asymptomatic
infectious class (gametocyte carriers) and an asymptomatic chronic infected class
(individuals with low parasitemia).
We developed a malaria transmission model that considers age-structure of the
human host, factors representing various age dependent immune responses as well
as environmental factors that stimulate parasite development and human infectious-
ness. The model is formulated in a way that allows us to capture several important
malaria features including age-dependent anti-disease, anti-parasite and transmission-
reducing immunity, asymptomatic infectious and asymptomatic chronic infected in-
dividuals, age-dependent infectivity and susceptibility of humans to mosquitoes, as
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well as relapse of asymptomatic chronic infections triggered when bitten by (even only
susceptible) mosquitoes. One of the main objectives of this study is to determine how
age-dependent host immunity, asymptomatic chronic infections and parasite adapta-
tion to a variable number of mosquito bites may impact malaria dynamics, which
to the best of our knowledge has not been simultaneously studied previously using
mathematical models. The formulation of our model will also allow us to identify
the targeted age group(s) for vaccination and treatment/diagnosis strategies. Cur-
rently, there are several malaria vaccines under development. One approach is based
on targeting one of the different stages of parasite development in the human body.
Those vaccines would either aim to prevent clinical symptoms or aim for reductions of
human infections. Another approach in vaccine development is based on reducing the
disease transmission of the parasites to the mosquito, resembling the transmission-
reducing immunity [128]. Because of the fact that different vaccines generate different
immunity involved in the malaria transmission process, it is helpful to study models
that can be used to examine how distinct immunity aspects, as well as other factors,
contribute to the malaria burden. Our model can also be used to identify the most
effective disease control strategies. We demonstrate this by examining the effects of
these vaccines and treatment on reducing either the reproduction number R0 and/or
the disease prevalence.
In Section 2.2, we present the chronological-age-dependent model, which consists
of a system of partial differential equations for humans coupled with a system of
ordinary differential equations for mosquitoes. Section 2.3 includes the derivation of
the basic reproduction number R0 with a biological interpretation of its components
using biologically relevant quantities. This section also includes a stability analysis
of the infection-free steady-state, which is shown to be determined by R0. In Sec-
tion 2.4, we derived from the PDE model a system of ordinary differential equations
with multiple age groups of the human host under the assumption that the model
parameters are constant within each age group. The basic reproduction number for
this ODE model is obtained using the next generation matrix approach from [10].
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Section 2.5 is devoted to numerical simulations of the ODE system, which illustrate
the effect of various biological factors on the disease prevalence and on R0 . A sen-
sitivity and uncertainty analysis is also presented in this section. Section 2.6 collects
the conclusions and discussions.
2.2 The PDE model
To incorporate chronological-age-dependent immunity, susceptibility, and infectiv-
ity for humans, we consider the age density of individuals in each epidemiological class.
Specifically, let s(t, a), i(t, a), iA(t, a), and jA(t, a) denote the densities of susceptible,
symptomatic infectious, asymptomatic infectious, and asymptomatic chronic infected
(non-infectious, parasite carriers with low parasitemia) individuals, respectively, at
time t of chronological age a. For example, the number of suscpetible humans at
time t in the chronological-age interval [a0, a1] is given by
∫ a1
a0
s(t, a)da. Let Iv(t) and
Sv(t) denote the numbers of susceptible and infectious mosquitoes, respectively, at
time t. When modeling malaria transmission dynamics, different functional forms
have been used for the transmission rates between humans and mosquitoes. Observe
that in our definition of the force of infection terms we assume frequency dependent
transmission. Its biological meaning was discussed in Chapter 1. In this work we
will refer to the transmission rate at which one host is infected by vectors as “force
of infection”. Hence in this work it will be used on a per-human basis. The force
of infection from infectious mosquitoes to susceptible humans, which is denoted by
λ1(t, a), is




Here, β is the number of bites a mosquito can give per day, d(a) is the proportion
of susceptible host infected per bite by infectious mosquito, and Nh(t) is the total




n(t, a)da with n(t, a) := s(t, a) + i(t, a) + iA(t, a) + jA(t, a). (2.2)
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Given a successful bite from an infectious mosquito to a susceptible human host, as-
sume that a proportion k of it leads to a symptomatic infection. Let γ(a) denote the
rate of recovery of a symptomatic infectious individual of age a. An asymptomatic
infectious individual of age a (iA(a)) is assumed to become asymptomatic chronic
infected (jA(a)) at rate γA(a). Assume that asymptomatic infectious and asymp-
tomatic chronic infected individuals do not die from the disease. As pointed out in
the Introduction (Section 2.1), there is a possibility for non-infectious jA individuals
to relapse and become asymptomatic infectious (iA), which can be triggered by sus-
ceptible mosquito bites. We assume that this happens during a fraction p of a year
when the mosquito number rises due to rainfall. We model this rate of relapse by
λ2(t, a) with the following form




where dA(a) is the proportion of human relapse per bite. The transmission rate from













where c(a) and cA(a) are the probabilities that a susceptible mosquito becomes infec-
tious per bite from infectious symptomatic and asymptomatic humans, respectively.
All variables and parameters are listed in Tables 2.1 and 2.2.
The transitions of humans between the epidemiological classes are depicted in
























= −pλ2(t, a)jA(t, a) + γA(a)iA(t, a)− µ(a)jA(t, a) (2.5)




f(a)n(t, a)da, i(t, 0) = 0, iA(t, 0) = 0, jA(t, 0) = 0 (2.6)
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Table 2.1.
Description of variables and symbols used in the PDE model
Variable/Symbol Description
s(t, a) age density of susceptible humans
i(t, a) age density of symptomatic infectious humans
iA(t, a) age density of asymptomatic infectious humans
jA(t, a) age density of asymptomatic chronic infected humans
Nh(t) total number of humans
Sv(t) # of susceptible mosquitoes
Iv(t) # of infectious mosquitoes
Nv(t) total mosquito population
P (a) = exp[− ∫ a
0
µ(σ)dσ], survival probability from death
h:=humans, m:=mosquitoes.
and initial conditions (IC)
s(0, a) = s0(a), i(0, a) = i0(a), iA(0, a) = iA0(a), jA(0, a) = jA0(a). (2.7)
The forces of infection λ1, λ2 and λv are given in (2.1), (2.3) and (2.4), respectively.
The equations for mosquitoes are
dSv
dt
= bv − λv(t)Sv(t)− µvSv(t)
dIv
dt
= λv(t)Sv(t)− µvIv(t) (2.8)
with initial conditions Sv(0) = Sv0, Iv(0) = Iv0. The continuous age-structured model
is given by the system of equations in (2.5)–(2.8).
We assume the following conditions on parameters and initial conditions:
• s0(.),i0(.), iA0(.), jA0(.) ∈ L1([0,∞),R+0 ), with i0(a) > 0 for some a > 0.
• Sv0, Iv0 ≥ 0.
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Table 2.2.
Description of parameters used in the PDE model
Parameter Description Units
β # of bites one mosquito can give per day b
m·d
d(a) % of susceptible humans infected per bite h/b
dA(a) % of human relapses per bite h/b
c(a) % of mosquitoes infected per bite on humans in i(t, a) m/b
cA(a) % of mosquitoes infected per bite on humans in iA(t, a) m/b
f(a) per capita birth rate of humans of age a d−1
µ(a) per capita natural mortality of humans of age a d−1
δ(a) per capita disease death rate of individuals in i(t, a) d−1
γ(a) recovery rate of symptomatic humans of age a d−1
γA(a) recovery rate of asymptomatic humans of age a d
−1
bv per capita mosquito birth rate m/d
µv per capita mosquito death rate d
−1
p % of a year with high mosquito density unitless
k % of new infections being symptomatic unitless
λ1(t, a) human infection (see (2.1)) day
−1
λ2(t, a) human relapse (see (2.3)) d
−1
λv(t, a) mosquito infection (see (2.4)) d
−1
h:=humans, m:=mosquitoes, b:=bite, d:=day.
• µ(.), f(.), γ(.), γA(.), δ(.) are non-negative and piecewise continuous on [0,∞).
• f(a) > 0 ∀a ∈ (a′, a′′) and f(a) = 0 for a 6∈ (a′, a′′).
• ∃µ0, a∗ > 0 such that µ(a) > µ0, ∀a > a∗.
• d(.), dA(.), c(.), cA(.) are non-negative, piecewise continuous and bounded on
[0,∞).
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It can be shown that the system has a unique non-negative solution for non-
negative initial conditions and that the model is well-posed.
Figure 2.1. A diagram for the transitions between epidemiological classes
of the human population.
2.3 Computation of R0 and stability of the disease-free state for the PDE
model
As in most mathematical models for the spread of infectious diseases, one of
the most useful threshold quantities is the basic reproduction number R0, which for
endemic diseases usually determines whether the disease persists in the population
(when R0 > 1) or dies out (when R0 < 1). The basic reproduction number is defined
in general as the average number of secondary infections produced by one infectious
individual during the entire infectious period when introduced into a completely sus-
ceptible population. In this section, we derive an expression for R0 by first analyzing
the linearized system of (2.5) and (2.8) at the disease-free state, which provides a
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threshold quantity for the stability condition. By examining the biological interpre-
tation of the threshold quantity, we can confirm that it is indeed the R0 for the
chronological-age-structured model.
2.3.1 Stable age distribution of the human population in the absence of
disease
Various methods can be used to compute the reproduction number R0 for age-
structured models. We follow the approach of Hadeler and Mu¨ller [21,22]. We restrict
our attention to the case in which the human population has reached the stable age
distribution in the absence of disease. A solution with stable age distribution is a
separable solution of the form n(t, a) = A(a)T (t), where we will call A(a) the stable
age distribution. Observe that for this types of solution the proportion of individuals









independent of time, and we say that the solution with stable age distribution has
constant population structure. This distribution can be obtained by analyzing the
following equation, first introduced by McKenrick in [12], for the total population







= −µ(a)n(t, a) (2.10)




f(a)n(t, a)da := B(t), n(0, a) = n0(a). (2.11)






a−t µ(σ)dσ, if a ≥ t
B(t− a)e−
∫ a
0 µ(σ)dσ, if t > a.
(2.12)
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f(a)n(0, a − t)e−
∫ a
a−t µ(σ)dσda represents the number of new off-
springs generated by individuals of the population that are present at time t = 0. In
the classical analysis of this model, to find the asymptotic behavior of B(t) it can be
shown [1,27,45] that
B(t) = Λepˆt(1 + Ω(t)) (2.14)
where Λ is a non-negative constant, Ω(t) is a function with the property
lim
t→∞
Ω(t) = 0, and pˆ satisfies the equation (known as the Lotka-Sharpe equation [2])∫ ∞
0
f(a)P (a)e−pˆada = 1, (2.15)
where
P (a) := e−
∫ a
0 µ(σ)dσ, (2.16)
which represents the probability that an individual survived to age a from natural
death. Using the expression for B(t) from (2.14) and substituting it in (2.12) for large
t, one obtains for n(t, a) an exponential solution with stable age distribution:
n(t, a) = n˜(a)epˆt (2.17)
where
n˜(a) := Λe−pˆaP (a) (2.18)
is the stable age distribution. Hence any solution of system (2.10) approaches for
large t a separable solution of the form as in (2.17). It is easy to see from (2.17) that
if pˆ > 0 (< 0) then the human population will grow (decay) exponentially, in other
words, the asymptotic behavior of the population is determined by pˆ.
2.3.2 R0 and stability of the disease-free equilibrium
We determine R0 by analyzing the stability of the disease-free equilibrium. We
will assume that total human population in the absence of the disease has achieved
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the stable age distribution with constant population size, i.e., pˆ = 0 and (see (2.17)
and (2.18))
n(t, a) = ΛP (a) (2.19)
where P (a) is given in (2.16). In this case, the constraint (2.15) becomes∫ ∞
0
f(a)P (a)da = 1. (2.20)







By applying the theory of asymptotically autonomous systems [129–131], we assume
that the vector population has already reached the equilibrium N¯v in the absence of
disease.
For the remaining analysis in this section, we will consider the limiting system of
(2.5) and (2.8) under the conditions
n(t, a) = ΛP (a), Nh(t) = Λ
∫ ∞
0




In this case, the disease-free equilibrium E∗ is given by






v ) = (ΛP (a), 0, 0, 0, N¯v, 0). (2.23)
To linearize the system, let
x(t, a) = s(t, a)− ΛP (a), Xv(t) = Sv(t)− N¯v. (2.24)




, λ¯2(a) := βdA(a)
N¯v
N¯h






















































cA(a)iA(t, a) + c(a)i(t, a)
]
da− µvIv(t), (2.26)
where λ¯1(a), λ¯2(a) and λ¯v are given in (2.25). System (2.26) is linear in the dependent
variables.
We consider exponential solutions with stable age distribution of the form
x(t, a) = x(a)eωt, i(t, a) = i(a)eωt, iA(t, a) = iA(a)e
ωt, jA(t, a) = jA(a)e
ωt,
Xv(t) = X¯ve
ωt, Iv(t) = I¯ve
ωt, (2.27)
where ω is a constant. The stability of E∗ can be determined by the sign of ω.
Substituting these into equations in (2.26) and canceling eωt, we obtain the follow-
ing equations (it suffices in this case to consider only the i(a), iA(a), jA(a) and I¯v
equations):
i′(a) = kλ¯1(a)I¯v − (γ(a) + µ(a) + δ(a) + ω)i(a)
i′A(a) = (1− k)λ¯1(a)I¯v + pλ¯2(a)jA(a)− (γA(a) + µ(a) + ω)iA(a)




[cA(a)iA(a) + c(a)i(a)]da− µv I¯v. (2.28)





− ∫ aσ (γ(τ)+µ(τ)+δ(τ)+ω)dτdσ = I¯vkF (a, ω), where (2.29)
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− ∫ aσ (γ(τ)+µ(τ)+δ(τ)+ω)dτdσ. (2.30)
By solving the equation for iA(a) + jA(a) in (2.28), i.e.,
i′A(a) + j
′
A(a) = (1− k)λ¯1(a)I¯v − (µ(a) + ω)(iA(a) + jA(a))
we find






Solving for jA(a) from (2.31) and substituting it in the iA(a) equation in (2.28) we
obtain




− ∫ aσ (µ(τ)+ω)dτdσ
−(γA(a) + µ(a) + pλ¯2(a) + ω)iA(a), (2.32)
from which we have
iA(a) = (1− k)I¯vG(a, ω, p), (2.33)
where








− ∫ σξ (µ(τ)+ω)dτdξ]PA(a, σ, ω)}dσ
(2.34)
and PA(a, σ, ω) := e
− ∫ aσ (γA(τ)+µ(τ)+pλ¯2(τ)+ω)dτ .
Substituting i(a) and iA(a) into the I¯v equation in (2.28) and dividing by I¯v (6= 0),












The function Θ(ω) defined in (2.35) can be used to define the basic reproduction
number R0:










where the functions F andG are defined in (2.30) and (2.34), respectively. A biological
interpretation of the expression for R0 defined by (2.36) will be provided at the end
of this section. The following result shows that R0 = 1 provides a threshold condition
of the local stability of the disease-free equilibrium E∗.
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Theorem 2.3.1 The disease-free steady state E∗ is locally asymptotically stable if
R0 < 1 and unstable if R0 > 1.
Proof Consider first the case when ω ∈ R. Notice that
∂
∂ω





σ (γ(τ)+µ(τ)+δ(τ)+ω)dτdσ < 0,
∂
∂ω



















− ∫ σξ (µ(τ)+ω)dτdξ](σ − a)PA(a, σ, ω)} dσ
< 0


























and Θ(ω) is a continuous decreasing function. Moreover, since F (a, ω) → 0 and
G(a, ω, p)→ 0 as ω →∞, it is easy to see that lim
ω→∞
Θ(ω) = 0. Similarly, it can also
be shown easily that lim
ω→−∞
Θ(ω) = ∞. Therefore, there exists a unique real root,
denoted by ω0, of the characteristic equation Θ(ω) = 1 such that Θ(ω) > 1 (< 1) for
ω < ω0 (> ω0).
Next we show that when ω0 < 0, all complex solutions of the equation Θ(ω) = 1
will have a negative real part. Let z ∈ C and Θ(z) = 1. If Re{z} ≥ 0, then












Since Θ(ω) is a decreasing function, from the above inequality we have Re{z} ≤ ω0,
which is a contradiction. This implies that Re{z} < 0 whenever ω0 < 0.
Note that R0 := Θ(0). Thus, ω0 < 0 (> 0) if R0 < 1 (> 1). It follows that the
disease-free state E∗ is locally asymptotically stable if R0 < 1 and unstable if R0 > 1.
This completes the proof.
2.3.3 Interpretation of R0
For vector-borne diseases such as malaria, the reproduction number in general
includes two components. One is related to human-to-mosquito transmission, which
we denote by Rhm and the other is related to mosquito-to-human transmission, which
we denote by Rmh. As a consequence, the overall reproduction number is (usually)
a geometric mean
√RhmRmh. The expression for R0 defined in (2.36) is actually
RhmRmh, omitting the radical. However, this does not change the threshold condition
R0 = 1 for whether the disease will die out or persist in the population. For notational
convenience, we will use the expression of R0 in (2.36) to describe its biological
interpretation, and show that it gives the average number of new infected mosquitoes
that one infected mosquito can produce when introduced into a completely susceptible
population during its entire infective period.




























































PA(a, σ, 0) = e
− ∫ aσ (γA(τ)+µ(τ)+pλ¯2(τ))dτ . (2.38)








is the number of individuals infected at age σ with symptomatic infection by one









σ (γ(τ)+µ(τ)+δ(τ))dτdσ =: I(a) (2.40)
gives the density of symptomatic infectious humans of age a ∈ (0,∞) who got infected
at age σ < a and have not recovered or died at age a. The number of mosquitoes












N¯vda, which is the first term in (2.37).
Similarly, the second (third) term in (2.37) represents the contribution from
asymptomatic infectious individuals who have not (have) passed through the asymp-








σ (γA(τ)+µ(τ)+pλ¯2(τ))dτdσ =: IA1(a) (2.42)
gives the density of asymptomatic infectious humans of age a ∈ (0,∞) who were
infected at age σ < a but have not passed through the asymptomatic chronic stage,
and have not recovered or died at age a. Thus, the number of mosquitoes infected by







N¯vda, which is the second term in (2.37). For the
third term in (2.37), JA(σ) is the density of asymptomatic infected humans who were
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infected at age ξ < σ and were still alive and in the asymptomatic infectious- chronic













σ (γA(τ)+µ(τ)+pλ¯2(τ))dτdσ =: IA2(a) (2.44)
gives the density of asymptomatic infectious humans who have been through the
asymptomatic chronic stage, relapsed at age σ < a, and have not recovered or
died at age a. Thus, the number of mosquitoes infected by asymptomatic infec-





N¯vda, which is the third term in (2.37).
Observe that the third term in (2.37) would not be present in the expression for
R0 if the relapse would only occur due to infected mosquitoes (Iv(t)) instead of due
to susceptible mosquitoes (Sv(t)). This is because the term λ2(t, a)jA(t, a) in (2.5)
would vanish when linearizing system (2.5) around the disease free equilibrium.
The R0 formula (2.37) for the continuous age-structured model can be very
helpful for example for evaluating age-dependent vaccination strategies (see, e.g.
[21, 22, 132, 133]). For ease of numerical computations, we will derive a system of
ordinary differential equations from the PDE system by assuming that the human
population can be divided into several age groups such that the model parameters
within each age group are constant. We will use the ODE system to carry out numer-
ical simulations to examine the influence of various factors on both the reproduction
number and the disease prevalence.
2.4 Reduction of the PDE model to an ODE system for discrete age
groups
Due to the difficulty of analyzing the dependence of disease prevalence to model
parameters from the PDE model in Section 2.2, we follow the approach of Heth-
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cote [29] to convert the PDE system to an ODE system. This can be done by divid-
ing the human population into n age groups defined by the n disjoint age intervals,
[a0, a1), [a1, a2), . . . , [an−1, an =∞) and assuming that the model parameters in (2.5)
are constant in each interval. These age intervals do not need to have equal length.
It is important to point out that the ODE system obtained using this approach will
include a transition term from one age group to the next due to aging. Although an
ODE model that includes these aging terms may increase the difficulty of model anal-
ysis more dramatically than multiple age-group models ignoring these terms (which
seem to be common), it is necessary to consider the aging factor in order for the ODE
system to be comparable to the PDE system.
2.4.1 Derivation of the ODE model
We focus again on the limiting system of the PDE model with the stable age
distribution for humans n(t, a) = n(a) = ΛP (a), and the constant total population
sizes N¯h and N¯v for humans and mosquitoes, respectively. Let the constant parameter
values in the age interval a ∈ [ak−1, ak), k = 1, . . . , n, be denoted by f(a) = fk, d(a) =
dk, dA(a) = dAk , c(a) = ck, cA(a) = cAk , δ(a) = δk, γ(a) = γk,





denote the number of humans in age group k (i.e., ages in [ak−1, ak)) at time t. Then
the total number of humans is N¯h =
n∑
k=1
Nk(t). Similarly, let Ik(t), IAk(t), JAk(t)





































To derive the ODE for the susceptible humans of age group k we integrate the
s(t, a) equation in the limiting PDE system over the age interval [ak−1, ak), which
yields
S ′k(t) + s(t, ak)− s(t, ak−1) = −λ1k(t)Sk(t)− µkSk(t) + γkIk(t). (2.49)
From [29], s(t, ak) = αkSk(t) where αk is the aging rate out of the age group k, which









, for k = 1, ..., n− 1, (2.50)
and αn = 0. This rate, αk, for each age group is the same for all epidemiological
classes (i.e., s, i, iA, jA), and is a constant, independent of the state variables.













f(a)n(t, a)da = Λ
∫ ∞
0
f(a)P (a)da = Λ. (2.51)




fkNk(t) = Λ. (2.52)
Replacing s(t, a1) in (2.49) by α1S1(t) and using (2.52) for s(t, 0) we obtain
d
dt
S1(t) = Λ− α1S1(t)− λ11(t)S1(t)− µkS1(t) + γ1I1(t). (2.53)
Similarly, replacing the s(t, ak) in (2.49) by αkSk(t) for k ≥ 2 we get
S ′k(t) = −λ1k(t)Sk(t)− µkSk(t) + γkIk(t)− αkSk(t) + αk−1Sk−1(t). (2.54)
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We can use the same approach for other equations in system (2.5) and reduce the
PDE system in Section 2.2 to the following system of ordinary differential equations
S ′1(t) = Λ− (α1 + λ11(t) + µ1)S1(t) + γ1I1(t)
I ′1(t) = kλ11(t)S1(t)− (γ1 + µ1 + δ1 + α1)I1(t)
I ′A1(t) = (1− k)λ11(t)S1(t) + pλ21(t)JA1(t)− (γA1 + µ1 + α1)IA1(t)
J ′A1(t) = −(pλ21(t) + µ1 + α1)JA1(t) + γA1IA1(t)
S ′k(t) = −(αk + λ1k(t) + µk)Sk(t) + γkIk(t) + αk−1Sk−1(t)
I ′k(t) = kλ1k(t)Sk(t)− (γk + µk + δk + αk)Ik(t) + αk−1Ik−1(t)
I ′Ak(t) = (1− k)λ1k(t)Sk(t) + pλ2k(t)JAk(t)− (γAk + µk + αk)IAk(t)
+αk−1IAk−1(t)
J ′Ak(t) = −(pλ2k(t) + µk + αk)JAk(t) + γAkIAk(t) + αk−1JAk−1(t)
S ′v(t) = bv − λ˜v(t)Sv(t)− µvSv(t)
I ′v(t) = λ˜v(t)Sv(t)− µvIv(t) (2.55)
for k = 2, . . . , n with αn = 0.















for k = 1, ..., n.
2.4.2 The basic reproduction number R0 for the ODE model (2.55)
Although the formula for R0 given in (2.37) for continuous age is more convenient
to apply in some cases (e.g., age-dependent optimal vaccination problems considered
in [21,22,132,133]), the formula of R0 derived from the ODE system could be much
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easier to apply in other studies, particularly for numerical computations. We derive
a formula of R0 for discrete age using the next generation matrix approach [10]. The















, 0, ..., 0, N¯v, 0
)
. (2.57)
Note that the first n components of E¯ describe the age distribution of the population






, k = 1, 2, · · · , n (αn = 0). (2.58)
For ease of notation, let














for k = 1, 2, · · · , n with αn = 0. Note that Tk represents the death and aging
adjusted mean duration that individuals stay in the Ik stage each time they visit
it, TAk represents the death and aging adjusted mean period of an asymptomatic
infected individual during each visit to the IAk class in age group k, and Tv is the
mean infectious period of mosquitoes. The fraction θk represents the proportion of
symptomatic infectious humans in age group k that survived death and aged to age
group k + 1.
The system (2.55) has 3n+ 1 infected variables, which will be ordered as
(I1, IA1 , JA1 , ..., In, IAn , JAn , Iv).
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We adopt the notation in [10] to organize the matrix F for new infections and the




















(pλ21(t) + µ1 + α1)JA1(t)− γA1IA1(t)
...
γkIk(t)− αk−1Ik−1(t)
−pλ2k(t)JAk(t) + γAkIAk(t)− αk−1IAk−1(t)
(pλ2k(t) + µk + αk)JAk(t)− γAkIAk(t)− αk−1JAk−1(t)
...
(γn + µn + δn)In(t)− αn−1In−1(t)
−pλ2n(t)JAn(t) + (γAn + µn)IAn(t)− αn−1IAn−1(t)

























 , AAk :=
 γ¯Ak −pβdAk N¯vN¯h
−γAk pβdAk N¯vN¯h + µk + αk
 . (2.62)
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Then the Jacobian matrices of F and V at the DFE are then given by respectively
F =

0 0 · · · 0 0 · · · 0 0 kh1
0 0 · · · 0 0 · · · 0 0 (1− k)~hA1
...
...
0 0 · · · 0 0 · · · 0 0 khk
0 0 · · · 0 0 · · · 0 0 (1− k)~hAk
...
...
0 0 · · · 0 0 · · · 0 0 khn
0 0 · · · 0 0 · · · 0 0 (1− k)~hAn






γ¯1 0 0 0 · · · 0 0 0 0 0
0 AA1 0 0 0 0 0 0 0
−α1 0 γ¯2 0 · · · 0 0 0 0 0
0 −C1 0 AA2 · · · 0 0 0 0 0
...
...
0 0 0 0 · · · γ¯n−1 0 0 0 0
0 0 0 0 · · · 0 AAn−1 0 0 0
0 0 0 0 · · · −αn−1 0 γ¯n 0 0
0 0 0 0 · · · 0 −Cn−1 0 AAn 0




Note that the V −1 matrix can be written as
V −1=

T1 0 0 0 · · · 0 0 0
0 A−1A1 0 0 · · · 0 0 0




























αn−kA−1An−k· · · 0 A−1An 0
0 0 0 0 · · · 0 0 Tv

(2.65)
Thus, the matrix FV −1 is of the following form:
FV −1=

0 0 · · · 0 0 kh1Tv
0 0 · · · 0 0 (1− k)~hA1Tv
...
...
0 0 · · · 0 0 khkTv
0 0 · · · 0 0 (1− k)~hAkTv
...
...
0 0 · · · 0 0 khnTv
0 0 · · · 0 0 (1− k)~hAnTv













Fn,j · V −1j,n−2 = vnTn, Fn,j · V −1j,n−1 = ~vAnA−1n . (2.69)
Notice that FV −1 is of rank two and that its trace tr(FV −1) = 0. Therefore, the










−1) is the sum of the principal minors of order two of the matrix FV −1.
The case of one age group
To facilitate the biological interpretation of R0 given by (2.70) we first examine
the case of one age group, i.e., n = 1. A more detailed description for the matrices F
and V can be found in Appendix A.
In this case the matrix FV −1 becomes
FV −1=

0 0 0 kβd1
N¯h
N¯1Tv
0 0 0 (1−k)βd1
N¯h
N¯1Tv



















































kh1Tvv1T1 + (1− k)h1TvvA1Th1P IA1IA1 . (2.72)
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The biological meaning of the quantities in (2.72) are the following: Tv and T1 are as





is the number of humans infected by one mosquito per unit
of time in a completely susceptible human population; v1 := βc1
N¯v
N¯h
is the number of
mosquitoes (in a susceptible mosquito population) that one symptomatic infectious
human can infect per unit of time; vA1 := βcA1
N¯v
N¯h
is the number of mosquitoes (in a
susceptible mosquito population) that one asymptomatic infectious human can infect
per unit of time; Th1 :=
1
µ1














is the probability that an individual, who entered the IA1  JA1 loop through IA1 , is
in IA1 . A more detailed explanation for P
IA1
IA1
is given in Appendix A.
The case of n = 2 age groups
For the case of n = 2, the matrix FV −1 in (2.66) reduces to
FV −1=

0 0 0 0 kh1Tv
0 0 0 0 (1− k)~hA1Tv
0 0 0 0 kh2Tv
0 0 0 0 (1− k)~hA2Tv












where vk, ~hAk , hk, ~vAk and AAk (k = 1, 2) are given in (2.61) and (2.62) with α2 = 0.
Notice that for k = 1, 2, ~hAk is a 2 × 1 vector, ~vAk a 1 × 2 vector and AAk a 2 × 2
matrix. Hence, the matrix FV −1 has dimension seven.



























Here, the notation (e.g., hk, vk,P
IA1
IA1
) have similar meanings as in the case of n = 1




and h2 = β
d2
N¯h
N¯2 are the numbers of humans infected by one mosquito per unit of
time in the completely susceptible human populations in group one and group two,
respectively. vk = βck
N¯v
N¯h
is the number of mosquitoes (in a susceptible mosquito pop-




is the number of mosquitoes (in a susceptible mosquito population) that






are the average stage durations of individuals in age group one and age
group two, respectively; and θh1 =
α1
α1 + µ1
represents the disease independent prob-










ρk + µk + αk
γ¯Ak + ρk
, where ρk = pβdAk
N¯v
N¯h
, k = 1, 2, (2.76)
represents the probability that an individual, who entered the IAk  JAk loop through








represents the probability that an individual that entered the IA1  JA1 loop through








represents the probability that an individual, who entered the IA2  JA2 loop through
JA2 , is in IA2 . A more detailed explanation on the derivation of these quantities can
be found in Appendix A.
Therefore, (2.75) represents the secondary number of infected mosquitoes gen-
erated by an infectious mosquito via humans in different age groups and different
stages. Specifically, the first term corresponds to the contribution from symptomatic
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infectious individuals who were initially infected in age group one (a fraction θ1 aged
to group two). The second term corresponds to the contribution from asymptomatic
individuals who were initially infected in age group one. These individuals enter the
IA1  JA1 loop through IA1 and then they undergo one of the following three sce-
narios at a given time: i) they have not aged and are currently in IA1 where they
can infect mosquitoes (see the term vA1Th1P
IA1
IA1
in (2.75)); ii) they aged while in IA1







Th2 in (2.75)); and iii) they aged while in JA1 (so they entered the








The third term in (2.75) corresponds to the contribution from symptomatic infec-
tious individuals who were initially infected in age group two; and the fourth term
correspond to the contribution from asymptomatic individuals who were initially in-
fected in age group two.
Notice that, as we have already mentioned for the PDE R0, various terms in the
expression for R0, (2.75), that involve looping would not have appeared without the
assumption of relapse triggered by susceptible mosquito bites and instead by infec-
tious mosquito bites.
It is possible to rewrite the expression for R0 in (2.75) as a linear combination of
reproduction numbers of a children population only and an adult population only, in
the following way:
R20 = R201 +R202 +
h1θ1
h2






for k = 1, and






















for k > 1,
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where
R201 = kh1Tvv1T1︸ ︷︷ ︸
=:R201S




R202 = kh2Tvv2T2︸ ︷︷ ︸
=:R202S
+ (1− k)h2TvvA2Th2P IA2IA2︸ ︷︷ ︸
=:R202A
(2.82)
are the reproduction numbers for a children only and adult only population (no
aging involved) respectively, with their symptomatic (R201S, R202S) and asymptomatic
(R201A, R202A) contributions. For example in the case k = 1 (in which case our model
reduces to an SIS model), the term (h1θ1)/h2 in (2.79), represents the ratio of newly
infected children that age and newly infected adults. This demonstrates that when
aging from one group to the other is involved, the basic reproduction number is not
solely a sum of contributions of each age group, but has also extra terms that arise
from the equations being coupled by aging.
2.5 Numerical simulations and results
To illustrate how the disease dynamics in different groups may be influenced by
various factors represented by the model parameters, we carried out an extensive
number of numerical simulations of the ODE system in the case of two age groups.
Since the simulation results depend on the choice of parameter values, we performed
uncertainty and sensitivity analyses using the Latin Hypercube Sampling approach.
These analyses are conducted for both the reproduction number R0 and the disease
prevalence.
2.5.1 Parameter values and calibration of the model
We developed a computer code using the R computer Language and Environment
[134] for the ODE system (2.55) for two age groups: children from 0 to 15 years and
adults from 16 years on. Although we do not have an analytic result for the existence
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and stability of endemic equilibrium points, our large number of simulations of the
system suggest that when R0 > 1 there is a unique stable endemic equilibrium. We
run the simulations until the endemic equilibrium has been reached (which is 25 years
for the parameter values we used). We calibrated the mosquito demographics such
that the mosquito population remains constant in time, and calibrated the human
birth and death rates such that the population size and age distribution in the absence
of disease remain the same. We aim to study malaria in Sub-Saharan Africa, which is
greatly affected by malaria. Hence all model parameters and demographics are chosen
from data concerning that region. Based on the demographic data reported in [135],
the initial population age distribution is chosen to be 45% children and 55% adults,
which will be used for the fractions N¯1/N¯h = 0.45 and N¯2/N¯h = 0.55, respectively.
For a given Sub-Saharan population in Africa, assume that the total population N¯h
is known. Notice that, when using the DFE N¯1 = Λ/(µ1 + α1), fixing µ1 = 0.0002
(day−1) and assuming the aging rate in group one to be α1 = 1/(15 ∗ 365) per day,










Some of the model parameters have been commonly used in previous modeling
studies on malaria and can be adopted for our model. For the remaining parameters,
particularly the ones that are specific to our model, values are determined so that
the simulation results are consistent with available data related to malaria preva-
lence. For example, the reduction of the population (at the endemic equilibrium) due
to disease death is on average 0.25% [54, 56], which our model also produces. We
define symptomatic (asymptomatic infectious) prevalence in age group k (k = 1, 2)
as the fraction of symptomatic (asymptomatic) infectious individuals at the equilib-
rium, i.e., Ik/N¯h (IAk/N¯h). Our results show a symptomatic prevalence of children
of approximately 3.2% (see Fig. 2.2(a) in Section 2.5.2). This is concordant with
collected observations in countries of Sub-Saharan Africa like Tanzania, where in
regions where seasons are often characterized by mosquito bionomics [136,137], chil-
dren’s prevalence ranges between approximately 2.5% and 15% [136,138]. Out of the
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symptomatic cases, the majority correspond to children [139], as can be also seen in
Fig. 2.2(a) of Section 2.5.2. The parameter k represents the proportion of suscep-
tible individuals who become symptomatic upon infection, and depends on innate
resistance of individuals. For example genetically determined traits are selected over
generations and contribute to the innate protection against the risk of clinical ill-
ness [140–143]. In this study, we assume k to be a constant, although it would be of
interest for future work to consider k to be age dependent if significant evidence for it
can be found in the literature, and of which we do not have sufficient knowledge. In
a stable perennial transmission region, the mosquito population starts to grow with
the onset of the rainy season and relapse of asymptomatic chronic infected individ-
uals gets triggered by non-infectious mosquito bites [125]. The value 0.4 given to p
represents a rainy season of at least 4.8 months.
As for the two age groups we assume for the parameters representing human
susceptibility of becoming infectious, that d2 < d1 due to anti-parasite immunity
acquired by adults [58], even after a few malaria attacks [144]. Because of the higher
anti-parasite immunity of adults, we also assume dA2 < dA1 . It can be argued, that
asymptomatic adults have fewer asexual parasites in their blood as compared to
asymptomatic children, and are therefore less likely to create gametocytes.
For the parameters representing human infectiousness, we assume c2 < c1 due to
a fast gain of transmission-reducing immunity for susceptible humans, as observed
for malaria-naive individuals, and in general a higher gametocyte density observed in
children [118,145]. Also, a higher anti-parasite immunity in asymptomatic adults pro-
duces a lower gametocyte prevalence for these individuals compared to children. Since
the presence of gametocytes in the blood is necessary to acquire transmission-reducing
immunity, this could imply a lower transmission-reducing immunity in adults than
children [118], which is why we made the assumption cA1 < cA2 , as other studies also
suggest [146]. We chose c2 < cA2 since it has been observed that clinical symptoms
stimulate gametocytogenesis [147] and therefore symptomatic adults could develop a
better transmission-reducing immunity than asymptomatic individuals. Also, stud-
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ies have observed that infectiousness of asymptomatic carriers is higher than symp-
tomatic, once gametocytes are present in the blood [148]. Unlike for adults, we assume
for children cA1 < c1, since children are longer exposed to gametocytes because of the
assumed higher probability of relapse (dA2 < dA1) and the observation that they can
show a high density parasitemia without showing symptoms [147,149,150]. Therefore,
higher gametocyte densities in children induce higher levels of transmission-reducing
activity [146], which we assume that asymptomatic children keep developing, unlike
adults that we assume lose it due to increasing anti-asexual parasite immunity [145].
Complications due to malaria are worse in children, and their recovery rate is
lower than for adults, which is why we chose δ2 < δ1 and γ1 < γ2. We assumed a
lower duration in the asymptomatic infectious stage for both age groups compared
to the time spent in the symptomatic class, as well as a decreasing amount of time
spent in the asymptomatic infectious class with age (γA1 < γA2) [149,150].
The aging rate from one age group to the other is represented by the parameter
α1 and is chosen to be 1/15/365 assuming that each age is evenly distributed in the
children’s age group, such that a fraction of 1/15 individuals move each year from
age group one to age group two.
We used the parameters that satisfy our assumptions as base line values for our
simulations. Because of the uncertainty of some of the assumptions (due to the
difficulties in field studies), in Section 2.5.2 we include a choice of a reasonable range
for each of the parameters to check robustness of our results. More details on the
parameter values and their references can be found in Tables 2.3 and 2.4.
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Table 2.3.
Age-independent Parameter values and ranges used in the numerical sim-
ulations as well as in the uncertainty and sensitivity analyses.
Parameters Two age groups References Units
Fixed Values
bv 150 calibrated md
−1
µv 0.03 151,152 d
−1









T (0.1,0.5) 125 unitless
T:=triangular distribution w/ peak at the fixed value shown above each range.
U:= uniform distribution.
h:=humans, m:=mosquitoes, b:=bite, d:=day.
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Table 2.4.
Age-dependent parameter values and ranges used in the numerical simu-
lations as well as in the uncertainty and sensitivity analyses.
Parameters Two age groups References Units
Age-Dependent Age Group 1 Age Group 2
µk 0.0002 α1N¯1/N¯2 135 d
−1




T (0.000001,0.0001) T (0,0.0003) 153 d−1
dk
0.03 0.015
T (0.01,0.08) T (0.005,0.08) 153 hb−1
dAk
0.02 0.009
T (0.005,0.06) T (0.006,0.015) 125 hb−1
ck
0.3 0.24
T (0.05,0.4) T (0.12,0.4) 153 mb−1
cAk
0.12 0.4
T (0.005,0.15) T (0.01,0.8) 146,153 mb−1
γk
1/100 1/80
T (1/105,1/80) T (1/90,1/70) 153 d−1
γAk
1/65 1/50
T (1/100,1/30) T (1/80,1/30) 123,149 d−1
T:=triangular distribution w/ peak at the fixed value shown above each range.
U:= uniform distribution.
h:=humans, m:=mosquitoes, b:=bite, d:=day.
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2.5.2 Simulations results and interpretations
We conducted numerical simulations under two scenarios. In the first scenario we
used a fixed set of parameter values, and in the second scenario the parameters are
allowed to take on values from a set of given regions with a fixed distribution such
that the previously fixed value would be the most probable one. In the case of variable
parameter values, 1, 000 simulations were run with parameter values chosen randomly
out of their respective ranges. These simulations can be used to demonstrate the
sensitivity of model outcomes to the uncertainty of parameter choices.
Simulations and results with fixed parameter values
For the case of fixed parameter values, the choice of parameters leads to the repro-
duction number R0 = 3.4. We are mostly interested in the fraction of symptomatic
(I), asymptomatic infectious (IA), and asymptomatic chronic infected (JA) individu-
als, as well as the fractions of individuals for each age group (group 1 for children and
group 2 for adults) of these classes and their relative densities. Figs. 2.2 (a)-(c) illus-
trate the fractions of human populations in each of the infected classes within each age
group. We observe that for this set of parameter values the endemic equilibrium has
been reached after 25 years. Fig. 2.2 (a) and (b) show that the asymptomatic infec-
tious individuals contribute 2-3 times more than symptomatic infectious individuals.
In particular, the fraction of asymptomatic infectious individuals (gametocyte carri-
ers), which are the asymptomatic individuals with parasites in their blood capable of
infecting mosquitoes, can be observed in Fig. 2.2 (b). There, we can see a combined
age group prevalence of 16% and a decrease in prevalence with age, which has also
been observed in previous studies [123]. Detection of low P.falciparum parasitemia
is a great challenge. Methods like the classic thick blood smear method or rapid
diagnostic tests (RDTs) often show decreased sensitivity at lower parasitemia. It has
been demonstrated that up to an overall asymptomatic adult prevalence of 52% can
be detected by more sensitive tests [121], a result that our model confirms (see Fig. 2.3
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(d)) for R0 > 2. Studies have also estimated, that in some malaria endemic settings
90% of the exposed individuals are likely infected with asymptomatic malaria [154].
For that, our model gives an estimate of approximately 80% (Figs. 2.3 (c) and (d))
when combining overall asymptomatic children and adult populations. This value is
close to what can be found in the literature and represents individuals with sexual
and asexual parasites in their blood. Figs. 2.3 (c) and (d) also show that the propor-
tion of overall asymptomatic infection is higher among adults than among children,
as can be expected for a malaria endemic area [58, 59]. Because of the difficulty of
detecting low parasitemia it is important to develop mathematical models that can
give information about individuals with low parasitemia. In our model, we call these
individuals asymptomatic chronic parasite carriers (JA), who serve as a reservoir for
malaria parasites before the parasites in their body develop into gametocytes.
Our simulations show that the majority of symptomatic infectious (I) and asymp-
tomatic infectious (IA) individuals are children (see Figs. 2.2(a) and (b)), which is
consistent with observed patterns of malaria prevalence and the higher expected ga-
metocyte densities in children [118, 139, 145]. Nevertheless it is of great importance
to notice that over 60% of the population is asymptomatic chronic infected, with
twice as many adults than children (see Fig. 2.2 (c))). Adults in this class could
be responsible for the persistence of malaria in many regions of Sub-Saharan Africa
and need to be taken into consideration. They possibly undergo a relapse of human
infectiousness and contribute to the infectious pool for mosquitoes. This indicates
that the number of infected cases might be underestimated in field studies due to
commonly undetectable parasite loads.
The fractions of infectious and susceptible mosquitoes are plotted in Fig. 2.2(d).
For ease of comparison, Figs. 2.2(e) and (f) show the plots of relative magnitudes of
different infected classes within each age group and between age groups. In these plots,
we observe a similar trend among age groups for all infected classes. Nevertheless,
a significantly higher fraction of asymptomatic chronic infected individuals (JA) is
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Figure 2.2. Numerical simulations of the ODE model with two age groups
using fixed parameter values given in Tables 2.3 and 2.4. These parameter
values produce an R0 of 3.4. Plots in (a)-(c) show the fractions of symp-
tomatic infectious individuals, asymptomatic infectious individuals, and
asymptomatic chronic infected individuals, respectively, for the two age
groups. The plot in (d) is for the mosquito population. Plots in (e) and
(f) show all four epidemiological classes for groups 1 and 2, respectively.
observed for age group 2 compared to age group 1 relative to their fractions in I and
IA, which reinforces the importance of asymptomatic chronic infected adults.
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Figure 2.3. Numerical simulations of the ODE model with two age groups
for different R0 values, obtained from varying β. For the other parame-
ters the values in Tables 2.3 and 2.4 were used. Plots (a) and (b) show
the fractions of symptomatic infectious individuals for age group 1 and
2 respectively, while (c) and (d) illustrate overall asymptomatic (asymp-
tomatic infectious and asymptomatic chronic infected) individuals for the
two age groups.
In Figs. 2.2(a),(b),(c), the curve for the total fractions (two age groups combined)
for each of the infected classes and the curves in Fig. 2.3 will also be useful later for
the comparison with the simulations with variable parameter values.
Fig. 2.3 also shows how different R0 values affect the value at equilibrium (preva-
lence), and is therefore an indicator of what happens at the endemic state. For
R0 = .83 < 1 the disease dies out as expected. For values of R0 = 2, 3, 4, 5 > 1, we
reach after 25 years a non-trivial equilibrium. The prevalence of symptomatic children
(Fig. 2.3 (a)), asymptomatic children (Fig. 2.3 (c)) and asymptomatic adults (Fig. 2.3
(d)) decrease when R0 decreases. This can also be observed in Fig. 2.4, which shows
R0 vs symptomatic and asymptomatic prevalence of age group 1 (plot (a)) and age
group 2 (plot (b)). But it is interesting to notice that for the symptomatic adult
population there is a slight increase in prevalence when lowering R0 (see Fig. 2.2 (b)
and Fig. 2.4 (b) black curve). This indicates that a policy based solely on lowering
R0 might come with a cost of appearance of symptomatic adult cases, which might
need to be accounted for.
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Figure 2.4. The plots illustrate R0 versus percent of age group 1 (plot (a))
and age group 2 (plot (b)) of Symptomatic (black line) and Asymptomatic
(grey line) individuals, taken at equilibrium.
Uncertainty analysis
Although we have chosen the parameter values based on available information, it
is important to examine how the uncertainty associated with the estimates of these
parameter values may influence the model outcomes, such as the disease prevalence
and the reproduction number. To do this, we consider a range of values for most of
the parameters (as described in Tables 2.3 and 2.4). Using a method based on Latin
Hypercube Sampling, we simultaneously varied these parameters and performed un-
certainty and sensitivity analyses. For the probability density function (pdf) used
in Latin Hypercube Sampling, we used either a triangular (T) or uniform (U) distri-
bution (see Tables 2.3 and 2.4). For each pdf, we divided the parameter range into
equally probable regions (one for each simulation), and sampled each region exactly
once, creating a Latin Hypercube [155,156]. This statistical sampling method allows
us to explore the dynamics of our model more efficiently and broadly than varying pa-
rameters individually, by using each parameter value chosen from the range only once
in the simulations [155]. Our simulation results suggest that 1, 000 sets of parameter
values are enough to produce consistent results.
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We conducted uncertainty analysis for the prevalence of malaria and for the re-
production number R0. To illustrate the variability in prevalence that results from
uncertainty in the parameter values, we present in Figs. 2.5 and 2.6 the box plots of
the fraction of individuals over time. Each plot divides the results of 1, 000 simula-
tions into quartiles at each moment in time, plotted every six months for 25 years.
The median value is represented by the thicker curve and the box around the me-
dian value represents the interquartile range. The dotted lines extend to cover the
95% confidence interval for our outcome distributions. It shows a very similar trend
among the 1, 000 simulations, with the interquartile range having the same shape and
a small range of values concentrated around the median. We can compare the median
values from the uncertainty analysis in Figs. 2.5 and 2.6 with the simulation results
presented in Figs. 2.2 (a)-(d) and 2.3 respectively, when fixed parameter values were
used. We observe that the medians in the plots for I, IA and JA in Figs. 2.5 (a)-(c)
and for I1, I2, IA1 + JA1 , IA2 + JA2 in Fig. 2.6 are very close to the corresponding
curves in Figs. 2.2 (a)-(c) (see the thin curve) and the trend of the curves seen in
Fig. 2.3 for R0 > 1. This indicates that the choice of parameter ranges is robust.
Figs. 2.7(a) and (b) are similar to Figs. 2.5 and 2.6 except that they provide
information for the frequency distributions of infections at the endemic equilibrium
(prevalence). For example, Fig. 2.7(a) shows the symptomatic prevalence in children
relative to the total symptomatic prevalence, I1/(I1 + I2), and Fig. 2.7(b) is for the
asymptomatic prevalence in adults relative to the total asymptomatic prevalence,
(IA2 + JA2)/(IA1 + JA1 + IA2 + JA2). The black triangle labels the mean of the 1, 000
simulations, and the gray triangle indicates the value from the simulations with fixed
parameter values. The model predicts that among the symptomatic infections (I),
children contribute to the majority of the cases (see Fig. 2.7(a)), which is concordant
with collected observations [139]. We observe from Fig. 2.7(b) that adults form a
majority of the asymptomatic infections (IA + JA), which is also consistent with
reported data [157]. This again confirms that the model is capable of producing
reasonable outcomes in terms of malaria prevalence.
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Figure 2.5. Time-dependent uncertainty analysis with 1, 000 simulations
and parameter values from distributions given in Tables 2.3 and 2.4. Plots
in (a)-(c) illustrate time-dependent density distributions of the popula-
tions in the symptomatic infectious (I), asymptomatic infectious (IA) and
asymptomatic chronic infected (JA) classes, respectively, and (d) shows
the fraction of infectious mosquitoes. Each graph consists of boxplots plot-
ted every six months for 25 years. The thick black curve is the median
value and the interquartile range is the box around the median value. The
dotted lines extend to cover the 95% confidence interval for our outcome
distributions.
Figure 2.6. Time-dependent uncertainty analysis with 1, 000 simulations
and parameter values from distributions given in Tables 2.3 and 2.4.
Plots (a) and (b) illustrate the time-dependent density distributions of
the symptomatic infectious class for age group 1 and 2, respectively, while
(c) and (d) show that of the combined asymptomatic classes (asympt. in-
fectious and asympt. chronic infected) for age group 1 and 2, respectively.
The thick black curve is the median value and the interquartile range is
the box around the median value. The dotted lines extend to cover the
95% confidence interval for our outcome distributions.
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Figure 2.7. Results of the uncertainty analysis from 1, 000 simulations
with variable parameter values for (a) the symptomatic prevalence in chil-
dren relative to symptomatic prevalence, (b) asymptomatic infectious and
asymptomatic chronic prevalence in adults relative to asymptomatic in-
fectious and asymptomatic chronic prevalence, and (c) the reproduction
number R0. The black triangle represents the mean prevalence in these
1, 000 simulations with the median represented by a black dot, while the
gray triangle indicates the prevalence from the fixed parameter setting.
See text for more detailed explanations.
Fig. 2.7(c) illustrates the distribution of the values of the reproduction number
R0 in the 1, 000 simulations under the chosen parameter ranges. Let Rv0 denote
the mean of the distribution (v for variable parameter values) and let Rf0 denote the
reproduction number obtained when the fixed parameter values are used (f for fixed).
The black triangle labels Rv0 = 4.01 and the gray triangle indicates Rf0 = 3.4. The
relatively low variability of the distribution and the fact that Rv0 is very close to Rf0
indicate that the chosen parameter ranges are robust. Notice in Fig. 2.7 that in all
simulations we have an R0 value greater than 1, indicating that malaria is likely to
persist, as observed in malaria endemic regions.
Sensitivity analysis
To examine the sensitivity of the model outcomes (e.g., the reproduction number
R0 and the time-dependent disease prevalence) to model parameters, we calculate
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partial rank correlation coefficients (PRCC) using the same 1, 000 sets of parameter
values. This statistical method produces a sensitivity index, which determines the
effect of varying one parameter on the outcome while fixing other parameters at
the expected value from their pdf [155, 156, 158]. These sensitivity indices have a
value between −1 and 1. A positive (negative) PRCC indicates a positive (negative)
relationship between the parameter and outcome. Furthermore, the absolute values
of PRCC indices can help determine which parameter value(s) may have the strongest
influence on the outcome variable, with a magnitude of 0 having almost no influence
and 1 having the most influence [155,156,158,159].
Fig. 2.8 shows the PRCC for (a) the reproduction number R0, (b) combined
symptomatic and asymptomatic infectious prevalence, (c) symptomatic prevalence
alone, and (d) asymptomatic infectious prevalence alone.
Figure 2.8. Outcomes from the sensitivity analysis with parameter ranges
defined in Tables 2.3 and 2.4. Partial rank correlation coefficients (PRCC)
for each parameter are plotted for four epidemiological outcomes: (a)
R0, (b) overall infectious prevalence, (c) symptomatic prevalence, and (d)
asymptomatic infectious prevalence. A larger absolute value of the PRCC
indicates a greater impact on the epidemiological outcome, with positive
(negative) values indicating a positive (negative) relationship.
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First, we remark that disease-induced death (δ1, δ2) is not included in Fig. 2.8 since it
had a minimal impact on all of the epidemiological outcomes. Next, we will give a brief
description of the impact that parameter values have on each of the epidemiological
outcomes based on Fig. 2.8 and how age of the human host plays a role.
The parameters which have the most influence onR0 can be observed in Fig. 2.8(a).
The biting rate β influences R0 most, followed by k (symptomatic fraction after a
susceptible individual becomes infected) and d2 (probability of infection per bite in
susceptible adults). It is important to notice that k affects R0 negatively, which
may be counterintuitive. This is closely related to the unique feature in the model
that chronically infected individuals may relapse when bitten by even susceptible
mosquitoes. The intensity of the relapse depends heavily on the ratio of human to
mosquito in addition to other parameters as indicated in the expression for R0 (see
(2.75)). Such kind of negative relationship between R0 and k cannot be identified if
the model does not consider relapse triggered by susceptible mosquitoes. The differ-
ence between age groups on the parameters that affectR0 can be observed by noticing
that the magnitudes of PRCC of dA2 and γA2 are larger than that of dA1 and γA1 , re-
spectively. This indicates that the R0 value is more strongly influenced by relapse of
the adult group. The figure shows that in general infectiousness of individuals in the
first age group (c1, cA1) does not have as much influence over R0 as the infectiousness
of those in the second age group (c2, cA2). Last we can observe, that the difference in
magnitude of d1 and d2 on the outcome R0 is not significant.
Figs. 2.8 (b), (c) and (d) show infectious prevalences of the disease. When con-
sidering the sensitivity of malaria prevalence to the change in parameters, the most
influential parameters identified may not be the same as the ones when sensitivity of
R0 was being analyzed.
Figs. 2.8(b) and (d) suggests that, for the overall infectious prevalence and asymp-
tomatic infectious prevalence respectively, the most influential parameters are p (pro-
portion of the year with high mosquito presence), dA1 (probability of relapse of age
group 1), followed by β. The parameter d1 is noticeably more influential than its
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equivalent for age group 2 (d2), as was not the case for R0, since in the case of R0,
the susceptibility d1 and d2 of the two groups have a similar effect. In general, it is
interesting to notice in Figs. 2.8(b) and (d), that most of the influential parameters
correspond to age group 1. Moreover, the parameters with the most influence are the
ones related to relapse. Also, infectiousness of humans to mosquitoes (i.e., ci and cAi,
i = 1, 2) as well as recovery rates (γi, i = 1, 2) have not a significant influence on the
overall infectious and the asymptomatic infectious prevalence.
Finally, from Fig. 2.8(c) we observe that symptomatic prevalence is most sensitive
to k, then β, followed closely by γ1 (recovery rate of symptomatic children). It is
surprising that the recovery rates γ1 and γ2 have dramatically different influence on
symptomatic prevalence, with γ1 having a much stronger impact. However, for the
symptomatic prevalence, d1 has a much stronger impact than d2, as we could also
observe for asymptomatic infectious and overall infectious prevalences and not for
R0. Thus, the use of R0 as a measure for evaluation of policy decisions may not be
optimal. It can also be observed for symptomatic prevalence that infectiousness of
asymptomatic infectious adults (cA2) has a stronger positive impact than the other
infectiousness parameters (c1, c2, cA1), which have a very small impact if at all.
Figs. 2.9 (a)-(c) are similar to Figs. 2.8(b)-(d), respectively, except that Fig. 2.9
shows the PRCC of the solution as a function of time. The total infectious fraction
(see Fig. 2.9(a)) and the asymptomatic infectious fraction (see Fig. 2.9(c)) show sim-
ilar trends and both are less variable, while the symptomatic infectious fraction (see
Fig. 2.9(b)) shows noticeable fluctuations during the first 15 years in several parame-
ters including β, γ1, d1 and d2. We observe from Fig. 2.9(b) that, at the beginning of
the simulation, β has a high positive impact (close to 1) on the symptomatic fraction.
During the first 5 years, the PRCC of β decreases and starts to increase until the equi-
librium level is reached after about 15 years. The two other influential parameters d1
and d2 also illustrate similar behavior; that is, the PRCC decreases during the initial
10 years of the simulation and then increases to reach the equilibrium level. However,
the impact of d1 on I is always positive, whereas the impact of d2 is negative between
67
Figure 2.9. Outcomes from the time-dependent sensitivity analysis with
parameter ranges defined in Tables 2.3 and 2.4. Partial rank correlation
coefficients for each parameter are plotted over time for three outcomes:
(a) overall prevalence, (b) symptomatic prevalence, and (c) asymptomatic
prevalence.
approximately years 4 and 18, with the equilibrium level close to zero. The fluctua-
tion behaviors suggest that, when implementing a control measure, it is best achieved
when the fluctuations of the parameter are minimal. Notice that the constant effects
of parameters on IA (see Fig. 2.9(c)) dominate the effects on overall prevalence I+IA
(see Fig. 2.9(a)), which again shows the importance of asymptomatic individuals in
malaria prevalence and control.
2.6 Discussion
Eradication efforts in the past 30 years have failed to control malaria in many
parts of Sub-Saharan Africa. An important factor of this failure is due to a poor un-
derstanding in the mechanisms of acquired immunity [58] as well as human behavior
with respect to control measures [160]. The lack of understanding of how different
types of immunity correlate and affect the disease dynamics has been an obstacle
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to the development of a malaria vaccine [128]. So far vector control measures have
been successful but still do not seem to be sufficient. Vector control measures are
part of the solution to control malaria but have to be applied in conjunction with
human control measures and better implementation approaches. Although there have
been mathematical models for the disease transmission dynamics of malaria focusing
on various factors, to the best of our knowledge, none of the existing models con-
sider all the relevant factors considered in our model. Immunity of human host to
malaria infection has been modeled either as a separate epidemiological class or by
considering loss of immunity for recovered individuals. These types of models do not
specify which immunity is being referred to. We include chronological age of the
human host, multiple types of age-dependent immunity (each represented by a spe-
cific parameter), asymptomatic infectious and asymptomatic chronic infected human
classes, and relapse of chronic infected individuals triggered by susceptible mosquito
bites as a reason for reappearance of gametocytemia, i.e. reappearance of human
infectiousness. Our model allows the correlation between all these factors to play a
role.
This section presents conclusions as well as an alternative modeling approach
for reactivating chronic infections (relapse), which assumes relapse not only due to
susceptible mosquitoes but also due to infectious mosquitoes.
2.6.1 Conclusions
The model presented in this chapter shows that asymptomatic infectious individu-
als contribute 2-3 times more than symptomatic individuals to malaria transmission.
This indicates that control measures based on the information from reported clinical
cases might not be adequate. This is well known in the malaria literature, but what
has not been sufficiently studied yet is: where do so many asymptomatic infectious
individuals come from? Is there a reservoir of asymptomatic chronic infected hu-
mans waiting to become infectious? Those questions are difficult to answer in field
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studies but need to be addressed. One hypothesis found in the literature is that reap-
pearance of infectious asymptomatic individuals is triggered by even non-infectious
mosquito bites. In other words, parasites within the human body adapt and respond
to a variable number of mosquito bites in order to become gametocytes at the time
when mosquitoes are biting. We included this hypothesis in our model and realized
that it plays a fundamental role. The R0 expression is considerably affected by this
assumption. This suggests that it is very important to further study the reasons for
reappearance of gametocytemia, especially since many times public hearth decisions
are based on R0.
It is known that low parasitemia and therefore asymptomatic chronic infections
are difficult to measure. Our model produced the result that at least 60% of the
population is asymptomatic chronic infected (not yet infectious), with twice as many
adults than children. This means that this part of the population contributes to
the infectious pool for mosquitoes, by eventually becoming asymptomatic infectious.
This indicates as well, that the number of infected cases might be underestimated
in field studies and the utilization of more sensible measuring methods are strongly
advised.
The structure of the model makes it also possible to investigate control mea-
sures that target a specific factor (represented by the parameters in our model). We
could observe some commonly expected results, e.g., that reducing the biting rate of
mosquitoes (β) can have the most effective impact on the reduction of R0 as well
as on the reduction of symptomatic, asymptomatic infectious and overall infectious
prevalence. Parameters affecting especially infectivity (c, cA) and susceptibility (d,
dA) of individuals were carefully chosen to represent specific types of age-dependent
host immunity developed in malaria endemic countries and their ranges for the sen-
sitivity analysis take these immunity features into consideration. Hence, our model,
via the sensitivity analysis conducted, can help determine the age group of humans
to target for a specific type of vaccination and/or treatment implementation strategy,
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to achieve the most effective reduction in R0 and disease prevalence in the whole
population. Most importantly, our model can help generate non-intuitive results.
For example, a Pre-erythrocytic vaccine aims to generate antibodies responsible
to neutralize sporozoites (stage of the parasite that goes from the mosquito saliva
into the human body when bitten by an infectious mosquito) [128]. This leads to a
reduction in the probability of transmission from mosquitoes to susceptible humans
and therefore the parameters that would be reduced by implementing a vaccine of this
type are d1 and d2. Our simulation results show that by basing a Pre-erythrocytic
vaccine implementation on R0 it would not be clear which age group to target, since
the parameters d1 and d2 are almost equally impacting R0. If at all d2 has a slightly
more positive effect on R0 than d1. But in fact, the best vaccination strategy would
be to target children, i.e. lowering d1, as the parameter d1 has a significantly stronger
positive effect on prevalence than d2 (see Fig. 2.9), i.e. to target children would lower
overall prevalence most efficiently. This provides an example for caution that in some
cases a control measure determined based on R0 alone may not be optimal.
While vaccines targeting the pre-erythrocytic stages of the parasites would affect
the infectiousness of humans indirectly, transmission-blocking vaccines aim to reduce
infectiousness directly. These vaccines are based on antigens expressed on the sur-
face of the sexual and mosquito mid-gut stages of malaria parasites. These antigens
are the targets of antibodies induced by vaccination of the host and ingested with
the parasites when a mosquito takes a blood meal. The antibodies act by inhibit-
ing the parasite’s development within the mosquito and thereby reduce the human
infectiousness directly [161]. The parameters in our model related to transmission-
blocking vaccines are c1, c2, cA1 and cA2 (probabilities of mosquito infection). Our
results suggest that age group 2 (adults) should be targeted when implementing
a transmission-blocking vaccine with focus on asymptomatic infectious adults (see
Fig. 2.8 (a) and (c)). To target asymptomatic infectious adults would effectively
lower R0 as well as symptomatic prevalence.
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As important as considering optimal vaccination strategies and vector control is
effective treatment and diagnosis of malaria. Improving case management through
strengthening health services in many countries is needed. Malaria control strongly
depends on correct diagnosis, prescription and availability of effective treatment [162].
Our results emphasize this and the importance of symptomatic children for malaria
transmission. Our simulations show that the infectious period of symptomatic chil-
dren (γ1) has a significantly higher influence on the symptomatic prevalence than
that of adults (γ2). This suggests the importance to monitor the effective diagnosis
and treatment especially of children, to reduce the symptomatic malaria prevalence
efficiently.
We point out that many of the conclusions mentioned above depend critically on
the rate of relapse triggered by mosquito bites on asymptomatic chronic individuals.
A key parameter that determines the level of relapse is p, which depends on the
length of time in a year when the mosquito density rises. Both R0 and the disease
prevalence are very sensitive to the changes in p. A decrease in p (e.g., by reducing
mosquito breeding sites when rainy season starts) will no doubt have a significant
impact on malaria control as it will greatly reduce the influence of asymptomatic
chronic humans on the overall malaria prevalence.
In summary, by incorporating several relevant factors such as relapse of asymp-
tomatic chronic infected individuals triggered by non-infectious mosquitoes and differ-
ent age-specific host immunity (anti-disease, anti-parasite and transmission-reducing
immunity), our model is capable of generating important insights into the disease dy-
namics of malaria, which are not possible to obtain from existing models for malaria
transmission. The model can be useful for evaluating the effectiveness of various con-
trol measures including vaccination and drug treatment for humans as well as vector
control. The sensitivity and uncertainty analyses help identify the most influential
factors for reducing the reproduction number R0 and the disease prevalence. The age
structure of the model makes it possible to determine specific age group(s) to target
for vaccination or other control programs. We demonstrated the simulation results
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for the case of two age groups, since we found reasonable parameter values in the
literature for 0− 15 year old individuals. However, the model can be applied to any
finite number of age groups. Although the model has already included many complex-
ities associated with malaria transmission, there are assumptions made for simplicity.
For example, p is taken constant but can be considered as a time-dependent function
to allow for a seasonally variable relapse rate. Another extension would be to allow
superinfection of asymptomatic chronic infected individuals, and, if at all realistic, to
make k age dependent. We plan to consider these extensions in future studies.
2.6.2 Alternative approach of modeling the relapse
We have focused so far on the assumption that only susceptible mosquitoes re-
activate chronic infections, i.e., individuals with asymptomatic chronic infection (jA)
can relapse and become asymptomatic infectious (iA) when bitten by susceptible
mosquitoes only. This assumption is based on the observation that such relapse have
occurred during certain times of a year when only susceptible mosquitoes are present.
Because our model involves only time-independent parameters and seasonality is not
considered, it is expected that infected mosquitoes are always present as long as the
there are infected humans. Hence, alternatively, we can assume that chronic infections
can be reactivated by bites from either susceptible or infected mosquitoes. Under this
assumption the model takes the form as in (2.5)–(2.8), including in the relapse rate
λ2(t, a) susceptible mosquitoes as well infectious mosquitoes (compare with (2.3)),
i.e.,




whereas λ1(t, a) and λv(t) remain as in (2.1) and (2.4) respectively.
Notice that the expression for the reproduction number R0 (see Section 2.3.3
equation (2.37)) remains the same under the modification on λ2(t, a) given in (2.83).
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In fact, the third expression in (2.37), which is associated with relapse, would not be
affected. This is because the second term in







appearing in system (2.5) would vanish when linearizing the system around the disease
free equilibrium.
For this alternative modeling approach we conducted numerical simulations corre-
sponding to those presented in Section 2.5. We observe that the two models produce
almost identical results. In fact, this is illustrated by comparing Fig. 2.10 with Fig. 2.2
in Section 2.5. Similarities can also be observed when comparing other figures in Sec-
tion 2.5 (except for Fig.2.8) under the alternative relapse assumption. These figures
are omitted here.
A slight difference can be observed when comparing Fig. 2.11 with Fig. 2.8 in Sec-
tion 2.5. The parameter cA2 now has a positive impact on the prevalence in both the
overall infections (see Fig. 2.11(b)) and the asymptomatic infections (Fig. 2.11(d)),
while it appears to be insignificant in Fig. 2.8(b) and (d). The effects of cA2 onR0 and
on symptomatic prevalence are the same as in Fig. 2.8, and the same is true for other
parameters with respect to all epidemiological outcomes presented. Recall that cA2
represents the infectivity of adults with asymptomatic infections and it can be affected
for example when implementing a vaccination campaign with a transmission-blocking
vaccine. Hence, given our parameter ranges, targeting asymptomatic infectious adults
with such a vaccine would be more effective than targeting children. The same con-
clusion was drawn in Section 2.6.1. Additionally, under this alternative modeling
assumption, such a vaccination campaign would have an impact not only on reducing
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(f)
Figure 2.10. Numerical simulations of the ODE model considering the
alternative assumption (2.83). Two age groups are assumed and fixed
parameter values given in Tables 2.3 and 2.4 are used. These parameter
values produce an R0 of 3.4. Plots in (a)-(c) show the fractions of symp-
tomatic infectious individuals, asymptomatic infectious individuals, and
asymptomatic chronic infected individuals, respectively, for the two age
groups. The plot in (d) is for the mosquito population. Plots in (e) and
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Figure 2.11. Outcomes from the sensitivity analysis with parameter ranges
defined in Tables 2.3 and 2.4. Partial rank correlation coefficients (PRCC)
for each parameter are plotted for four epidemiological outcomes of the
alternative model considering (2.83): (a) R0, (b) overall infectious preva-
lence, (c) symptomatic prevalence, and (d) asymptomatic infectious preva-
lence. A larger absolute value of the PRCC indicates a greater impact on
the epidemiological outcome, with positive (negative) values indicating a
positive (negative) relationship.
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3. A VACCINE-AGE STRUCTURED MODEL TO STUDY
THE EFFECT OF A PRE-ERYTHROCYTIC VACCINE
ON MALARIA PREVALENCE
This work started on my stay as a short term visitor at the National Institute for
Mathematical and Biological Synthesis (NIMBioS) at the University of Tennessee, in
Knoxville TN. The initial idea of this modeling study originated there as a collabo-
ration with Dr. Calistus Ngonghala.
3.1 Introduction
Current malaria control measures recommended, such as the use of long-lasting
insecticidal nets and indoor residual spraying for vector-control, the use of prophy-
lactic drugs to prevent malaria infection, early and confirmed diagnosis and timely
treatment with anti-malarial drugs, etc. [52] have proven to be effective in reducing
malaria prevalence in endemic areas over the past decade [52], but are still incapable
in fully containing malaria. Hence other methods are needed to supplement the cur-
rent efforts, among which introducing a safe and effective malaria vaccine could be a
cost-effective and efficacious way that is being seriously considered [61,64,65]. Efforts
for development of a malaria vaccine have been pursued since the 1960s but as of
today there is no licensed vaccine yet. Nevertheless, efforts continue and there are
over 20 vaccine candidates in phase 1, phase 2 clinical trials or in preclinical develop-
ment [66]. At present, the only promising vaccine for malaria is RTS,S/AS01, which is
currently undergoing phase 3 clinical trials (the last stage of testing before licensing).
The clinical trials assess, among others things, the safety and efficacy of the vaccine
candidate. RTS,S/AS01 is the first malaria vaccine candidate to advance this far
[52,64,65,163,164]. This vaccine is a pre-erythrocytic stage vaccine for P. falciparum
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and it triggers an immune response that attacks the stage of the parasite either before
or while it matures in the human’s liver cells, prior to entering red blood cells [64].
The latest available clinical trial results reveal that during an 18 months follow up
(after the required three vaccine doses) a vaccine efficacy against clinical malaria
in children (5-17 months at time of vaccination) of 46% could be observed, varying
across sides between 40% and 77%. A significant lower vaccine efficacy of 27% during
the same period of time could be observed for young infants (6-12 weeks at time of
vaccination). For both age groups it was observed that vaccine efficacy wanes over
time (being highest close to vaccination) and the question arises if an additional fourth
dose or booster dose after 18 months of the initial three doses would again increase
efficacy (results of the clinical trials about the effects of a booster dose is expected by
the end of 2014) [52, 65,163–165]. Nevertheless, the study shows that even a modest
vaccine efficacy may prevent a substantial number of malaria cases and hence that
RTS,S/AS01 could have a major impact complementing existing interventions [166].
In this chapter, we will develop a vector-host mathematical model for malaria at
population level where susceptible humans are subjected to a vaccination campaign.
Most existing mathematical models that include vaccination have focused on two
approaches, one is to assume that all individuals are vaccinated at birth and the other
one is to assume that individuals can be vaccinated at any time but only susceptibles
will be vaccinated. These models include only a single vaccination class. However,
recent studies suggest that vaccination campaigns for malaria will most likely include
multiple (three) initial vaccination doses possibly followed by an additional booster
dose. Hence, in order to capture the malaria dynamics in a vaccinated population
where the vaccine efficacy varies for individuals with and without the booster dose,
the model needs to include more than one vaccination compartment. For this purpose,
we incorporate in our model two vaccinated classes: the first class for individuals with
the initial dose(s) of vaccination and the second for individuals who are also given
a booster dose. When applying the model to the RTS,S/AS01 malaria vaccine we
will assume that the first vaccination class includes individuals that have received
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the required three initial doses and that the second class includes individuals that
received also the additional booster dose. Both of the vaccination classes in our
model are structured by vaccine-age (i.e., the time elapsed after the initial dose(s)).
The temporal variable for vaccine-age starts running once an individual enters the
first vaccination class and continues throughout the subsequent vaccination class for
individuals with the booster dose. The use of vaccine-age structure in the model allows
us to consider a vaccine-age dependent reduction in susceptibility due to immunity
waning and to explore how the timing in administering a booster dose may affect the
outcome of a vaccination campaign. Consideration of such timing is important and
relevant because of two reasons: First, an optimal immune response can usually be
obtained only when vaccine doses are received not too close from one another. Second,
the benefit of a booster dose could be significantly reduced if its administration is
delayed, i.e., individuals in the first vaccination class will not receive the booster
dose until at a higher vaccine-age, especially in underdeveloped countries. The main
objectives of this study are (i) to investigate how the vaccine efficacy and the timing
of administering a booster dose may affect disease prevalence and the reproduction
number; and (ii) to determine the threshold vaccination coverage needed for malaria
eradication if at all possible.
The existing models structured by vaccine-age have been, to the best of our knowl-
edge, developed for diseases transmitted directly between human (see Section 1.1.2
and references therein). None has focused on vector-transmitted diseases such as
malaria. Therefore, the model developed in this study is a novel contribution to
modeling of vector-transmitted diseases with multiple vaccination classes structured
by vaccine-age.
This chapter is organized as follows. In Section 3.2 we present the model formu-
lation and parameter explanation. In Section 3.3 we derive the control reproduction
number and analyze the local and global stability of the disease free equilibrium. Sec-
tion 3.4 proves conditions for the existence of possible endemic equilibria, and Section
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3.5 shows results of numerical simulations including the existence of backward bifur-
cation. Section 3.6 discusses the final results and conclusions.
3.2 The model formulation
In this section, we present a vector-host population model that includes two vac-
cination classes and is structured by vaccine-age. This model will be used to study
the effects of a vaccination campaign for malaria. We divide the host population
into four epidemiological classes: Susceptible (S), Infectious (I), Vaccinated with the
initial dose(s) (Vh1), and Vaccinated with a booster dose (Vh2). We assume a con-
stant birth/recruitment rate Λh entering the class of susceptible humans Sh(t) and a
natural death rate µh exiting all human classes. Susceptible humans become infected
by infected mosquitoes with a transmission rate βvh(t) (see (3.1)) and enter the in-
fected class Ih(t). These infected humans either recover at a rate γh, returning to the
susceptible class, or die at a rate µh + δh, where δh represents the disease induced
death rate. The mosquito population is divided into Susceptible (Sv) and Infectious
(Iv) classes. Susceptible mosquitoes have a constant recruitment rate Λv and exit the
class due to either death at constant death rate µv or infection at the rate βhv(t) (see
(3.4)) when biting an infected host. We assume that once a mosquito gets infected it
does not recover and can leave the infected class only through death.
The model includes two vaccinated classes for humans with the density functions
Vh1(t, τ) and Vh2(t, τ), where τ represents vaccine-age. Thus, the numbers of indi-
viduals in these vaccinated classes with vaccine-ages in the interval (τ1, τ2) are given
by ∫ τ2
τ1
Vhi(t, τ)dτ, i = 1, 2.
We assume that a vaccination campaign aims at vaccinating susceptible humans at a
constant rate νh1 . Susceptible humans include both, individuals who have never been
infected and individuals who have recovered from an infection. Once a susceptible
human has been vaccinated this individual enters the first vaccination class Vh1(t, τ)
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with vaccine-age zero. Individuals in the Vh1 class will leave at a rate νh2p(τ) due to a
booster dose and enter the Vh2(t, τ) class, in which τ is still the age from the first vac-
cination. Here νh2 represents a constant background vaccination rate for individuals
in the Vh1 class, and p(τ) will determine the minimum time that must elapse for an
individual in Vh1 to receive a booster dose. We model the vaccine efficacy the same
way as has been done in other studies [167,168], that is, it represents the proportion
by which the force of infection is reduced. This is directly related to the reduction in
susceptibility of a vaccinated individual. The percentage to which the susceptibility of
individuals in Vh1(t, τ) is reduced to is measured by the vaccine-age dependent param-
eter d1(τ), with 0 ≤ d1(τ) ≤ 1, which appears in the force of infection term λvh1 (see
(3.2) below). Equivalently, the vaccine efficacy for these individuals is represented by
1 := 1−d1(τ). We assume that the susceptibility reduction is vaccine-age dependent
because the vaccine efficacy is believed to wane over time [164, 165]. Similarly, indi-
viduals in the vaccinated class Vh2(t, τ) have reduced susceptibility measured by the
parameter d2(τ), with 0 ≤ d2(τ) ≤ 1. The transitions between the epidemiological
classes are depicted in Fig. 3.1. Tables 3.1 and 3.2 list the variables and parameters





λvh1(t, τ) = d1(τ)βvh(t), (3.2)






Nh(t) := Sh(t) + Ih(t) +
∫ ∞
0
(Vh1(t, τ) + Vh2(t, τ)) dτ. (3.5)
represents the total human population at time t.
The force of infection terms in (3.1) and (3.4) are explained as follows. The
parameter bv is the number of bites one mosquito can give per unit of time. Hence,
bvIv(t) is the number of bites from the total infectious mosquitoes at time t per unit
of time. pvh is the proportion of host infection per bite from an infectious mosquito
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when biting a susceptible host. Hence βvh(t) = bvIv(t)pvh1/Nh(t) is the rate at which
one susceptible host becomes infected. Similarly, phv is the proportion of mosquito
infection per bite from a susceptible mosquito when biting an infectious host. Hence,
phvIh(t)/Nh(t) is the proportion of mosquito infection per bite from a susceptible
mosquito when biting infectious humans at time t, and βhv(t) = bvphvIh(t)/Nh(t)
is the rate of mosquito infection per susceptible mosquito when biting infectious
hosts. Observe that in our definition of the force of infection terms, we adopted a
frequency dependent transmission. We assume that there are enough humans in the
population such that each single female mosquito can get it’s daily requirement for
blood meals. Hence, the number of bites each mosquito gives daily (bv) is constant
and independent of the number of hosts in the population. On the other hand, the
number of bites one human host receives from infected mosquitoes (bvIv(t)/Nh(t))
increases with fraction of infected mosquitoes and is dependent on the mosquito-to-
human ratio, which increases if the total number of humans decreases. This makes
sense, since the constant number of bites have to be distributed among all humans.
Hence, for a given mosquito population size, if there are fewer humans in a population
then each human host will be expected to receive more bites.
























= νh2p(τ)Vh1(t, τ)− (λvh2(t, τ) + µh)Vh2(t, τ)
(3.6)
with boundary conditions (BC)
Vh1(t, 0) = νh1Sh(t), Vh2(t, 0) = 0, (3.7)
where Vh1(t, 0) represents newly vaccinated individuals from the susceptible class Sh(t)
(i.e., vaccine-age zero). The condition Vh2(t, 0) = 0 implies that no one in the Vh2
82
class has vaccine-age zero, i.e., no one receives initial vaccine dose(s) and a booster
dose simultaneously. The initial conditions (IC) are as follows
Sh(0) = Sh0, Vh1(0, τ) = V
0
h1
(τ), Vh2(0, τ) = V
0
h2
(τ), Ih(0) = Ih0. (3.8)
The equations for mosquitoes are
dSv
dt





with initial conditions Sv(0) = Sv0, Iv(0) = Iv0. The total mosquito population is
represented by Nv(t) := Sv(t) + Iv(t).
We make the following assumptions on parameters and on the initial conditions in
order to allow the mathematical treatment and for them to be biologically significant:
• p(.) and di(.) ∈ L∞[0,∞), in fact 0 ≤ di(τ), p(τ) ≤ 1 ∀τ ≥ 0, i = 1, 2.
• All parameters are non-negative.
• Sh0, Ih0, Sv0, Iv0 ∈ [0,∞].
• V 0hi(.) ∈ L1([0,∞),R+0 ) and limτ→∞V
0
hi
(τ) = 0, i = 1, 2.
For ease of analysis, we can consider an equivalent system that can be obtained
from (3.6)-(3.9) when solving the last two equations in (3.6) by using the method of
characteristics [169], which yields:
Vh1(t, τ) =
νh1Sh(t− τ)e
− ∫ τ0 λvh1 (t−τ+s,s)dsP (τ)L(τ); t ≥ τ
V 0h1(τ − t)e−
∫ t
0 λvh1 (x,x−t+τ)dxP (t) L(τ)







νh2p(s)Vh1(t− τ + s, s)e−
∫ τ
s λvh2 (t−τ+x,x)dx P (τ)
P (s)
ds; t ≥ τ
V 0h2(τ − t)e−
∫ t






y λvh2 (x,x+τ−t)dx P (t)
P (y)
νh2p(y + τ − t)Vh1(y, y + τ − t)dy; t < τ,
(3.11)
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Figure 3.1. A diagram for the transitions between epidemiological classes.
where
P (τ) := e−
∫ τ
0 µhds




is the probability of not yet having been administered a booster dose while in the
first vaccination class. Observe that lim
τ→∞
P (τ) = 0, which means that the survival
probability is low at increased vaccine-age, which is a desired property since humans
do not live forever. Observe also that L(τ) could take values anywhere between zero
and one depending on the bounded function p(τ). Substituting (3.10) and (3.11)
84
Table 3.1.
Description of variables used in the model
Variable Description
Sh(t) Number of susceptible humans at time t.
Vh1(t, τ) Density of vaccinated humans, with initial dose(s),
at time t with vaccine-age τ .
Vh2(t, τ) Density of vaccinated humans, with booster dose,
at time t with vaccine-age τ .
Ih(t) Number of infected humans at time t.
Nh(t) Total human population at time t. See (3.5)
Sv(t) Number of susceptible mosquitoes at time t.
Iv(t) Number of infected mosquitoes at time t.
Nv(t) Total mosquito population at time t.



















νh2p(s)Vh1(t− τ + s, s)e−
∫ τ
s λvh2 (t−τ+x,x) P (τ)
P (s)
dsdτ +Qh2(t)
−(γh + µh + δh)Ih(t)
dNh
dt
= Λh − µhNh(t)− δhIh(t)
dSv
dt







Description of parameters used in the model
Variable Description Units
i = 1, 2 Initial dose(s), booster dose sub-index.
i(τ) := 1− di(τ) Vaccine efficacy of ith vaccination dose unitless
at vaccine-age τ (0 ≤ di(τ) ≤ 1, i = 1, 2).
νhi ith dose vaccination rate. d
−1
bv Number of bites one mosquito can give per day. b(md)
−1
γh Recovery rate for humans. d
−1
Λh,Λv Constant birth rate for human, mosquitoes. hd
−1,md−1
µh, µv Per capita death rate of humans, mosquitoes. d
−1
δh Disease induced death rate d
−1
phv % of susceptible mosquitoes infected per bite on mb
−1
infectious humans.
pvh % of susceptible humans infected per bite from hb
−1
an infectious mosquito.
βvh(t) Infection from infectious mosquitoes to susceptible d
−1
human. See (3.1)
λvhi(t, τ) Infection from infectious mosquitoes to vaccinated d
−1
human in Vhi(t, τ), i = 1, 2. See (3.2), (3.3).
βhv(t) Infection from infectious humans to susceptible d
−1
mosquito. See (3.4).
p(τ) Proportion of human with vaccine-age τ that is
eligible to receive the booster dose. unitless



















V 0h2(τ − t)e−
∫ t






y λvh2 (x,x+τ−t)dx P (t)
P (y)




System (3.12) is equivalent to the original system (3.6)-(3.9); and thus, we will study
the model properties by focusing on the system (3.12).
We examine the well-posedness of the model by verifying the positivity and bound-
edness of solutions of system (3.12). Observe that the total mosquito population size
Nv(t) converges to a constant N
0
v := Λv/µv as t → ∞, we can assume, applying the
theory of asymptotically autonomous systems [129–131], that the mosquito popula-
tion has already reached the asymptotical constant N0v . Then Sv(t) = N
0
v − Iv(t) and
we only need to consider the Iv equation in (3.12) for our analysis. Let us define the
biologically feasible region













The following lemma can be proved.
Lemma 3.2.1 The biologically feasible region Ω ⊂ R3+ × R+ is positively invariant
for system (3.12) with non-negative initial conditions in Ω and Nh(0) ≤ Λh/µh.
Proof We first prove positivity, i.e., the solutions of (3.12) stay non-negative for
non-negative initial conditions. We will show this by proving that if a solution, which
started in the interior of Ω, hits for the first time at time t0 > 0 the part of the
boundary of Ω where one of the variables is zero, then that solution will either return
into Ω or stay on the boundary.
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Suppose for some t0 > 0, Ih(t0) = 0, Sh(t), Nh(t), Iv(t) ≥ 0 and Nh(t) 6= 0,
∀0 ≤ t ≤ t0. Then, using the Ih equation in (3.12), from (3.10), (3.11) and the
positivity of the initial densities of vaccinated people V 0hi(τ), i = 1, 2, we obtain that
dIh
dt
(t0) > 0. Hence, the trajectory remains in Ω. Similarly, from the Sh equation




(t0) > 0, which again makes the trajectory return to Ω.
A similar argument can be applied to the other variables in (3.12). The positivity of
solutions follows.
Note from the Nh equation in (3.12) that
dNh
dt




(t0) < 0 if Nh(t0) ≥ Λh/(µh + δh). Hence, if 0 < Nh(0) < Λh/µh then
min{Nh(0),Λh/(µh + δh)} ≤ Nh(t) ≤ Λh/µh, which implies that for positive initial
conditions Nh(t) is positive and bounded above and away from zero for all t > 0.
From (3.10) and (3.11) one can conclude the positivity of the densities Vh1 and Vh2
given the postitivity of the other variables and of the initial densities. Then, from
(3.5), the positivity of solutions and the boundedness of Nh(t) we can conclude that
Sh(t), Ih(t) ≤ Λh/µh.
Similarly we can show that Iv(t) is bounded above and remains in Ω. It follows that
Ω is positively invariant.























Hence, using 0 ≤ d1(τ), p(τ) ≤ 1, the boundedness of Nh(t) away from zero from
below (call 0 < m ≤ Nh(t)), Iv(t) ≤ N0v and the positivity of the variables and the
parameters, we obtain

















where the last equality was obtained by making a change of variables. Hence, since
P (t) = e−µht and V 0h1(u) ∈ L1([0,∞),R+0 ), we can conclude that limt→∞Qh1(t) = 0.
Similarly, using the boundedness of d2(τ) and from (3.10) that Vh1(y, y + τ − t) =
V 0h1(τ − t)e−
∫ y
0 λvh1 (x,x+τ−t)dxP (y)
L(y + τ − t)
L(τ − t) one can show that















and hence, since V 0hi(u) ∈ L1([0,∞),R+0 ), i = 1, 2, and P (t), tP (t)→ 0 when t →∞
we conclude that lim
t→∞
Qh2(t) = 0.
In particular Qh1(t) = Qh2(t) = 0 if the initial vaccinated human distributions are




A limiting system of (3.12) is given by
dSh
dt















νh2p(s)Vh1(t− τ + s, s)e−
∫ τ





−(γh + µh + δh)Ih(t)
dNh
dt





v − Iv(t))− µvIv(t).
(3.20)
The limiting sysetem (3.20) has the same qualitative behaviors as (3.12). The analyses
below will focus on this limiting system.
From the first part in (3.10) we have
Vh1(t− τ + s, s) = νh1Sh(t− τ)e−
∫ s
0 λvh1 (t−τ+x,x)dxP (s)L(s). (3.21)
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If we replace the Vh1 in the Ih equation of (3.20) by the right-hand-side of (3.21),
then systems (3.20) can be solved independent of the variables Vh1 and Vh2 . Thus,
once (3.20) can be solved, Vh1 and Vh2 can be determined from (3.10) and (3.11).
3.3 Reproduction number and stability of the disease free equilibrium
In this section we derive a threshold condition that determines the local stability
of the infection-free steady state. As in most epidemiological models, an important
quantity is the basic reproduction number associated with the pathogen, which is
usually denoted by R0. It is usually used to determine whether or not a disease can
invade into a population that is free of the disease. This quantity is biologically defined
as the expected number of secondary infected cases a “typical” infected individual
produces in a totally susceptible population during its infectious period [9,10]. In most
models for endemic diseases, the disease dies out if R0 < 1 and it persists if R0 > 1.
When a model includes also vaccination, the population in the absence of a disease
will consist of both susceptible and immune individuals. In this case, a new threshold
quantity will take the place of R0, which is called the net reproduction number or
control reproduction number, usually denoted by R. The biological definition of R
is similar to that of R0 except that the population consists of both susceptible and
vaccinated individuals.
This section includes the derivation of the control reproduction number R for
the model (3.6)-(3.9). We prove analytically the local stability of the disease free
equilibrium and a global stability result in Theorem 3.3.1 and Theorem 3.3.2, re-
spectively. For the case of vector-borne diseases, the control reproduction number
can be considered as the average number of secondary infected mosquitoes that arise
from one infected mosquito in a complete vector-host-vector transmission cycle when
introduced into an environment in which the mosquito population is completely sus-
ceptible and the humans are either susceptible or vaccinated. Equivalently, it can
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be considered as the second number of infected humans generated by one infected
human host after a complete human-mosquito-human transmission cycle.
To derive the reproduction number R, we will linearize system (3.20) around the
disease free equilibrium





















, I0h = I
0
v = 0.
In general, the stability condition of E0 will lead to a characteristic equation, which
can be used to derive an expression for R.
We introduce new variables
















































We observe that the linearization (3.24) is a system of ordinary differential equa-
tions. Hence, to find the characteristic equation we look for solutions to (3.24) of the
form
Sh(t) = S˜he
ωt, Ih(t) = I˜he
ωt, Nh(t) = N˜he
ωt, Iv(t) = I˜ve
ωt,
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with X˜ 6= 0 for X = Sh, Ih, Nh, Iv. The constant ω is an eigenvalue, which will
determine the stability of E0 [170]. Substituting these solutions into the system
(3.20) and rearranging the equations in the order Sh, Nh, Ih, Iv, we obtain
ωS˜h =− cvhI˜vS0h + γhI˜h − (νh1 + µh)S˜h























− (γh + µh + δh)I˜h
ωI˜v =chv I˜hN
0
v − µv I˜v.
(3.25)
Non-trivial exponential solutions exist if ω satisfies the equation
det

−(ω + νh1 + µh) 0 γh −cvhS0h
0 −(ω + µh) −δh 0
0 0 −(ω + γh + µh + δh) cvhS0hV
0 0 chvN
0
v −(ω + µh)
 = 0 (3.26)
where















Note that the matrix in (3.26) is a block upper triangular matrix with 2× 2 blocks.





Note also that the matrix A corresponds to the Sh and Nh equations in (3.25) and
has two negative eigenvalues (−(νh1 + µh) and −µh). Hence, the stability of E0 is
determined by the eigenvalues of D, for which the characteristic equation is
det
−(ω + γh + µh + δh) cvhS0hV
chvN
0
v −(ω + µh)


































=: R(νh1 , νh2p, d1, d2, ω).
(3.28)
Define Th := 1/(γh + µh + δh) and Tv := 1/µv, which represents the times a human
host and a mosquito spend in their respective infected classes. Then the following
definition can be stated.
Definition 3.3.1 The control reproduction number, as a function of νh1 , νh2p, d1, and
d2, can be defined as






























It can be challenging to provide a clear biological interpretation for expressions
such as the one defined in (3.29), particularly for the case when age-dependent param-
eter functions are involved. Here, we will provide an interpretation of the quantity
defined in (3.3.1) and its connection to the reproduction number. Suppose one in-
fectious mosquito is introduced into a malaria-free environment in which the human
population consists of only susceptible and vaccinated individuals and the mosquito
population is completely susceptible. In such a situation, the number of susceptible
humans is given by S0h and the density of vaccinated humans of vaccine-age τ in the
first vaccinated class is νh1S
0
hP (τ)L(τ). Recall that P (τ) represents the survival prob-
ability for humans and L(τ) is the probability of not having been given the booster
dose at vaccine-age τ . The number of vaccinated humans in the Vh2 class, who en-









ds, and the total number of susceptible mosquitoes is
N0v . When an infectious mosquito is introduced, the number of susceptible humans
infected by the mosquito per unit of time is cvhS
0
h. The number of individuals in the
Vh1 class infected by the mosquito per unit of time when being of vaccine-age τ is
cvhd1(τ)νh1S
0
hP (τ)L(τ). The number of individuals in the Vh2 class infected by the













Adding all human infections together and multiplying by the infectious period of
mosquitoes, Tv, we get the total number of infectious humans produced by the initially
infected mosquito during it’s infectious period Tv. Each of these infected humans then
infect chvN
0
v mosquitoes per unit of time; and thus, ThchvN
0
v is the total number of
infected mosquitoes during the expected infectious period Th of humans. Hence, the
expression in Definition (3.3.1) gives us the average number of secondary mosquito
infections produced by one infectious mosquito when introduced into a disease free
population.
The following Theorem states a result on how R determines the local stability of





Theorem 3.3.1 The disease free equilibrium E0 is locally asymptotically stable (l.a.s.)
if R(νh1 , νh2p, d1, d2) < 1, and it is unstable if R(νh1 , νh2p, d1, d2) > 1.
Proof For ease of presentation, introduce a function F defined by























Then, (3.28) can be rewritten as
R(νh1 , νh2p, d1, d2, ω) =
1





· F (νh1 , νh2p, d1, d2). (3.30)
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Let m := max{−µv,−(γh + µh + δh)} < 0. Then, for ω ∈ R, it is easy to see that
R(νh1 , νh2p, d1, d2, ω) is a decreasing function of ω for ω > m, and that
lim
ω→∞
R(νh1 , νh2p, d1, d2, ω) = 0, lim
ω→m+
R(νh1 , νh2p, d1, d2, ω) =∞.
Thus, there exists a unique real number ω0 > m such that R(νh1 , νh2 , d1, d2, ω0) = 1.
Let now ω ∈ C, i.e. ω = a + bi with a, b ∈ R, a > m, such that ω satisfies the
characteristic equation R(νh1 , νh2p, d1, d2, ω) = 1. Then
R(νh1 , νh2 , d1, d2, ω0) = 1 =|R(νh1 , νh2p, d1, d2, a+ bi)|
=| 1





· F (νh1 , νh2p, d1, d2)|




|a+ µv|F (νh1 , νh2p, d1, d2)
=R(νh1 , νh2p, d1, d2, a).
Since R(νh1 , νh2p, d1, d2, ω) is a decreasing function of ω we can conclude that a =
Re{ω} ≤ ω0 if Re{ω} > m. Let ω = c+di be any complex root of R with c, d ∈ R. If
c ≤ m then c ≤ m < ω0, which concludes that Re{ω} ≤ ω0 for any complex solution
of the equation R(νh1 , νh2p, d1, d2, ω) = 1. From the definition of R we know that if
R(νh1 , νh2p, d1, d2) < 1 then ω0 < 0, which implies that Re{ω} < 0 for all complex
solution of R(νh1 , νh2p, d1, d2, ω) = 1. This implies that E
0 is l.a.s. On the other hand,
if R(νh1 , νh2p, d1, d2) > 1 then ω0 > 0; and thus, E0 is unstable. This completes the
proof.
Notice that (3.29) can be written as


















From νh2p(s)L(s) = −L′(s) and L(0) = 1, we have∫ τ
0
νh2p(s)L(s)ds = L(0)− L(τ) = 1− L(τ). (3.32)
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Therefore, from 0 ≤ di(τ) ≤ 1 (i = 1, 2) and S0h = Λh/(νh1 + µh), we have





















































where R0 is the basic reproduction number of the disease without vaccination, i.e.,
R0 := R(0, 0, ., .). Hence, we have proved the following result.
Proposition 3.3.1 Introduction of vaccination can help reduce the magnitude of the
reproduction number. That is,
R(νh1 , νh2p, d1, d2) ≤ R0 ∀ νh1 , νh2 ≥ 0.
Theorem 3.3.1 provides only the local stability of the DFE whenR(νh1 , νh2p, d1, d2)
< 1. It does not exclude the possibility for the existence of an endemic equilibrium
under the same condition. In fact, we demonstrate in Section 3.5 that an endemic
equilibrium may exist when R(νh1 , νh2p, d1, d2) < 1. Nevertheless, we show below in
Theorem 3.3.2 that in the case of a perfect vaccine (i.e., d1(τ) = d2(τ) = 0), the
DFE is globally asymptotically stable (g.a.s.) if R(νh1 , νh2p, 0, 0) < 1 and the disease
induced death is ignored (i.e., δh = 0). Numerical simulations suggest that the same
is true when δh 6= 0.
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If d1(τ) = d2(τ) = 0 system (3.20) reduces to
dSh
dt
= Λh − (βvh(t) + νh1 + µh)Sh(t) + γhIh(t)
dIh
dt
= βvh(t)Sh(t)− (γh + µh + δh)Ih(t)
dNh
dt





v − Iv(t))− µvIv(t)
(3.34)
Theorem 3.3.2 Let d1(τ) = d2(τ) = 0, δh = 0 and Nh(0) > 0. If R(νh1 , νh2p, 0, 0) <
1 then the DFE E0 is globally asymptotically stable. In particular, if R0 < 1 then the
DFE is globally asymptotically stable.
Proof Observe that R0 = R(0, 0, ., .). Hence, the global asymptotic stability of E0
when R0 < 1 is implied from the first statement in the theorem.











Let f(t) := Ih(t)e
∫ t
0 γh+µhdσ and g(t) := e
∫ t
0 γh+µhdσ. f, g : R+ → R and are both
differentiable. Also, g′(t) = (γh + µh)e
∫ t
0 γh+µhdσ 6= 0 for all t ≥ 0 and g is unbounded.
Then the Generalized L’Hospital Rule in Lemma 4.1 of [171] and (3.35) imply that
lim sup
t→∞








































Let us now define for this case f(t) := Iv(t)e
∫ t
0 βhv(σ)+µvdσ and g(t) := e
∫ t
0 βhv(σ)+µvdσ.
Both are differentiable functions, f, g : R+ → R and g′(t) = (βhv(t) + µv)g(t) 6= 0
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for all t ≥ 0. Also, g(t) := e
∫ t
0 βhv(σ)+µvdσ ≥ eµvt since βhv(t) := bvphvIh(t)/Nh(t) ≥ 0;
hence g is unbounded. Then, using the Generalized L’Hospital Rule in [171] and the
expression (3.4) we obtain, similarly to above, the inequalities
lim sup
t→∞


















v := lim sup
t→∞


















I∞v = R(νh1 , νh2p, 0, 0)I∞v . (3.40)
Which implies that if R(νh1 , νh2p, 0, 0) < 1 then
0 ≤ (R(νh1 , νh2p, 0, 0)− 1)I∞v < 0 (3.41)
from which follows that I∞v = 0 and I
∞
h = 0.
On the other hand we define S∞h := lim sup
t→∞
Sh(t) and Sh∞ := lim inf
t→∞
Sh(t). We use
Corollary 2(a) in [172], that is consequence of a fluctuation lemma in [171], on the Sh
equation in system (3.34). To check the assumptions needed to use the Corollary, we
define g(t, x) := Λh−(βvh(t)+νh1 +µh)x+γhIh(t), which corresponds to the right hand






)e−µht, Nh(t) is bounded. Therefore, since Sh(t) ≤ Nh(t),
we conclude that x : (0,∞)→ D where D is a bounded interval. Also, since Ih(t) ≤
Nh(t) and Iv(t) ≤ N0v , both infected solutions are bounded and since Nh(0) > 0 also
1/Nh(t) is bounded. Hence, g(t, x) : (0,∞) × D → R is a bounded function. Also
∇g = 〈bvpvh(I ′v(t)/Nh(t)−Iv(t)N ′h(t)/Nh(t))x+γhI ′h(t), βvh(t)+νh1 +µh〉 is bounded,
hence g(t, x) is uniformly continuous. Applying the Corollary we can then conclude
that
0 ≤ Λh − (νh1 + µh)S∞h , (3.42)
0 ≥ Λh − (νh1 + µh)Sh∞ (3.43)
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which imply
0 ≤ Λh − (νh1 + µh)S∞h ≤ Λh − (νh1 + µh)Sh∞ ≤ 0 (3.44)
from what follows that Sh
∞ = Λh/(νh1 + µh) = Sh∞. This completes the proof.
Figure 3.2. Each picture represents: (A) fraction of infected humans
Ih(t)/Nh(t) and (B) fraction of infected mosquitoes Iv(t)/Nv, (Nv =
Λv/µv) at time t. The different curves in each plot represent different
initial conditions used to solve system (3.34), these satisfy Nh(0) = 950,
Sh(0) = Nh(0) − Ih(0) and Iv(0) = 300. The disease induced death
rate for these plots is δh = 8.8 ∗ 10−6. The parameters used are:
Λv = 90, µv = 0.03, phv = 0.3, pvh = 0.042, µh = 9 ∗ 10−5,Λh = 0.09, νh1 =
0.0002, δh = 8.8 ∗ 10−6, γh = 1/90, bv = 0.12 and produce R0 = 1.6.
Fig. 3.2 shows that the infected human (picture (A)) and the infected mosquito
population (picture (B)) reach an endemic equilibrium when no vaccination campaign
was introduced into the population and assuming a disease induced death rate of
δh = 8.8 ∗ 10−6 6= 0, which is equivalent to a probability of death of 0.003 per year,
considering that 627000 deaths due to the disease and 207 million cases of malaria
occurred in 2012 [11]. The basic reproduction number is R0 = 1.6. If vaccination is
introduced into the malaria endemic population to reduce the control reproduction
number below 1, Fig. 3.3 shows that also when considering disease induced death,
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the infected human and mosquito populations approach the disease free equilibrium
for different initial conditions. Depicted are only some special cases, but we can
reproduce the same result for a range of different δh values, initial conditions and
vaccination rates νh1 (that make R(νh1 , 0, 0, 0) < 1 < R0 = 1.6), which generalize
Theorem 3.3.2 for δh 6= 0.
Figure 3.3. Pictures (A) and (B) show the fraction of infected humans and
infected mosquitoes respectively at each moment in time. The vaccination
rate applied is νh1 = 0.0002 (vaccination coverage of ∼ 7% per year).
The disease induced death rate for these plots is δh = 8.8 ∗ 10−6. The
different curves in each plot represent different initial conditions used to
solve system (3.34), these satisfy Nh(0) = 950, Sh(0) = Nh(0)− Ih(0) and
Iv(0) = 300. The other parameters used are as for Fig. 3.2 and produce
R(νh1 , 0, 0, 0) = 0.5.
3.4 Existence of endemic equilibria
In this section we will determine the conditions under which an endemic equi-
librium of (3.20) exists. The analytic results are obtained for the case when the
disease-induced mortality is ignored (δh = 0) and are used in Section 3.5 to produce
numerical simulations. We will study the case including disease induced death in a
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future study that will involve more extensive numerical simulations. The analysis in
this section allows for imperfect vaccines, i.e., di(τ) 6= 0 (i = 1, 2).
Denote an endemic equilibrium of (3.20) by








h > 0, I
∗
v > 0.
Since we assume δh = 0, setting the equation for Nh in system (3.20) equal to zero
imply N∗h = Λh/µh = N
0
h . The remaining components of E
∗ satisfy the equations









































v − I∗v )− µvI∗v .
(3.45)












chv(N0v − I∗v )
. (3.47)






v (γhµv − Λhchv)





di(s)ds for i = 1, 2 and












−cvhI∗v [D1(s)+D2(τ)−D2(s))]L(s)P (τ)dsdτ. (3.50)
These and other symbols defined in the text are listed in Table 3.3.
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Using the second equation in (3.45) we can solve for S∗h and get
S∗h =
(γh + µh)µv
chv(N0v − I∗v )cvh [1 +D1(I∗v ) +D2(I∗v )]
. (3.51)





v (γhµv − Λhchv)
(cvhI∗v + νh1 + µh)
=
(γh + µh)µv
cvh [1 +D1(I∗v ) +D2(I∗v )]
, (3.52)
or equivalently
1 +D1(I∗v ) +D2(I∗v ) =
(cvhI
∗
v + νh1 + µh)(γh + µh)µv
(ΛhchvN0v + I
∗
v (γhµv − Λhchv))cvh
. (3.53)
To further simplify the notation, let
c1 := ΛhchvN
0
v , c2 := γhµv − Λhchv, c3 := (γh + µh)µv c4 := νh1 + µh, (3.54)
and let G(I∗v ) and H(I
∗






(c1 + I∗v c2)cvh
(3.55)
and
H(I∗v ) := 1 +D1(I∗v ) +D2(I∗v ). (3.56)
Recall that the functions d1(τ) and d2(τ) represent the decrease in susceptibility due
to vaccination with di(τ) ∈ [0, 1] (i = 1, 2). Assume that d1(τ) ≥ d2(τ) (the efficacy
of the booster dose is not lower than the efficacy of the initial dose(s)). Moreover,
if the vaccines do not confer complete protection, which is a biologically reasonable
assumption, then there exist positive constants σ1 and σ2 such that σ1 ≤ d1(τ) ≤ 1
and σ2 ≤ d2(τ) ≤ 1 for all τ ≥ 0. Under these assumptions, we have σ1τ ≤ D1(τ) ≤ τ ,



























vσ2(τ−s) = 0 for τ > s.
(3.57)
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The integrands of D1(I∗v ) and D2(I∗v ) are positive and bounded above by the inte-
grable functions P (τ) and P (τ)τ respectively. Hence, using the Lebesgue Conver-





D2(I∗v ), which imply that lim
I∗v→∞
H(I∗v ) = 1. The latter also holds in the case
when di(τ) = 0 (i = 1, 2), or only d2(τ) = 0.
Notice from (3.54) (also listed in Table 3.3) that c1, c3 and c4 are all non-negative,
but c2 can be either positive or negative. We need to discuss both cases of c2. If
c2 > 0, then both G and H are continuous functions for I
∗







> 1 = lim
I∗v→∞
H(I∗v ). (3.58)
If c2 < 0, then G is a continuous function for 0 ≤ I∗v < −c1/c2 and
lim
I∗v→−c1/c−2
G(I∗v ) =∞, (3.59)
while H is continuous for all I∗v > 0. By applying Theorem 8.75 in [174] (changing the
order of differentiation and integration) and the Weierstrass M-test (Theorem 6.35
in [174]) it is easy to see that
H ′(I∗v ) =
d
dI∗v
(1 +D1(I∗v ) +D2(I∗v )) < 0 ∀I∗v ,
H ′′(I∗v ) > 0 ∀I∗v .
(3.60)






(c1 + I∗v c2)2
,




(c1 + I∗v c2)3
.
(3.61)
Hence, when c2 > 0, G
′(I∗v ) > 0 and G
′′(I∗v ) < 0 if c1cvh − c2c4 > 0, and G′(I∗v ) < 0
and G′′(I∗v ) > 0 otherwise. It follows that G(I
∗
v ) is convex, and is either monotone
increasing or monotone decreasing for all I∗v > 0. When c2 < 0, G
′(I∗v ) > 0 and
G′′(I∗v ) < 0 for 0 ≤ I∗v < −c1/c2; and thus, G is increasing and concave in that
interval.
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When substituting S0h = Λh/(νh1 +µh) in Definition 3.3.1 and using (3.54) we can
obtain the following expressions:
R(νh1 , νh2p, d1, d2) =
c1cvh
c4c3






H(0) = 1 +D1(0) +D2(0) = R(νh1 , νh2p, d1, d2)G(0).
(3.63)
As will be shown in Theorem 3.4.1, we need to introduce a new threshold quantity,
which is denoted by Th and defined by
Th := Th(νh1 , νh2p, d1, d2) := (c2/c3)(1 +D1(0) +D2(0)). (3.64)
The following theorem provides the conditions for the existence of endemic equi-
libria. It focuses on three scenarios according to the properties of vaccine efficacies
described by the functions di(τ):
(i) Perfect vaccine efficacies, i.e., d1(τ) = d2(τ) = 0 for all τ .
(ii) Imperfect initial dose(s) and perfect booster dose efficacies, i.e. there exists a
constant σ1 > 0 such that σ1 ≤ d1(τ) ≤ 1 and d2(τ) = 0.
(iii) Imperfect vaccine efficacies, i.e., there exist constants σ1 > 0 and σ2 > 0 such
that σ1 ≤ d1(τ) ≤ 1 and σ2 ≤ d2(τ) ≤ 1, and d2(τ) ≤ d1(τ) for all τ .
Theorem 3.4.1 Consider the three scenarios (i)-(iii) described above, and let Th be
the quantity defined in (3.64).
1. If R(νh1 , νh2p, d1, d2) > 1, then there exists exactly one endemic equilibrium.
2. If R(νh1 , νh2p, d1, d2) < 1, then
(a) for Th < 1, there exists no endemic equilibrium;
(b) for Th > 1 and c2 > 0, it is possible to have none, one or two endemic
equilibria; and
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(c) there is no endemic equilibrium when c2 < 0.
Before proving Theorem 3.4.1 we remark that when R(νh1 , νh2p, d1, d2) < 1, the
condition Th(νh1 , νh2p, d1, d2) < 1 is a sufficient condition for the non-existence of
endemic equilibria but not a necessary one. We will illustrate in Section 3.5 that there
are cases of R(νh1 , νh2p, d1, d2) < 1 and Th(νh1 , νh2p, d1, d2) > 1 in which endemic
equilibiria do not exist. Hence, Th(νh1 , νh2p, d1, d2) does not play the role of a lower
bound for R(νh1 , νh2p, d1, d2) below which disease extinction is expected.
Table 3.3.
Symbols used throughout the text. Parameters used in the expressions













c2 γhµv − Λhchv = γhµh(µv/µh − bvphv/γh)
c3 (γh + µh)µv
























R(νh1 , νh2p, d1, d2) [(c1cvh)/(c4c3)](1 +D1(0) +D2(0))
Th(νh1 , νh2p, d1, d2) (c2/c3)(1 +D1(0) +D2(0))
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Next we prove Theorem 3.4.1.
Proof From (3.56) we know that the function H has the properties that it is a
positive convex function for I∗v > 0 and decreasing to 1 with H(0) > 1. From (3.48)
and (3.54) we can see that S∗h > 0 if and only if I
∗
v > 0 > −c1/c2 for c2 > 0 or
0 < I∗v < −c1/c2 for c2 < 0.
Proof of Part 1. Since R(νh1 , νh2p, d1, d2) > 1, from (3.63) we get H(0) > G(0).





> 1 = lim
I∗v→∞
H(I∗v ). If
any of the following situations occur, G(0) < 1 < c3/c2 < H(0), 1 < G(0) < c3/c2 <
H(0), G(0) < 1 < H(0) < c3/c2 or 1 < G(0) < H(0) < c3/c3 (see Fig. 3.4), then
G′(I∗v ) > 0 and G
′′(I∗v ) < 0 since in all these cases G(0) < c3/c2 which, by (3.63),
is equivalent to c1cvh − c4c2 > 0 which by (3.61) makes G′(I∗v ) positive and G′′(I∗v )




v ) is monotone
decreasing, therefore the equation H(I∗v ) = G(I
∗
v ) has exactly one positive root. In
the remaining scenario, i.e. 1 < c3/c2 < G(0) < H(0) (see Fig. 3.4), we observe that
G′(I∗v ) < 0 and G
′′(I∗v ) < 0, hence G(I
∗
v ) is decreasing to c3/c2 > 1 and since H(I
∗
v )
is decreasing to 1 while H(0) > G(0) the equation H(I∗v ) = G(I
∗
v ) has exactly one
positive root. This concludes the existence of exactly one endemic equilibrium for the
case where c2 > 0.
Case 2: c2 < 0. Since H(0) > 0, G(0) > 0, c3 > 0 (see (3.54)) and c2/c3 < 0, the
only cases possible are c3/c2 < 0 < G(0) < 1 < H(0) and c3/c2 < 1 < G(0) < H(0)
(see Fig. 3.5). Since c2 < 0 from (3.61) we know that G is increasing and concave
in [0,−c1/c2). Also, from (3.59) lim
I∗v→−c1/c−2
G(I∗v ) = ∞ and we know that H is de-
creasing to 1. Hence, since G(0) < H(0) there exist exactly one root of the equation
G(I∗v ) = H(I
∗
v ) in the interval (0,−c1/c2) and since G is negative for I∗v > −c1/c2
while H is a positive function there are no roots for in (−c1/c2,∞), as was required
for S∗h to be positive in the case where c2 < 0. This proofs the existence of exactly
one endemic equilibrium in this case (1(b) in the theorem).
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Figure 3.4. Illustrations for proof of Theorem 3.4.1. Part 1 Case 1:
R(νh1 , νh2p, d1, d2) > 1, c2 > 0.
Proof of Part 2(a). Since R(νh1 , νh2p, d1, d2) < 1, from (3.63) we get H(0) <





> 1 = lim
I∗v→∞
H(I∗v ). Note that
c2/c3 < Th < 1. If Th < 1 < c2/c3G(0), then 1 < H(0) < c3/c2 < G(0) (see
Fig. 3.6). In this case G is decreasing to c3/c2 > H(0) and H is decreasing to 1. This
implies that the equation G(I∗v ) = H(I
∗
v ) has no roots. Hence, there is no endemic
equilibrium. If Th < c2/c3G(0) < 1, then 1 < H(0) < G(0) < c3/c2 (see Fig. 3.6).
Here G is increasing, H is decreasing and H(0) < G(0). Hence, there exist no positive
roots of the equation G(I∗v ) = H(I
∗
v ) and endemic equilibria do not exist.
Proof of Part 2(b). Since Th > 1 and R(νh1 , νh2p, d1, d2) < 1, we have 1 <
c3/c2 < H(0) < G(0) (see Fig. 3.6). In this case G is convex and decreases to
c3/c2 > 1 and H is convex and decreases to 1. Then, there exist none, exactly one
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or two endemic equilibria, if and only if the equation G(I∗v ) = H(I
∗
v ) has no, exactly
one or two roots.
Proof of Part 2(c). Since c2 < 0, the only possibility in this case is c3/c2 < 0 <
1 < H(0) < G(0) (see Fig. 3.5). Using a similar argument as above, G is increasing
and limI∗v→−c1/c−2 G(I
∗
v ) = ∞. Since H is decreasing to 1, H(0) < G(0) and G is
negative for I∗v > −c1/c2 there is no positive endemic equilibrium for c2 < 0.
Figure 3.5. Illustrations for proof of Theorem 3.4.1. Part 1 Case 2:
R(νh1 , νh2p, d1, d2) > 1, c2 < 0 and Part 2(c): R(νh1 , νh2p, d1, d2) < 1,
c2 < 0.
Corollary 3.4.2 Let νh1 = 0 = νh2, i.e. there is no vaccination in the population.
Under these assumptions R0 = R(νh1 , νh2p, d1, d2). If R0 > 1 then there exists exactly
one endemic equilibrium. If R0 < 1 then there are no endemic equilibria and the
disease free equilibrium is globally asymptotically stable.
Proof If R0 > 1 the consequence is immediate from Theorem 3.4.1. If R0 < 1 then
if νh1 = 0 = νh2 it follows that 1 + D1(0) + D2(0) = 1 and since c2/c3 < 1 always
holds, we can use Case 2(a) in Theorem 3.4.1 to justify existence. Theorem 3.3.2 for
global stability concludes the proof.
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Figure 3.6. Ilustrations for proof of Theorem 3.4.1. Part 2(a):
R(νh1 , νh2p, d1, d2) < 1 and Th < 1. Part 2(b): R(νh1 , νh2p, d1, d2) < 1,
Th > 1 and c2 > 0.
3.5 Numerical simulations
In this section we illustrate numerically the dynamics of the model. The simula-
tions were created using the computer programming languages Wolfram Mathemat-
ica [175] and MATLAB [176]. The simulations assume different vaccine efficacies,
vaccination campaigns with and without a booster dose, and demonstrate the impor-
tance of the timing of a booster dose (determined by p(τ)). Recall that the compart-
ment Vh1(t, τ) includes individuals who received initial vaccine dose(s) τ days ago,
and that these individuals move to the Vh2(t, τ) class when they receive a booster
dose.
From the proof of Theorem 3.4.1 we know that an endemic equilibrium exists if
the equation G(I∗v ) = H(I
∗
v ) has a positive solution I
∗
v , or equivalently, the function
H(I∗v )/G(I
∗
v ) intersects with 1 at a point I
∗
v > 0, (3.65)
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where G(I∗v ) and H(I
∗
v ) are defined in (3.55) and (3.56). Several of the numerical
results presented in this section are based on this statement.
Section 3.5.1 focuses on the case in which initial dose(s) and booster dose have
constant efficacy and discusses cases with and without a timed booster dose admin-
istration (determined by p(τ)). Section 3.5.2 deals with the case where the efficacy
of the initial dose(s) varies with vaccine-age (τ).
3.5.1 Constant vaccine efficacy
Let 1 and 2 denote the constant efficacies for the initial and booster vaccination
doses, respectively, with i ∈ [0, 1] for i = 1, 2. We will study first the dynamics for
the model consisting of only one vaccinated class (initial dose(s)), i.e. no subsequent
booster dose is administered (νh2 = 0); second we will study the behavior of the model
including a booster dose, distributed at a constant rate νh2 6= 0 with p(τ) = 1; and
third we will consider a timed booster dose administration, i.e. νh2 6= 0 and p(τ) 6= 1.
Initial dose(s) vaccination without subsequent booster dose (νh2 = 0)
Assume that the initial vaccine dose(s) is (are) administered at a constant rate νh1
with an efficacy of 1 without a subsequent booster dose, i.e. νh2 = 0. From νh2 = 0
we obtain D2(I∗v ) = 0 (see (3.50) or Table 3.3). From the relationship between vaccine
efficacy and its reduction in susceptibility we have d1(τ) = 1− 1. In this case (3.49)
becomes






c∗vhI∗v (1− 1) + µh
,
(3.66)
and the threshold quantity Th = Th(νh1 , νh2p, d1, d2) defined in (3.64) reduces to
Th(νh1 , 0, 1− 1, d2) =
c2
c3









From (3.62) and (3.54), the reproduction number has the form,







where Th, Tv, chv, cvh, N
0
v , and S
0
h are defined as used in (3.29).
The epidemiological parameter values used to generate Fig. 3.7-3.11 are listed in
Table 3.4. This parameter set produces the basic reproduction number R0 = 2.53.
Table 3.4.
Epidemiological parameter values used in the figures. These parameters
produce R0 = 2.53.
Parameter Value References Units
bv 0.15 151,153 b(md)
−1
µv 0.03 151,152 d
−1
phv, pvh 0.3, 0.042 153 mb
−1, hb−1
γh 1/90 153 d
−1














h:=humans, m:=mosquitoes, b:=bite, d:=day.
Figs. 3.7 and 3.9 show the intersections of H(I∗v )/G(I
∗
v ) with 1 for different cov-
erages of the initial vaccination dose(s) (% of humans vaccinated per year). Fig. 3.7
assumes 1 = 0.5 and Fig. 3.9 uses 1 = 0.65. The corresponding values of the control
reproduction number R and the threshold Th are also shown.
We observe from Fig. 3.7 that for initial vaccination dose(s) with efficacy 1 = 0.5,
no coverage can reduce the reproduction number below 1; and thus, there always exists
an endemic equilibrium. Nevertheless, the prevalence in mosquitoes (represented by
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the I∗v component of the endemic equilibrium E
∗) decreases when vaccination coverage
increases.
Figure 3.7. Each curve shows H(I∗v )/G(I
∗
v ) for different vaccination rates
νh1 which in the legend are represented by their corresponding yearly
coverage. Initial dose(s) with efficacy 1 = 0.5 is assumed. The value of
R(νh1 , 0, 1−0.5, d2) and Th(νh1 , 0, 1−0.5, d2) are also shown in the legend.
Epidemiological parameters used for this figure can be found in Table 3.4.
Fig. 3.8 shows this clearly, it plots the infected mosquitoes and the infected hu-
mans at the endemic equilibrium E∗ as curves depending on vaccination coverage
(represented by the vaccination rate νh1) for different initial dose(s) vaccine efficacies
1. It shows that for efficacies 1 = 0.3, 0.4, 0.5, 0.6 the prevalence level for mosquitoes,
I∗v , and for humans, I
∗
h, decrease with increasing vaccination coverage.
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Figure 3.8. Each curve shows the endemic equilibrium for mosquitoes, I∗v
(left), and for humans, I∗h (right) for varying initial dose(s) vaccination
rates νh1 . The different curves represent different vaccine efficacies. The
vertical lines represent the coverage (% of people vaccinated per year)
that corresponds to the particular vaccination rate νh1 . Epidemiological
parameters used for this figure can be found in Table 3.4.
Observe from Fig. 3.7 that the prevalence decreases when the control reproduc-
tion number decreases. Hence, if vaccination produces a reduction in the control
reproduction number then a reduction in prevalence will be observed.
For a higher vaccine efficacy, extinction of the disease may be possible for certain
coverages. Figs. 3.8 and 3.9 show that for initial dose(s) efficacy 1 = 0.65, a vaccina-
tion coverage greater than approximately 69% per year produce no endemic equilibria,
i.e. the only equilibrium is the disease free equilibrium. Notice from the legend of
Fig. 3.9, that for such coverages the threshold quantity Th > 1 while R < 1, hence
the condition Th < 1 when R < 1 is not a necessary but only a sufficient condition for
non-existence of endemic equilibria (see Theorem 3.4.1 and the remark after). Later
in Section 3.5.1 we will discuss cases when Th < 1 and R < 1 guaranty the extinction
of the disease. From Figs. 3.8 and 3.9 one can also observe that for 1 = 0.65 a back-
ward bifurcation occurs, i.e. endemic equilibira exist when R < 1. For example, a
vaccination coverage between 36% and 69% results in a control reproduction number
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Figure 3.9. Each curve shows H(I∗v )/G(I
∗
v ) for different vaccination rates
νh1 which in the legend are represented by their corresponding yearly
coverage. Initial dose(s) with efficacy 1 = 0.65 is assumed. The value
of R(νh1 , 0, 1− 0.65, d2) and Th(νh1 , 0, 1− 0.65, d2) are also shown in the
legend. Epidemiological parameters used for this figure can be found in
Table 3.4.
less than one but nevertheless endemic equilibria exist. The curve in Fig. 3.8 for
1 = 0.65 exhibits a typical behavior of a backward bifurcation in which the bifurca-
tion parameter is νh1 . Traditionally R is used as the bifurcation parameter, hence it
is worth to point out that in Fig. 3.8 for 1 = 0.65 the value νh1 = 0.0012 corresponds
to R = 1 and νh1 = 0.0032 corresponds to a lower bound (RL) for R such that
R = RL < 1 is a new threshold value for disease eradication. One can also observe,
that in these cases that produce backward bifurcation Th > 1. Fig. 3.10 confirms
the dynamical behavior of a backward bifurcation for νh1 = 0.0025 and 1 = 0.65. It
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plots infected mosquitoes (Iv(t)) and infected humans (Ih(t)) with respect to time t
for different initial conditions. One can observe that for initial conditions near the
disease free equilibrium the disease dies out. For initial conditions located far from
the DFE the disease persist in the population and approaches the equilibrium com-
ponents I∗v and I
∗
h, whose value is the larger value in the bifurcation plot shown in
Fig. 3.8. Hence a typical backward bifurcation occurs, i.e. if two endemic equilibria
occur when R < 1, the steady state with the larger value is stable while the smaller
one is unstable.
Figure 3.10. Each curve shows infected mosquitoes, Iv(t) (left), and in-
fected humans, Ih(t) (right) for different initial conditions. The thin curves
result for initial conditions (IC) near the disease free equilibrium (DFE)
and the thick curves for IC far from the DFE. An initial dose(s) vaccination
rate of νh1 = 0.0025 was assumed with efficacy 1 = 0.65. Epidemiological
parameters used for this figure can be found in Table 3.4.
Fig. 3.11 shows the control reproduction number reduction that can be achieved
for different vaccination coverage. Each curve represents the reduction for a specific
initial dose(s) efficacy 1. One can observe that the higher the efficacy the larger the
reduction. The figure in particular shows, that for 1 = 0.5 a reduction of almost 50%
can be achieved for a vaccination coverage greater than 30%. Also, the net reduction
achieved for coverages between 30% and above is similar.
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Although reducing the control reproduction number implies reducing the preva-
lence, the percentage in reduction is not equivalent. For instance, Fig. 3.11 shows
that a 10% coverage reduces the control reproduction number by almost 40% when
the efficacy is 1 = 0.5, but from Fig. 3.8 for 1 = 0.5 one can observe that the
reduction in prevalence for the same amount of coverage is minimal. Also, contrary
to the net reduction in R, the net reduction in prevalence between a 30% coverage
and coverages above might be significant, especially when the efficacy is high (see
Fig. 3.8).
Figure 3.11. Each curve shows the reproduction number reduction, (R0−
R(νh1 , 0, 1 − 1, d2))/R0 as a function of νh1 for different initial dose(s)
efficacies 1. The vertical lines represent the coverage that corresponds to
the particular vaccination rate νh1 . Epidemiological parameters used for
this figure can be found in Table 3.4.
Initial dose(s) vaccination with subsequent booster dose (νh2 6= 0)
Assume that initial vaccine dose(s) and a booster dose are administered at a
rate νh1 and νh2 respectively with respective constant efficacies of 1 and 2, i.e.
d1(τ) = 1 − 1 and d2(τ) = 1 − 2. We assume here that p(τ) = 1 and hence
νh2p(τ) = νh2 . This means that the expected amount of time that any individual in
the first vaccination class Vh1 (independent of its vaccine-age) spends in that class is
1/νh2 (since we assume that the time spent in the class is exponentially distributed
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with parameter νh2). Hence, everybody vaccinated with initial dose(s) is eligible to
receive a booster dose.
In this case (3.49) and (3.50) become
D1(I∗v ) =
νh1(1− 1)





(c∗vhI∗v (1− 2) + µh)(c∗vhI∗v (1− 1) + µh + νh2)
. (3.70)
The threshold quantity Th and the control reproduction number are given by


































where Th, Tv, chv, cvh, N
0
v , and S
0
h are defined as used in (3.29).
For the epidemiological parameters chosen (see Table 3.4) and assuming 2 < 1,
the threshold value Th is generally greater than one. Hence, to validate Theorem
3.4.1 we first analyze the case in which the booster dose confers complete protection,
i.e. the booster dose is perfect with efficacy 2 = 1. It might be possible to decrease
Th below one when considering other control strategies in combination with imperfect
vaccination, which we have not studied yet. We will however consider imperfect vac-
cination later in this section without making use of Th as a threshold for eradication
when R < 1.
In Fig. 3.12 the number of intersections of the function H(I∗v )/G(I
∗
v ) with 1 rep-
resent the number of endemic equilibria that the system exhibits. We assumed an
initial dose(s) vaccination rate νh1 = 0.00015, which represents a vaccination cover-
age of approximately 5%. We also assumed that the efficacy of the initial dose(s) is
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1 = 0.5. We varied the coverage of the booster dose and assumed it to be 100% effec-
tive (2 = 1). We know from Fig. 3.7 that without administering a booster dose, i.e.
νh2 = 0, the system produces one endemic equilibrium, independently of the initial
dose(s) coverage. On the contrary, Fig. 3.12 shows that when introducing a perfect
booster dose with coverage greater than 56% per year, the existence of only the dis-
ease free equilibrium can be observed. Hence, disease extinction can be achieved even
Figure 3.12. The figure shows H(I∗v )/G(I
∗
v ) for a constant initial vaccina-
tion rate νh1 = 0.00015 which represents ∼ 5% initial dose(s) vaccination
coverage per year. Initial dose(s) efficacy 1 = 0.5 was assumed. Each
curve represents a different booster vaccination rate νh2 , which in the leg-
end is represented by its corresponding yearly coverage. A perfect booster
dose is assumed (2 = 1). The value of R(0.00015, νh2 , 1− 0.5, 1− 1) and
Th(0.00015, νh2 , 1− 0.5, 1− 1) are also shown in the legend. Epidemiolog-
ical parameters used for this figure can be found in Table 3.4.
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when considering a low initial dose(s) coverage (∼ 5% per year).
Theorem 3.4.1 states that if R < 1 and Th < 1 then endemic equilibria do
not exist. One can see from Fig. 3.13 that coverage above 75% yearly of a perfect
booster dose, given a ∼ 5% initial vaccination dose(s) coverage with efficacy 1 =
0.5, produces values R < 1 and Th < 1. Hence, under these assumptions, disease
eradication is guarantied by the theorem. Observe however from Fig. 3.12, that
Figure 3.13. The Figure shows the reproduction number
R(0.00015, νh2 , 1 − 0.5, 1 − 1) and the threshold quantity
Th(0.00015, νh2 , 1 − 0.5, 1 − 1) as a function of νh2 for a constant
initial dose(s) vaccination rate νh1 = 0.00015 which represents ∼ 5%
coverage per year. Initial dose(s) efficacy 1 = 0.5 and a perfect booster
dose, 2 = 1, is assumed. Epidemiological parameters used for this figure
can be found in Table 3.4. The different regions separated by vertical
lines indicate the existence of zero, one or two endemic equilibria.
numerical simulations produce a lower bound coverage for disease extinction, which
is less than 75% a year. In fact, Fig. 3.12 shows that a booster dose coverage greater
than 56% yearly results in the extinction of the disease. Observe from Fig. 3.13 that
Th > 1 and R < 1 for a booster dose coverage between 56% and 75%, showing
hereby that Th < 1 when R < 1 is not a necessary condition for extinction. On
the other hand, observe from Fig. 3.12 that booster dose coverages between 40% and
56% produce Th > 1 and a control reproduction number less than 1, and that even
119
though R < 1 two endemic equilibria exist. This is clearly illustrated in Fig. 3.13.
Hence R < 1 is not a guaranty for disease extinction when Th > 1. This shows the
possibility for backward bifurcation when individuals are subjected to vaccination.
Since possible malaria vaccines seem to be far from perfect, we next illustrate in
Figs. 3.14 and 3.15 imperfect booster dose (2 < 1) administration at a high coverage
(95% per year) and we consider varying the initial dose(s) coverage. In practice
Figure 3.14. The figure shows H(I∗v )/G(I
∗
v ) for a constant booster dose
vaccination rate νh2 = 0.00082 which represents ∼ 95% booster coverage
yearly. The efficacy of the booster dose is assumed to be 2 = 0.65.
Each curve represents a different initial dose(s) vaccination rate νh1
with constant efficacy 1 = 0.5. The vaccination rate νh1 is in the
legend represented by its corresponding yearly coverage. The value of
R(νh1 , 0.0082, 1 − 0.5, 1 − 0.65) and Th(νh1 , 0.0082, 1 − 0.5, 1 − 0.65) are
also shown in the legend. Epidemiological parameters used in the figure
can be found in Table 3.4.
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it is reasonable to assume a low initial dose(s) coverage and a higher booster dose
coverage. For instance, in the case of the RTS,S/AS01 malaria vaccine, it is planed
that initially only children will be subjected to vaccination. Hence, the percentage
that will actually be reached by the vaccination campaign may represent a small
proportion of the total population. However, out of these vaccinated children, it is
hoped to reach as many as possible with a subsequent booster dose.
Fig. 3.14 shows that if the booster dose’s efficacy is 2 = 0.65 < 1, then an
approximate 5% initial dose(s) coverage per year of a 50% effective vaccine does not
suffice to achieve eradication even when considering a high booster dose coverage
of 95% per year. In fact, an initial dose(s) vaccine coverage greater than 73% per
year is required for the disease to go extinct. This is also illustrated in Fig. 3.15
for 2 = 0.65. Fig. 3.15 plots the infected mosquitoes and the infected humans
Figure 3.15. The Figure shows the endemic equilibrium for mosquitoes
(left) and humans (right) varying the initial dose(s) vaccination rate νh1
with constant efficacy 1 = 0.5. A constant booster dose vaccination
rate νh2 = 0.0082 is assumed which represents a 95% coverage per year.
Each curve assumes a different booster dose efficacy 2. The vertical lines
represent the coverage (% of people vaccinated per year) that corresponds
to the particular vaccination rate νh1 . Epidemiological parameters used
in the figure can be found in Table 3.4.
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at the endemic equilibrium E∗ as curves depending on initial dose(s) vaccination
coverage (represented by the rate νh1) for different booster dose efficacies 2. Backward
bifurcation can also be observed for 2 = 0.65 considering νh1 as the bifurcation
parameter. In fact, for initial dose(s) coverage between 37% and 73% yearly and
booster dose coverage of 95% per year two endemic equilibira exits whilst R < 1. As
mentioned before in the discussion of Fig. 3.8, the backward bifurcation that can be
observed here also corresponds to the typical bifurcation diagram when R is taken as
the bifurcation parameter. Here νh1 = 0.0012 corresponds to R = 1 and νh1 = 0.0036
corresponds to a lower bound for R that is less than one and is the new threshold for
disease eradication.
In cases when there exist two endemic equilibria and R < 1, i.e. when backward
bifurcation occurs, the larger equilibrium is in general stable while the smaller one is
unstable. Fig. 3.16 verifies this for parameters as in Fig. 3.15, for the case 2 = 0.65
and νh1 = 0.0025. Fig. 3.16 shows that for initial conditions near the disease free
Figure 3.16. Each curve shows infected mosquitoes, Iv(t) (left), and in-
fected humans, Ih(t) (right) for different initial conditions. The thin curves
result for initial conditions (IC) near the disease free equilibrium (DFE)
and the thick curves for IC far from the DFE. Initial dose(s) vaccination
rate νh1 = 0.0025 was assumed with efficacy 1 = 0.5. The booster dose
vaccination rate was assumed to be νh2 = 0.0082 with efficacy 2 = 0.65.
Epidemiological parameters used for this figure can be found in Table 3.4.
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equilibrium the infected solution curves approach zero (thin curves), whereas for
initial conditions away from the DFE the infected mosquitoes and infected humans
converge to the larger endemic equilibrium illustrated in Fig. 3.15 (thick curves).
Also, the unique endemic equilibrium when R > 1 is generally stable. Hence,
one can see clearly in Fig. 3.12 that the value of the stable endemic equilibrium for
each booster dose coverage decreases when coverage increases and decreases when R
decreases. Hence, as was discussed before, reducing the control reproduction number
would reduce disease prevalence. From Fig. 3.15 it can also be observed that the
higher the booster dose efficacy is the likelier it is to achieve extinction or the higher
is the prevalence reduction.
Initial dose(s) vaccination with timed administration of a subsequent booster
dose
In this section we assume initial and booster vaccination doses with constant
efficacies 1 and 2, administered at rates νh1 and νh2p(τ) respectively. We will assume
that p(τ) is as shown in Fig. 3.17, such that only individuals with vacccine-age at
least τ0 can leave the class at a rate νh2 and their time in the Vh1 class is exponentially
distributed with parameter νh2 . In other words, only individuals that received the
initial vaccination dose(s) at least τ0 days ago are eligible to receive the booster dose.
We will refer to τ0 as the minimum vaccine-age.
Under these assumptions, (3.49) and (3.50) become
D1(I∗v ) =
νh1(1− 1)
c∗vhI∗v (1− 1) + µh
(
1− νh2

















v (1−1)+µh)τ0 . (3.74)
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Figure 3.17. The figure shows the step function p(τ) that is 0 for τ < τ0 and
1 for τ ≥ τ0. Depicted is the special case of τ0 = 540 days.
The threshold quantity Th := Th(νh1 , νh2p(τ), 1 − 1, 1 − 2) and the control repro-








































We want to analyze how the inclusion of a minimum vaccine-age τ0 will affect
malaria disease dynamics. Such a minimum vaccine-age is important to consider,
since for instance in practice a booster dose is usually administered some time after
receiving the initial vaccine dose(s). In particular, in the case of the RTS,S malaria
vaccine, a booster dose will be distributed to individuals after 18 months elapsed since
the initial three vaccine doses.
We will first analyze in Figs. 3.18-3.20 the case of a perfect booster dose (2 = 1)
in order to validate Theorem 3.4.1 and will discuss later in the section scenarios where
2 < 1. We will assume for Figs. 3.18-3.20 a low initial dose(s) coverage (∼ 5%) with
efficacy 1 = 0.5. Additionally, the booster dose coverage (represented by νh2) and the
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minimum vaccine-age τ0 will be varied in Fig. 3.18 and a 95% booster dose coverage
will be assumed in Figs. 3.19 and 3.20.
Fig. 3.18 (A) and (B) show the Threshold value Th and the control reproduction
number R respectively as functions of νh2 and τ0. (C) and (D) show cross-sections for
fixed νh2 and (E) and (F) cross-sections for fixed τ0. From Fig. 3.18 (A) one can see
Figure 3.18. Depicted is (A) the threshold value Th(0.00015, νh2p(τ), 1−
0.5, 1−1) and (B) the reproduction numberR(0.00015, νh2p(τ), 1−0.5, 1−
1) as a function of νh2 and τ0. (C) and (D) show Th and R respectively
as functions of τ0 for different yearly booster dose coverages. (E) and
(F) depict Th and R respectively as functions of νh2 for different τ0. We
assume initial dose(s) vaccination rate νh1 = 0.00015 (∼ 5% coverage)
with efficacy 1 = 0.5. A perfect booster dose (2 = 1) is considered. The
remaining parameter values can be found in Table 3.4.
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that Th < 1 for a high booster dose vaccination coverage, νh2 , and a low minimum
vaccine-age τ0. Comparing with Fig. 3.18 (B) it can be observed that all (νh2 , τ0)
values that achieve Th < 1 also produce R < 1. From Fig. 3.18 (C), one can see that
a booster dose vaccination coverage of for example 80% yearly allows for a minimum
vaccine-age of up to 60 days such that Th < 1, and a vaccination coverage of 95%
yearly permits a minimum vaccine-age of up to 160 days for Th to remain below 1.
The higher the coverage, the larger τ0 is allowed to be in order to maintain Th < 1.
Fig. 3.18 (E) shows that for example for τ0 = 100 days, a vaccination rate νh2 > 90%
brings the threshold below one, but on the other hand for τ0 = 270 not even a high
booster dose vaccination rate νh2 achieves Th < 1. For the cases in which Th < 1 and
R < 1 Theorem 3.4.1 guaranties extinction of the disease. Fig. 3.18 (B) also shows
that if the booster dose vaccination rate is too low or the minimum vaccine-age is
too high, then R > 1 and hence one endemic equilibrium exists. Indeed, Fig. 3.18
(D) shows that for example for a high booster dose vaccination coverage of 95%, if
τ0 > 610 days then R > 1. Fig. 3.18 (F) shows that for instance if τ0 = 270 days
then a booster dose coverage of below 60% brings the control reproduction number
above 1.
Fig. 3.19 shows the function H(I∗v )/G(I
∗
v ), whose intersections with 1 represent
the number of endemic equilibria the system exhibits (see (3.65)). We assume a 95%
booster dose coverage per year. Under this booster coverage, comparably, we have
observed previously (see Fig. 3.12 with τ0 = 0) that extinction was achieved, i.e. the
disease was eradicated if all initially vaccinated individuals are eligible to receive the
booster dose. In Fig. 3.19 we vary the minimum vaccine-age τ0, starting with τ0 = 0.
We can observe from the figure that low minimum vaccine-ages are accepted before
endemic equilibria appear. This is clearly illustrated in Fig. 3.20 that shows Th and
R as functions of τ0.
We can observe from Fig. 3.20 that if τ0 < 150 days then Th < 1 and R < 1
and hence Theorem 3.4.1 guaranties the extinction of the disease. Additionally, from
Fig. 3.19, one can see that an even higher minimum vaccine-age is allowed before
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Figure 3.19. The figure shows the function H(I∗v )/G(I
∗
v ) for a constant
initial dose(s) vaccination rate νh1 = 0.00015 and a booster dose vac-
cination rate νh2 = 0.0082 which represent ∼ 5% and 95% vaccination
coverage per year respectively. Initial dose(s) efficacy is 1 = 0.5 and for
the booster dose 2 = 1 is assumed. Each curve represents a different
minimum vaccine-age τ0. Epidemiological parameters used for this figure
can be found in Table 3.4.
endemic equilibria appear, in fact for τ0 < 270 days the disease free equilibrium is the
only steady state of the system. For τ0 > 610, Fig. 3.20 shows that R > 1 and hence
one endemic equilibrium exists. One can also observe from Figs. 3.19 and 3.20 that
for 270 < τ0 < 610 two endemic equilibria exist and that in theses cases (see Fig. 3.20)
Th > 1 and R < 1, and hence backward bifurcation can occur when Th > 1.
Next, we will refer to Figs. 3.21 and 3.22 to discuss an imperfect booster dose
vaccination scenario (2 < 1). Fig. 3.21 shows infected mosquitoes and infected
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Figure 3.20. The figure shows the reproduction number
R(0.00015, 0.0082p(τ), 1 − 0.5, 1 − 1) and the threshold quantity
Th(0.00015, 0.0082p(τ), 1 − 0.5, 1 − 1) as functions of τ0 (for p(τ) as in
3.17) for constant vaccination rates νh1 = 0.00015 and νh2 = 0.0082 which
represent ∼ 5% and 95% coverage per year respectively and respective
efficacies of 1 = 0.5 and 2 = 1. The different regions separated by
vertical lines indicate the existence of zero, one or two endemic equilibria.
Epidemiological parameters used for this figure can be found in Table
3.4.
humans at the endemic equilibrium E∗ as curves depending on minimum vaccine-age
τ0. Each curve represents a different booster dose efficacy 2, including cases 2 < 1.
We assume a 95% booster dose coverage in all pictures of the figure. Scenarios with
three different initial dose(s) coverages ∼ 5%, 50% and 77%) are depicted in Fig. 3.21,
each with efficacy 1 = 0.5. Fig. 3.21 (A) and (B) assume an initial dose(s) coverage
of ∼ 5%. From these pictures one can observe that for the case 2 = 1 the increase in
prevalence for mosquitoes as well as for humans occurs rapidly for 270 < τ0 < 1000
and then, for high τ0 approaches the endemic value for 2 = 0.5. If 2 = 0.5 = 1
then the booster dose does not confer additional protection to the initial dose(s) and
hence for high τ0 values no added protection from the booster dose is being observed.
We can also observe from Fig. 3.21 (A) and (B) that for an imperfect booster dose
(2 < 1), no disease extinction can be achieved not even when τ0 = 0, and that the
reduction in prevalence due to booster is minimal.
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Figure 3.21. The figure shows the endemic equilibrium for mosquitoes
(left) and humans (right) as curves varying τ0, for a constant booster dose
vaccination coverage of ∼ 95% (νh2 = 0.0082) per year, an initial dose(s)
vaccination coverage of ∼ 5% (νh1 = 0.00015) in (A) and (B), of ∼ 50%
(νh1 = 0.0019) in (C) and (D) and of ∼ 77% (νh1 = 0.0044) in (E) and (F)
per year with constant efficacy 1 = 0.5. Each curve represents a different
booster dose efficacy 2. Epidemiological parameters used for this figure
can be found in Table 3.4.
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Hence, in cases of an imperfect booster dose, a higher initial coverage is needed
to lower the prevalence significantly or to achieve disease eradication. For instance,
Fig. 3.21 (C) and (D) show that for an initial dose(s) yearly vaccination coverage
of ∼ 50%, disease extinction can be achieved for high booster dose efficacies. For
relatively low efficacies on the other hand this is not possible. For instance, if 2 =
0.65, the system will always exhibit two endemic equilibria, and if 2 = 0.6 one
endemic equilibrium will always exist. If the initial dose(s) vaccination coverage is
even higher, e.g. ∼ 77% yearly (see Fig. 3.21 (E) and (F)), then extinction can be
achieved for a booster dose efficacy as low as for instance 2 = 0.65.
In all cases depicted in Fig. 3.21 it can be observed that if the minimum vaccine-
age, τ0, is too high, then the prevalence approaches an endemic level at which the
booster dose does not confer additional protection to the initial doses. How high τ0
is allowed to be in order for the booster dose to give an added benefit depends on
booster dose’s efficacy and on the initial dose(s) yearly coverage.
Next we will analyze Fig. 3.22 to discuss how the control reproduction number
changes according to τ0 and assuming different booster dose efficacies 2.
Figure 3.22. The figure shows the reproduction number
R(0.0044, 0.0082, 1 − 0.5, 1 − 2), as a function of τ0. Each curve
represents a different booster dose efficacy 2. The horizontal gray line
represents R = 1. The initial dose(s) vaccination rate is νh1 = 0.0044
(∼ 77% coverage) and the booste dose vaccination rate νh2 = 0.0082
(∼ 95% coverage). Initial dose(s) efficacy is assumed to be 1 = 0.5.
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Fig. 3.22 depicts the reproduction numberR as a function of the minimum vaccine-
age τ0 for ∼ 77% initial dose(s) coverage with efficacy 1 = 0.5 and ∼ 95% booster
dose coverage. We can observe that the control reproduction number value does not
show large changes when τ0 varies, especially for low booster dose efficacies. For
instance for 2 = 0.65 the value of R remains below one at least up to τ0 = 2000 days
(∼ 5.5 years) and increases only from 0.94 to 0.98. The change in the R value may
not be large, however, from Fig. 3.21(E) and (F) one can observe that the change in
prevalence may be significant once τ0 increases.
3.5.2 Initial vaccination dose(s) with waning efficacy
In this section we will assume waning efficacy of the initial dose(s) of the vaccine
and compare it with constant efficacy cases in order to point out the importance of
including continuous vaccine-age dependent efficacy (susceptibility) in our model.
The first scenario we will consider is depicted in Fig. 3.23, where






We assume the efficacy of the initial vaccination dose(s) is highest at the beginning,
with an efficacy of 0.5 and then decreases to 0.35 = 1 − d1(365) after one year. We
also assume that if somebody received the initial vaccine dose(s), then, in the long
term the vaccine would provide an efficacy of 0.2, i.e. lim
τ→∞
d1(τ) = 0.8 = 1− 0.2.
We assume that a perfect (2 = 1, d2(τ) = 0) booster dose gets administered at a
constant rate νh2 . In this case D2(I∗v ) = 0 and (3.49) becomes






0 d1(s)dse−(µh+νh2 )τdτ, (3.78)
The threshold quantity and the control reproduction number are given by















Figure 3.23. The figure shows the function d1(τ) = 0.8 − ˜1+(τ/365)9 (left),
which represents the proportion to which the susceptibility of an individual
that received initial vaccine dose(s) is reduced to. Equivalently, the vaccine
efficacy, 1 − d1(τ) (right) is waning. τ represents vaccine-age, 1 the initial
dose(s) efficacy and ∞ the limiting efficacy. Here ˜ = 0.3, and hence d1(0) =
0.5 = 1− 1, d1(365) = 0.65 and lim
τ→∞ d1(τ) = 0.8 = 1− 
∞.
and










where d1(τ) is as in (3.77) and Th, Tv, chv, cvh, N
0
v , and S
0
h are defined as used in
(3.29).
Fig. 3.24 can be compared to Fig. 3.12. In both figures we assume ∼ 5% initial
dose(s) coverage and a varying booster dose coverage with efficacy 2 = 1. The
difference between the figures is that in Fig. 3.12 we assumed a constant efficacy,
1 = 0, for the initial dose(s), while in Fig. 3.24 we consider waning efficacy as
depicted in Fig. 3.23. Fig. 3.24 shows that a booster dose vaccine coverage of 56%
per year is not the lower bound for disease eradication anymore, as was previously
observed from Fig. 3.12. In fact, we can observe from Fig. 3.24, that a booster dose
vaccination coverage of at least 61% is needed for the disease free equilibrium to
be the only steady state of the system. We also observe existence of two endemic
equilibria in certain cases.
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Figure 3.24. Each curve shows H(I∗v )/G(I
∗
v ) for different booster vac-
cination rates νh2 , which in the legend are represented by their cor-
responding yearly coverage. The legend also shows the values of
R(0.0015, νh2 , d1(τ), 1− 1) and Th(0.0015, νh2 , d1(τ), 1− 1). We assumed
d1(τ) to be as in Fig. 3.23. Epidemiological parameters used can be found
in Table 3.4.
Fig. 3.25 compares existence of endemic equilibria for different efficacy assump-
tions of the initial dose(s). We assume an initial dose(s) coverage of ∼ 5% and a
booster dose coverage of ∼ 60% with efficacy 2 = 1. The curves without mark-
ers represent waning efficacy equal to 1 − d1(τ), where d1(τ) is as in (3.77). In
each case depicted we assume d1(0) = 0.5 (hence the efficacy at the beginning is
1 = 1 − d1(0) = 0.5) and that the efficacy wanes to the limiting efficacy value
∞ = 1 − d∞1 , where d∞1 := limτ→∞ d1(τ). The curves with markers represent con-
stant initial dose(s) efficacy 1.
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Figure 3.25. The figure shows H(I∗v )/G(I
∗
v ) for different efficacy assump-
tions. In the legend ∞ stands for the limiting efficacy obtained from
∞ = 1−d∞1 , where d1(τ) := d∞1 − ˜/(1+(
τ
365
)9) and d∞1 := limτ→∞ d1(τ).
The lines without markers represent waning efficacy and the curves with
markers represent constant efficacy 1. We assume vaccination rates
νh1 = 0.00015 and νh2 = 0.0025 which represent coverages of ∼ 5% and
60% per year respectively and a booster dose efficacy of 2 = 1. Epi-
demiological parameter values used for this figure can be found in Table
3.4.
One can observe from Fig. 3.25 that there are no endemic equilibria if a constant
initial dose(s) vaccination efficacy 1 = 0.5 is assumed or if the efficacy wanes from
only 0.5 to 0.4, i.e. only by 10%. If the efficacy wanes by a higher amount, then we
can see that endemic equilibria appear. We can also observe that comparing the case
when the efficacy wanes to zero (∞ = 0) with the constant efficacy case 1 = 0.2,
that the stable endemic equilibrium (usually the larger one) for the waning case is
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much smaller than the one appearing for the constant efficacy case. Hence, the high
efficacy shown by the waning efficacy function at the beginning, has an important
impact on reducing the prevalence, even though ultimately the efficacy wanes to zero.
One can make an analogous observation comparing the cases ∞ = 0.2 and 1 = 0.4
even though the difference in prevalence for these cases is not as pronounced.
Fig. 3.27 shows the comparison between scenarios, in which different efficacies are
considered for the initial vaccination dose(s). These include two cases where the initial
dose(s) efficacy is assumed to wane from 0.5 to 0.2. The first case is as depicted in
Fig. 3.23 and the second case is as shown in Fig. 3.26. Also scenarios where constant
efficacy is assumed are included in the figure. In this figure we again consider an
initial dose(s) coverage of ∼ 5% and a booster dose coverage of ∼ 60% with efficacy
2 = 1. When two endemic equilibria occur we assume that the larger equilibrium to
be the stable one.
Figure 3.26. The Figure shows the function d1(τ) = 0.8 − ˜1+(τ2/700)1/2
(left), which represents the reduction in susceptibility of an individual
that received the initial vaccination dose(s), while the vaccine efficacy,
1− d1(τ) (right) is waning. Here ˜ = 0.3, and hence d1(0) = 0.5 = 1− 1
and lim
τ→∞
d1(τ) = 0.8 = 1− ∞.
One can see in Fig. 3.27 that if the efficacy wanes as shown in Fig. 3.26 then
the prevalence observed for this type of waning efficacy is higher than if an average
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efficacy of (0.5 + 0.2)/2 = 0.65 is assumed. Hence, to not considering waning efficacy
but taking a simple arithmetic mean of initial efficacy with limiting efficacy could
underestimate the prevalence. On the other hand if a waning efficacy as in Fig. 3.77 is
assumed, then the prevalence is lower than the prevalence obtained when an average
efficacy is considered. Hence, in this case, to not consider waning efficacy could
overestimate the prevalence.
Figure 3.27. The figure shows H(I∗v )/G(I
∗
v ) for different efficacy assump-
tions of the initial dose(s). The initial dose(s) and booster dose yearly cov-
erage is assumed to be ∼ 5% (νh1 = 0.00015) and ∼ 60% (νh1 = 0.0025)
respectively per year with efficacy 2 = 1 for the booster dose. Epidemio-
logical parameters values used for this figure can be found in Table 3.4.
136
3.6 Results and Conclusions
Malaria remains a huge international health problem even after successful im-
plementation of existing control measures, such as insecticide treated bed-nets and
treatment with anti-malarial drugs. Because of an increasing development of drug-
resistance of the parasite and insecticide resistance of the mosquito, a malaria vaccine
is urgently needed to complement existing control efforts. In recent years, there has
been accelerated progress towards malaria vaccine development research [64], but a
licensed malaria vaccine is not yet available. The most advanced malaria vaccine is
the RTS,S/AS01 vaccine, which is under phase-3 clinical (the last phase before licens-
ing). Vaccines often work best when given in several doses followed by booster doses,
as is the case for example for the varicella (chickenpox) or rotavirus vaccine [178].
The most promising malaria vaccine is not an exception. In fact, the RTS,S/AS01
malaria vaccine is considered to be distributed in three initial doses followed by a
booster dose [64].
Most mathematical models, modeling vaccination with a separate compartment,
include only one vaccinated class. We observed for example in Section 3.5.1 that a
model including one vaccination class concludes that only a vaccine with a high effi-
cacy, when distributed at a high coverage, will allow disease extinction (see Fig. 3.8).
Considering a model that includes the more realistic scenario of several doses (sev-
eral vaccinated classes), allows us to study outcomes of vaccination campaigns with
a vaccine that increases its efficacy after each dose, starting with a low efficacy. For
instance, the about to be licensed RTS,S/AS01 vaccine for malaria, shows an efficacy
on average close to 0.5 after the initial three doses and an subsequent booster dose
is planed after 18 months, which is hoped to increase efficacy that may have waned
over time [64]. Due to the available efficacy data after the three required doses of the
RTS,S/AS01 malaria vaccine, we combine in our analysis individuals that received
these initial doses into the first vaccination class. We study the effect of a booster
dose and consider individuals that received that subsequent booster dose to be in the
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second vaccinated class. If we assume the initial three doses to have an efficacy of 0.5
and the additional booster dose an efficacy of 0.65, then we can observe from results
in Section 3.5.1, Fig. 3.15, that an initial doses coverage of 73% and a final dose cov-
erage of 95% yearly would suffice for disease eradication. Hence, it is not necessary
for a vaccine to have a high efficacy due to initial doses vaccination to achieve disease
extinction, i.e. a vaccine that starts with a relatively low efficacy (0.5) but increases
its efficacy if additional doses are administered, also allows under the right coverage
for extinction of the disease.
We can observe from numerical results presented in Section 3.5.1 that for imperfect
vaccination the model excibits backward bifrucation for certain vaccination rates.
This type of backward bifurcation in a model with imperfect vaccines have been
observed in previous studies such as [179].
In general for the vaccines to be most effective it is important that the doses are not
given too close to each other [178]. As mentioned before, for the RTS,S/AS01 malaria
vaccine, an additional booster dose is considered to be given to individuals that
have received the initial three doses. For best immune response this additional dose
will be received at least 18 months after having received the initial three doses [64].
Hence, a realistic model should also include this “eligibility criterion” for booster
vaccination. In this study we defined minimum vaccine-age (τ0) to be the minimum
time that must have elapsed since vaccination with the initial dose(s) for an individual
to become eligible to receive the booster dose. In other words, individuals eligible
for booster vaccination must have vaccine-age at least τ0. Assume that to achieve
an optimal immune response from a booster dose with efficacy 0.65 it has to be
administered after 18 months from receiving the initial three doses, i.e. the vaccine-
age of individuals in the initial vaccinated class has to be at least 18 months (547 days).
Under this assumption the coverage needed to achieve extinction, if at all possible,
can be discussed using results in Section 3.5.1 for timed administration of a booster
dose. For instance, from Fig. 3.21 (E) and (F) one can observe that a high initial
doses coverage of ∼ 77% and booster dose with coverage ∼ 95% and efficacy 0.65,
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would allow extinction of the disease only if the immune response would be optimal
after less than around τ0 = 150 days of initial doses vaccination. However, endemic
equilibria are inevitable if the booster dose is administered after only τ0 = 547 days
from initial doses vaccination, and actually two endemic equilibira appear.
Worth mentioning is that although disease extinction may not be possible, one can
nevertheless observe a decrease in prevalence. It can also be observed that for higher
booster dose efficacy, e.g. 0.9, under the same coverage assumptions a vaccination
after 547 days (18 months) would achieve extinction of the disease. One can conclude
that a model that does not consider timed administration of a booster dose can
predict extinction of the disease (as can be seen in Fig. 3.21 (E) and (F) for τ0 = 0
and 1 = 0.65), although under realistic assumptions extinction may not be possible.
Many times a timely delivery of a vaccine is not possible because of administrative
difficulties, especially in underdeveloped countries [180]. Assume that it is suggested
that the optimal booster dose immune response can only be achieved after at least 18
months post initial vaccination doses. We can observe, that under this assumption,
an optimal prevalence reduction is achieved if the minimum vaccine-age to receive
the booster dose is exactly 18 months and not higher. In fact, we can see for instance
from Fig. 3.21 (E) and (F) for 1 = 0.65, that the higher the minimum vaccine-age
to receive the booster dose is, the higher the prevalence gets.
Suppose a vaccination campaign would vaccinated a certain percentage of individ-
uals each year with the initial three doses and distribute the booster dose in batches,
in the same chronological order in which the initial three doses batches were dis-
tributed. Suppose a delay in starting a booster dose vaccination campaign occurs,
i.e. the booster dose delivery cannot occur after 18 months of finishing the initial
doses administration (corresponding to that booster dose vaccine batch). This would
mean that everybody vaccinated initially has vaccine-age greater than 18 months. In
this case the booster dose may not give an added benefit to the three doses vacci-
nation. In fact, we can observe from Fig. 3.21 (E) and (F) for 1 = 0.65, that when
individuals vaccinated with the initial doses have a minimum vaccine-age of approx-
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imately 1500 days (approx. four years) and above, then the prevalence level is very
close to what it would have been if the booster dose would not confer additional im-
munity to the initial doses (initial and booster doses have the same efficacy). Hence,
we can conclude that if the cost of distributing a booster dose is high and the logistic
in implementing the booster dose vaccination campaign (that prioritizes in the way
stated above) is difficult and long-lasting, then the cost associated with it might not
be worth the obtained benefit added by it. In such a case we conclude that all efforts
(financial and logistical) should be put into the initial doses vaccination campaign.
The malaria RTS,S/AS01 vaccine is planed to reach first small children in Sub-
Saharan Africa [64], since they are most vulnerable to the disease. The coverage
achieved even for well established childhood vaccines in Sub-Saharan Africa is low;
for instance only a 50% of the targeted population for three doses of the DTP3
(diphtheria, tetanus, pertussis) vaccine and 20% for the Hepatitis B vaccine is reached
yearly [177]. The targeted population for malaria vaccines are in the first place
children, which constitute 10-15% of the population of many Sub-Saharan African
countries [181]. Taking this into consideration, a coverage of approximately 5% of the
total population yearly seems reasonable to consider in our model for vaccination with
RTS,S/AS01. Unfortunately, under these assumptions the reduction in prevalence
that our model shows is not large, even without considering timed administration of
a booster dose (see Fig. 3.15). Hence a larger coverage for the initial doses might
be necessarily and/or a vaccine with higher efficacy might be needed to significantly
reduce the prevalence and/or achieve the ultimate goal of disease extinction. In other
words, if a vaccine with a better efficacy cannot be produced, then to include adult
vaccination might have to be considered.
When a vaccination campaign is being designed its success is often measured
by how the control reproduction number will be affected by it. We have seen in
Section 3.5.1 that low vaccination coverages might have the greatest impact on the
control reproduction number; that between larger coverages the net reduction in the
reproduction number is not high and that the minimum vaccine-age for the booster
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dose does not impact R largely. Nevertheless, these observations on the control
reproduction number might not suffice to make an informed decision on the effects
on disease prevalence of a vaccination campaign. We observed that although for high
vaccination rates the net reduction in R is not large, the reduction in prevalence
might be. We also discussed that despite R not being largely affected by the timing
of the booster dose, i.e. by the minimum vaccine-age τ0, the disease prevalence might
be affected, especially for high vaccination coverages and high efficacies. We have
also observed that backward bifurcation occurs for different vaccination coverages
and minimum vaccine-ages. This means that endemic equilibria might exist whilst
R < 1, which usually guaranties extinction of the disease. Hence, public health
officials need to be cautious when deciding what optimal coverage is needed in order
to achieve their goals in reducing disease prevalence and policies can not be based
solely on the effects on the reproduction number.
The RTS,S/AS01 malaria vaccine’s efficacy is suspected to wane over time. We
analyzed in Section 3.5.2 scenarios in which the efficacy of the initial vaccination doses
wanes and a perfect booster dose is administered. We conclude that not considering
waning efficacy may underestimate or overestimate the actual disease prevalence,
depending on the shape of the vaccine-age dependent efficacy function. If a model
is constructed assuming constant efficacies, even extinction of the disease could be
wrongly concluded. Hence, it is important to understand the shape of the function
that describes efficacy waning in order to be able to make accurate predictions on the
prevalence.
In summary, our model shows several new aspects to be included when studying
vaccination of a vector-borne disease such as malaria in underdeveloped countries,
which to the best of our knowledge have not been studied yet. It shows the flexibility
and necessity of including more than one vaccination class in a model when analyzing
vaccination campaigns that require several vaccination doses. Also, to structure the
model according to vaccine-age is an important addition to existing models, since it
allows to incorporate and analyze timing of administration of a subsequent booster
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dose after receiving initial doses. This is important to consider in order to include the
time needed for the immune system to respond in an optimal way to an additional
vaccine dose. It is also needed in order to account for logistical difficulties in booster
dose vaccine implementation, a feature that needs to be considered especially in un-
derdeveloped countries. The vaccine-age structure also allows to analyze cases where
protection due to vaccination wanes. Without it, the model may underestimate or
overestimate disease prevalence. In general we can conclude that it is of great impor-
tance to obtain more accurate information on what efficacy is to be expected after
each dose. In fact, we saw in Section 3.5 that different efficacy assumptions (constant
and well as waning) make a big difference on what coverage is needed to achieve the
goals on prevalence. Hence research in that direction should be encouraged.
Although our model gives much new insight, it can still be improved in several
ways. First, to divide the model into age groups would be beneficial to make more
accurate predictions and recommendations. This is due to the different immune re-
sponses children and adults show to malaria, especially in endemic countries with
high malaria transmission, and also since children will be the first to be targeted once
a malaria vaccine gets licensed. Second, it would also be interesting to include a com-
partment for asymptomatic infections due to naturally acquired immunity, especially
for the adult population, since it is suggested that the efficacy against asymptomatic
parasitemia may persist longer than the efficacy against clinical malaria (symptomatic
parasitemia) [164,166]. Third, it would be of interest to study how the waning efficacy
of the initial doses in combination with its effect on the efficacy of the booster dose
(might wane as well), affect malaria dynamics. This can be analyzed once a better
understanding is achieved about the amount of protection children receive after each
dose, and about how/if immunity waning occurs after the booster dose.
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4. AN INFECTION-AGE STRUCTURED MODEL FOR
THE COUPLED DYNAMICS OF HIV AND HSV-2
The work presented in this chapter is in collaboration with Georgi Kapitanov and
Christina (Lorenzo) Alvey. It has been accepted is to appear in the Journal of Math-
ematical Biosciences and Engineering (MBE).
4.1 Introduction
In the current chapter we develop a structured model to study the dynamics of
HIV/HSV-2 co-infection. The model is based on [106], where Feng et al. present an
ODE model that incorporates HSV-2 latency as a separate class of the population.
We are focused on the effect of HSV-2 on HIV, hence we model HIV as a system
of ordinary differential equations. In the current article, HSV-2 is modeled by par-
tial differential equations with respect to chronological time and time-since-infection
(age-of-infection). There are advantages to incorporate age-of-infection dependent
functions for several of our parameters. One is reduction of the number of population
classes while still incorporating latency. Although we do not consider it in the cur-
rent chapter, another advantage would be to incorporate both, reduction of shedding
since the initial outbreak and reduction of the frequency of outbreaks as the disease
progresses. Asymptomatic shedding can be included implicitly in the construction
of the age-of-infection dependent transmission function. The disadvantage is in the
increased mathematical complexity of the model. We have several goals. First, to
identify the key aspects of the coupled dynamics of the two STDs and, more impor-
tantly, the parameters associated with HSV-2 that drive the HIV epidemics. Second,
we divide our population in three groups: males, general population females, and
female sex workers (FSWs). Considering only heterosexual relationships, we want to
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explore the effect of FSWs on the disease dynamics. Third, to explain the role of the
age-of-infection variable on the calculation of the reproduction numbers of the STDs.
The chapter is organized in the following manner: Section 4.2 introduces the
model, Section 4.3 presents the basic reproduction numbers for each disease. The
invasion reproduction numbers for each disease and their biological interpretations
are shown in Section 4.4. Section 4.5 deals with numerical simulations and sensitiv-
ity analysis, and Section 4.6 contains a discussion of our results. The calculation of
the invasion reproduction numbers is outlined in Appendices B and C. Appendix D
contains biological interpretations or the terms in the invasion reproduction numbers
and Appendix E explains how we chose the parameters for our numerical simulations
and sensitivity analysis.
4.2 Model formulation
In this section we present a model that describes the interaction and transmission
dynamics of HSV-2 and HIV among a heterosexual population. We consider three
basic population groups: males (denoted m), low-risk females (f1, members of the
general population), and high-risk females (f2, generally sex workers). We only con-
sider transmission due to sexual encounters. Since we focus on the influence of HSV-2
on HIV prevalence, we use ordinary differential equations to describe the transmission
dynamics of HIV in a simplified manner.
The population structure is compartmentalized at time t into the following classes
of individuals for each group i = m, f1, f2: susceptible (Si(t)), HIV-positive (Hi(t)),
HSV-2-positive (Vi(t, a), time-since-infection dependent), and co-infected (Pi(t, a),





Pi(t, a)da = Ni(t), represents the total population size of the group
and that the number of HSV-2 positive and co-infected individuals with time-since-







In our model there is a constant population recruitment rate Λi, which represents





µPi (a) represent a combination of mortality and sexual inactivity (due to age or acqui-
sition of AIDS). The force-of-infection terms are λHi (t) and λ
V
i (t) for HIV and HSV-2
respectively. The expression for these terms is in (4.3). The terms δHi and δ
V
i (a) refer
to the higher susceptibility of people with one STD to the other, i.e. individuals with
HIV have an enhanced chance of acquiring HSV-2 and individuals with HSV-2 have a
higher probability of getting HIV. δVi (a) is dependent on the time since infection be-
cause whether a person with HSV-2 is latent or shedding may have an effect on their
immune system and probability of being infected. The following two describe the
boundary conditions: susceptibles infected with HSV-2 become HSV-2-positive with
time-since-infection 0 and HIV-positive individuals infected with HSV-2 become co-
infected with time-since-infection 0. We also assume some initial values/distributions






i (a). Equation (4.1) presents the system, Ta-
bles 4.1 and 4.2 explain the variables and parameters, and for a visual representation
of the dynamics described in (4.1), refer to Fig. 4.1.
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Figure 4.1. Model dynamics in a diagram form.
Let bi be the number of partnerships an individual of group i has per unit time.
Also, let c1 and c2 be the fraction of those partnerships a male individual has with a
low-risk and a high-risk female partner, respectively. Note that c2 = 1− c1. A male
has the same number of partnerships with low-risk females as a low-risk female with
males. The same holds true for males and high-risk females. Therefore, the following
balance conditions emerge:
bmc1Nm = bf1Nf1
bmc2Nm = bf2Nf2 .
(4.2)
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, j = 1, 2.
(4.3)
We assume that all our parameters are non-negative, and need to fulfill the follow-
ing in order to allow the mathematical treatment and to be biologically significant:
• S0i ≥ 0, H0i ≥ 0, V 0i (.), P 0i (.) ∈ L1([0,∞),R+0 ), i ∈ {m, f1, f2};
• δVi (.), δPi (.), σPi (.) ∈ L∞[0,∞);
• δVi (a), δPi (a), σPi (a) ≥ 1, ∀a ≥ 0, δHi ≥ 1.
• µVi (.), µPi (.) ∈ L∞[0,∞), i ∈ {m, f1, f2};
• ∃µ0, a∗ > 0, such that µVi (a), µPi (a) ≥ µ0, ∀a > a∗
• βVm,fj(.), βVfj ,m(.) ∈ L∞[0,∞), j = 1, 2.
Positivity of solutions and well-posedness of the problem can be shown. Using
the method of characteristics [169], we have the following solutions for Vi(t, a) and








i (τ−t+a)λHi (τ)+µVi (τ−t+a)dτ , a > t





















i (τ)dτδi(x− t+ a)λHi (x)Vi(x, x− t+ a)dx, a > t
δHi λ
V






i (x+ t− a)Vi(x+ t− a, x)dx, t > a,
(4.5)
where LPi (a) := e
− ∫ a0 µPi (τ)dτ is the probability that an individual in class Pi will survive
until time-since-HSV-2-infection a. Note that it can be shown that the first parts of
(4.4) and (4.5) decay to 0 in L1 norm with respect to a as time goes to infinity. Since
we will be examining the behavior of the system at equilibria, we will only consider
the second parts of (4.4) and (4.5), namely the cases when t > a.
Table 4.1.
Description of variables used in the model.
Variable Description
i = m, f1, f2 Male, low-risk female, high-risk female sub-index.
Ni(t) Total population of group i at time t.
Si(t) Number of susceptible individuals of group i at time t.
Hi(t) Number of HIV-positive individuals of group i at time t.
Vi(t, a) Number of individuals of group i who have been infected
with HSV-2 for a months, at chronological time t.
Pi(t, a) Number of individuals of group i who have both HIV and
HSV-2 and have been infected with HSV-2 for a months,
at chronological time t.
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Table 4.2.
Description of parameters used in the model.
Parameter Description
i = m, f1, f2 Male, low-risk female, high-risk female sub-index.
µi Rate of exiting sexual activity for group i.
Λi Total recruitment rate of group i.
δVi (a) Enhanced susceptibility of individuals with HSV-2 to HIV.
δHi Enhanced susceptibility of individuals with HIV to HSV-2.
σPi (a) Enhanced infectivity of individuals with both STDs when
transmitting HSV-2.
δPi (a) Enhanced infectivity of individuals with both STDs when
transmitting HIV.
bm Rate of male sexual partnerships with females.
bfi Rate of sexual partnerships of group i females with males.




Probability of HIV transmission by an HIV-positive indi-




Probability of HIV transmission by an HIV-positive indi-
vidual of group fj to an m partner, per partnership, j = 1, 2.
βVm,fj(a) Probability of HSV-2 transmission by an HSV-2-positive
individual of group m with time-since-infection a to an fj
partner, per partnership, j = 1, 2.
βVfj ,m(a) Probability of HSV-2 transmission by an HSV-2-positive
individual of group fj with time-since-infection a to an m
partner, per partnership, j = 1, 2.
λHm(t) HIV infection rate of male individuals at time t.
λHfj(t) HIV infection rate of fj individuals at time t, j = 1, 2.
λVm(t) HSV-2 infection rate of male individuals at time t.
λVfj(t) HSV-2 infection rate of fj individuals at time t, j = 1, 2.
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4.3 The basic reproduction numbers
The following sections deal with finding the basic reproduction number of each
disease, i.e. RH0 for HIV and R
V
0 for HSV-2 when each disease is introduced in a popu-
lation that is at the disease free equilibrium (DFE). The DFE is (S0i := Λi/µ
S
i , 0, 0, 0),
i = m, f1, f2. In our analysis we want to consider constant population size for each






i (a) = µ
P
i (a). We will
keep the notation with the superscripts in each class for interpretation purposes.
4.3.1 Basic reproduction number for HIV (RH0 )
We derive first the basic reproduction number for HIV. Suppose that the number of
people with HSV-2 infection is and remains at the disease free equilibrium Vi(t, a) = 0,
Pi(t, a) = 0. Then the force of infection terms reduce to:















, j = 1, 2
and the system to analyze is
dSi
dt
= Λi − λHi (t)Si(t)− µSi Si(t)
dHi
dt
= λHi (t)Si(t)− µHi Hi(t)
Si(0) = S
0




System (4.6) has three infected variables with HIV, namely Hi, i = m, f1, f2.
Using the notation from [10], we construct the matrices F , F and V , V . F is a
vector of rates of appearances of new infections in the infectious compartments (Hm,
Hf1 , and Hf2), while V is a vector of rates of transfer of individuals in the infectious
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compartments by any other means. F and V are the Jacobian matrices of F and V ,






























Evaluating at the DFE (noting that S0i = N
0












































































For j = 1, 2, bmcjβ
H
m,fj
is the rate with which HIV-positive males infect fj females,




is the total number of fj females one HIV-positive male individual will infect within
his life-time of sexual activity. Similarly, bfjβ
H
fj ,m
/µHfj is the number of males an HIV-
positive fj individual will infect in her life-time of sexual activity. Therefore, (4.7) is
the average number of secondary male infections produced by one HIV-positive male
through partnerships with fj individuals.
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4.3.2 Basic reproduction number for HSV-2 (RV0 )
Assume HIV is and remains at the disease free equilibrium, i.e H0i = 0, P
0
i (a) = 0.
The force of infection terms are then as follows















, j = 1, 2.
(4.8)
Then, the system to consider is
dSi
dt






= −µVi Vi(t, a)
Si(0) = S
0
i ;Vi(0, a) = V
0
i (a);Vi(t, 0) = λ
V
i (t)Si(t), i = m, f1, f2.
(4.9)
For simplification of notation we will define LVi (a) := e
− ∫ a0 µVi (τ)dτ , which represents
the probability that an individual is still sexually active at time-since-HSV-2-infection
a. We will also call







(a)LVm(a), j = 1, 2. (4.10)
Substituting the second part of (4.4), i.e.
Vi(t, a) = λ
V




i (τ)dτ , a < t (4.11)
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into (4.8), integrating over a and adding the classes in order to get an expression




= Λi − λVi (t)Si(t)− µSi Si(t)
dNi
dt














, j = 1, 2,
(4.12)




i , i = m, f1, f2.
Analyzing the previous system is equivalent to analyzing system (4.9), since the
number of infectious individuals Vi can be obtained from Si(t), Ni(t), λ
V
i (t),
i = m, f1, f2.
Next, we linearize system (4.12) around the DFE and by assuming constant popu-
lation size we reduce the system to only the disease-related variables λVi , i = m, f1, f2,














, j = 1, 2.
(4.13)
To find eigenvalues of the linear operator, we look for solutions of the form λVi (t) =
λ¯Vi e
ωt, i = m, f1, f2, where λ¯i is positive for each i and ω is the eigenvalue. By


















, j = 1, 2.
(4.14)
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e−aωAVfj ,m(a)da, j = 1, 2.













(ω) = 1. (4.16)
It is easy to see that for real ω, lim
ω→∞
G(ω) = 0 and lim
ω→−∞
G(ω) =∞ and that G(ω) is
a decreasing function. Also, by standard techniques, it is easy to show that the real
root of the equation G(ω) = 1 is the leading root, i.e. if ω0 is the real root and ω is
any complex root, then Re(ω) < ω0.








































(a)LVm(a)da represents the number of fj individuals in-







(a)da male infections with HSV-2 during their entire period
of infection. Thus, the product of these two factors represents the average number
of secondary male infections produced by one infected male individual via females of
group j, j = 1, 2.
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4.4 Invasion reproduction numbers
In this section we describe and explain the invasion reproduction number (IRN)
for each STD, i.e. the reproduction number of one of the diseases when the other STD
is in an endemic state. Invasion reproduction number are well know in the literature
and their expressions have been widely used and computed for ODE models in the
literature. For instance, Martcheva et al. [182], Porco et al. [183] and Kribs et al. [184]
study invasion reproduction numbers for diseases involving different strains. A simple
explanation on how IRNs are computed for ODE models can be found in [183]. Also,
Feng et al. [106] study IRNs for an ODE model that studies the synergy between
HSV-2 and HIV. To the best of our knowledge IRNs for infection-age structured
model as the one presented in this chapter have not been computed yet.




i (a) = µ
P
i (a), i = m, f1, f2 and will keep the different
notation for easier interpretation of the results.
4.4.1 Invasion HIV reproduction number (RHV )
In this section we will present a biological interpretation of the invasion reproduc-
tion number for HIV, RHV , when invading an HSV-2 endemic population. We assume
the HIV disease invades an endemic HSV-2 population. The variables Hi, Pi will
be assumed to be disease variables and the HSV-2 endemic equilibrium is given by
(S0i , 0, V
0




where the detailed expression for GHV (0) is long and complicated and hence can be
found in Appendix B (B.11) with its derivation.
The invasion reproduction number RHV is a measure of how many secondary cases
one HIV infectious individual will produce on average during his/her infectious pe-
riod, when introduced into an HIV susceptible but HSV-2 endemic population. We
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understand by secondary infection the average number of new HIV cases that arise
in one of the population groups to which the initial infectious individual belonged.
Our model considers an enhanced susceptibility for HSV-2 only individuals to
HIV, measured by the parameters δVm(a), δ
V
fj
(a), j = 1, 2; 0 < a < ∞. Therefore, one
has to be cautious when introducing/choosing the initial HIV infectious individual,
for this person might be infected with HSV-2 before acquiring HIV. In the biological
interpretation we present in this section, we choose to start by introducing an infected
male individual into the HIV susceptible population. Hence, this first HIV infected
male individual can be chosen either from the susceptible male population S0m or from
the HSV-2 infected male population with time-since-HSV-2-infection x, V 0m(x). The









m respectively. This first male if chosen
to be susceptible becomes then part of the Hm class, and if chosen from the HSV-2
infected male population then becomes part of the Pm class (entering the co-infection
class at time-since-HSV-2-infection x).
Fig. 4.2 describes the paths that lead to new HIV infections starting with the
initial infected male individual. Each such path will be represented by terms in RHV ,
which will be explained in detail in the rest of this section.
We will rewrite (4.19) in a way that is easier to interpret biologically, but first
we introduce the following notations for ease of presentation: THi := 1/E
H
i (0) is the
average time an individual spends in class Hi, for i = m, f1, f2, where the definition
of EHi (0), i = m, f1, f2 can be found in Appendix B (B.12). Further, the rate at which
an HIV male (Hm) infects susceptible females (Sfj , j = 1, 2) and HSV-2 only females











is the rate at which a co-infected male Pm(a), with
time-since-HSV-2-infection a, infects a female with HIV where δPm(a) is the enhanced
HIV infectivity of a male with co-infection and time-since-HSV-2-infection equal to
a.
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fj HIV susceptible individuals to be infected Sfj Vfj
? ??






New generation of HIV infected males Nm
Infects with HIV -
Result of HIV infection -
Result of HSV-2 infection -
Figure 4.2. Transmission dynamics of HIV between classes m and fj.
In an analogous way, the rates of HIV infection from female to male are given by























m(a)da, for j = 1, 2
(4.20)
Then the probability that an HIV female individual (Hfj , j = 1, 2) becomes co-





THfj , j = 1, 2.
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Analogously, the probability that an HIV male individual (Hm) becomes co-infected







THm , j = 1, 2.
Expression (4.19) can then be rewritten in the following form:
(RHV )
2 = (RHV (m, f1,m))
























































































m(a)da represents the weighted HIV susceptible pop-
ulation. Each term on the right hand side of (4.21) represents the infection cycle
from male (m) to female (f1, f2) back to male. Table 4.3 shows detailed interpreta-
tions of abbreviations appearing in each of the terms of equation (4.22) and each one
corresponds to one of the paths in Fig. 4.2.
The first six terms in (4.22) correspond to secondary HIV cases due to the ini-
tial HIV case being a male individual in the Hm class and the last three terms in
158
(4.22) correspond to secondary HIV infections traced back to an initial co-infected
Pm individual. Each of the expressions listed in Table 4.3 is of the form X Z(U)(Y ) or
Pm(U) for X = Hfj ,Pfj ; Z = Hm,Pm, Pm; U = Hm, V 0m; Y = S0fj , V 0fj ; j = 1, 2. X
represents number of people in the X class, for X = Hfj , Pfj and Pm(U) represent
the probability that a person in class U moves to class Pm.
Also, X Z(U)(Y ) describes the following disease dynamics: a person in class U
moves to class Z infects people in class Y , who due to that infection end up in class
X.
The remainder of this section describes biologically the first term in equation






HHmfj (S0fj) represents the number of HIV females that got infected when being sus-
ceptible by one HIV male, throughout his sexual lifetime (see Table 4.3). This term
corresponds to the following disease dynamics pictured in Fig. 4.2,
Sm
initial−−−→ Hm infects−−−−→ Sfj become−−−−→ Hfj infect−−−→ Nm.
Then the interpretation is as follows. As can be seen in Table 4.3, the initial HIV





weighted population. This male infects susceptible females (HHmfj (S0fj)), who then as









For the remaining terms that are explained in Appendix D, we only present the
arrows appearing in Fig. 4.2 that correspond to the dynamics of the remaining of the
terms presented in equation (4.22):
Sm
initial−−−→ Hm becomes−−−−→ Pm infects−−−−→ Sfj become−−−−→ Hfj infect−−−→ Nm,
Sm
initial−−−→ Hm infects−−−−→ Sfj become−−−−→ Hfj become−−−−→ Pfj infect−−−→ Nm,
Sm
initial−−−→ Hm becomes−−−−→ Pm infects−−−−→ Sfj become−−−−→ Hfj become−−−−→ Pfj infect−−−→ Nm,
Sm































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































initial−−−→ Hm becomes−−−−→ Pm infects−−−−→ Vfj become−−−−→ Pfj infect−−−→ Nm,
Vm
initial−−−→ Pm infects−−−−→ Sfj become−−−−→ Hfj infect−−−→ Nm,
Vm
initial−−−→ Pm infects−−−−→ Sfj become−−−−→ Hfj become−−−−→ Pfj infect−−−→ Nm,
Vm
initial−−−→ Pm infects−−−−→ Vfj become−−−−→ Pfj infect−−−→ Nm.
4.4.2 Invasion HSV-2 reproduction number (RVH)
In this section we will present a biological interpretation for the invasion reproduc-
tion number for HSV-2, RVH , invading a susceptible and HIV endemic population. The
equilibrium reached by the population is given by (S0i , H
0
i , 0, 0). The full calculation
of this invasion reproduction number can be found in Appendix C.
The invasion reproduction number for HSV-2 measures, on average, the secondary
HSV-2 cases traced back to one HSV-2 individual introduced into a susceptible and
HIV endemic population, throughout his/her HSV-2 infectious period. Under sec-
ondary infection we understand a new HSV-2 infection of a person of the same pop-
ulation group as the initial introduced HSV-2 case.

















Each term on the right hand side of equation (4.24) represents the infection cycle
from one infected male individual, to one of the female classes (fj, j = 1, 2) and
back to males. In this case the first infected male can be chosen to come from the
susceptible population Sm or from the HIV infected population Hm. Hence the first
infected male introduced into the HIV endemic population can either be HSV-2 only
infected or co-infected. HSV-2 infection paths from male m to female fj back to male
m are shown in Fig. 4.3.
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fj HSV-2 susceptible individuals to be infected Sfj Hfj
? ??






New generation of HSV-2 infected males Nm
Infects with HSV-2 -
Result of HSV-2 infection -
Result of HIV infection -
Figure 4.3. Transmission dynamics of HSV-2 between classes m and fj.
We will rewrite (4.4.2) in a way that facilitates its biological interpretation and
makes it consistent with the biological interpretation of RVH . To facilitate interpreta-




(a), j = 1, 2
the rate at which an HSV-2 only infected male of time-since-infection a infects sus-







tively, the rate at which an HSV-2 only infected male infects an HIV female with
enhanced susceptibility to HSV-2 δHfj and the rate at which a co-infected male with





piVm,fj(a) is the rate at which a co-infected male with time-since-
HSV-2-infection a infects an HIV infected female.
We define analogously the rates of female to male infection in the respective cases
as above by
piVfj ,m(a) := bfjβ
V
fj ,m























































































































m is the weighted HSV-2 susceptible population and
LVi (a) := e
− ∫ a0 µVi (τ)dτ , i = m, f1, f2,
pVm(a) := e











− ∫ a0 FVfj (τ)dτ (with FVfj (τ) = δVfj(τ)bfjβHm,fjH0mN0m
)
,
−p˙Vfj(x) = FVfj (x)pVfj(x). for j = 1, 2.
Here, LVi (a) := e
− ∫ a0 µVi (x)dx is the probability that an individual in the Vi class,
i = m, f1, f2, is still sexually active at time-since-infection a; p
V
i (a) represents the
probability that an individual in the Vi class, i = m, f1, f2, remains in the HSV-2 only
class when time-since-infection equal to a has been reached without acquiring HIV.
The quantity−p˙Vi (x) represents the rate at which a person in the Vi class,i = m, f1, f2,
becomes infected with HIV at time-since-HSV-2-infection x.
Table 4.4 provides the expressions and the biological interpretations of the abbre-
viated terms in (4.25). Each term has the form X Z(Y ) or [Pm(Vm)](a). The latter
is described in the table and X = Vfj ,Pfj ; Z = Vm, Pm,Pm(Vm), Y = Sf1 , Hf1 . The
disease dynamics described by X Z(Y ) follows the path Z infects−−−−→ Y becomes−−−−→ X, where
X represents the number of people in class X.
The biological meaning of the terms in equation (4.25) can be explained in a
similar manner to what was shown for the HIV invasion reproduction number in the
previous section. The first six terms in equation (4.25) are traced back to infections
by an initial HSV-2 only male and the last three to infections by an initial co-infected
male individual. Each term corresponds to the following paths, with each of them
being one of the nine paths shown in Fig. 4.3.
The first six terms in equation (4.25) follow the paths initiated from the susceptble
male class (Sm):
Sm
initial−−−→ Vm infects−−−−→ Sfj become−−−−→ Vfj infect−−−→ Nm,
Sm

































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































initial−−−→ Vm becomes−−−−→ Pm infects−−−−→ Sfj become−−−−→ Vfj infect−−−→ Nm,
Sm
initial−−−→ Vm becomes−−−−→ Pm infects−−−−→ Sfj become−−−−→ Vfj become−−−−→ Pfj infect−−−→ Nm,
Sm
initial−−−→ Vm infects−−−−→ Hfj become−−−−→ Pfj infect−−−→ Nm,
Sm
initial−−−→ Vm becomes−−−−→ Pm infects−−−−→ Hfj become−−−−→ Pfj infect−−−→ Nm.
The last three terms in equation (4.25) follow the paths initiated from the HIV male
group (Hm):
Hm
initial−−−→ Pm infects−−−−→ Sfj become−−−−→ Vfj infect−−−→ Nm,
Hm
initial−−−→ Pm infects−−−−→ Sfj become−−−−→ Vfj become−−−−→ Pfj infect−−−→ Nm, and
Hm
initial−−−→ Pm infects−−−−→ Hfj become−−−−→ Pfj infect−−−→ Nm.
4.5 Numerical simulations
The current section represents our numerical results associated with the given
model - a representation of the total population dynamics using parameter values
taken from literature (consult Appendix E) and sensitivity analysis on the reproduc-
tion numbers. For the total population dynamics we used an ODE model, constructed
by integrating the population classes over the time-since-infection variable and assum-
ing that all our parameters dependent on time-since-infection are constants. To verify
the analytic results, we carried out simulations of the model for the special case when
the age-dependent parameter functions are constant. Because of the complexity of
the full model, numerical simulations of the model with age-dependent parameters
have been omitted in this study. We plan to publish our numerical results for the
more general case in future work.
4.5.1 Total population dynamics - ODE model
We performed a numerical simulation for the simplified ODE model to determine
the prevalence of HIV and HSV-2, as well as the co-infection obtained from our
model parameters (see Table 4.5). We then used these baseline values in conducting
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a sensitivity analysis for the basic and invasion reproduction numbers of the PDE
system. The analysis can be found in Section 4.5.2.
Table 4.5.
ODE Parameter Values.
Parameter Value Unit Parameter Value Unit





























































,j = 1, 2 prob
part














mo = month, yr = year, ind = individual, act = sex act, untls = unitless
part = partnership
Note that we did not assume there is any difference in the transmission proba-
bilities from males to either female group. Therefore, the infection probabilities per
partner satisfy: βVm,f1 = β
V
m,f2
and βHm,f1 = β
H
m,f2
. This assumption is made for both,
the ODE plots and the sensitivity analysis. Four of the parameters in Table 4.5 have
not appeared in the article so far: r, ρH , ρVm, and ρ
V
f . They are auxiliary parameters
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and are only used in the calculations of other parameters, as evident from the same
table. These parameters and their meanings are discussed in Appendix E.
In Figs. 4.4 and 4.5, 35.8% of the male population, 34.3% of the general female
population, and 46.6% of the FSW population will eventually become HIV positive
(including co-infection). Considering that our study does not include treatment or
prevention, the HIV prevalence levels we obtain are consistent with the average HIV
prevalence in the Republic of South Africa, which is a country that only recently
started strongly implementing policies in their goal to limit the spread of the disease
[185]. The HSV-2 prevalence levels (including co-infection) are, respectively, 33.9%,
42.5%, and 55.2%. These are again, consistent with available data [186, 187]. We
observe an overall higher prevalence of HSV-2 than HIV, with co-infection largely in
the FSW population. This high risk female class also contracts both diseases at a
much faster rate than the male or general female populations, as evident from Figs. 4.4
and 4.5. This may be due to the high number of partnerships for this population,


















(a)   Males (m)














(b)   Low − Risk Females (f1)














(c)   High − Risk Females (f2)









Figure 4.4. Prevalence of HIV, HSV-2, and co-infection among the three
population groups, based on the total population dynamics. Vˆ (t) =∫∞
0
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(b)   Low − Risk Females (f1)














(c)   High − Risk Females (f2)
0 100 200 300 400 500
HIV (total) HSV−2 (total)
Figure 4.5. Total HIV and HSV-2 (including co-infection) prevalence
among the three population groups, based on the total population dy-
namics.
The male and general female populations exhibit very similar HIV prevalence,
taking into account the co-infection with HSV-2. The general female population,
however, has a higher HSV-2 prevalence than the male population, which is consis-
tent with observed data [187]. The shape of the HSV-2 curves in Fig. 4.4 is due to
the appearance of a co-infected population with enhanced infectivity for HIV.
Fig. 4.6 gives a numerical verification for the properties of the HIV-invasion re-
production number, RHV . If R
H
0 < 1 and HSV-2 is not present in the population, HIV
cannot persist. However, if HSV-2 is endemic and RHV > 1, an HIV epidemic is appar-
ent, even though RH0 is still less than one. The values used are: R
H





























0 1200 2400 3600 4800 6000100 200 300 400 500
HIV infected cases 
 in the model 
 with HSV−2
HIV infected cases 
 in the model 
 without HSV−2
Figure 4.6. Total number of HIV cases among all population groups when
RH0 < 1. When HSV-2 is not present, HIV cannot persist. When HSV-2
is present and RHV > 1, HIV epidemics occurs. For this figure, R
H
0 =
0.86, RVH = 1.62.
4.5.2 Sensitivity analysis of the PDE system
To explore the sensitivity of the basic and invasion reproduction numbers to the
chosen model parameters, we performed an analysis using a method based on Latin
Hypercube Sampling [155, 156] and calculated partial rank correlation coefficients
(PRCC) [158,188]. To use this method, it is necessary to obtain a range of values for
each parameter (see Table 4.6), as well as determine a probability density function
(pdf) for each parameter. It is important to note that the infection transmission en-
hancement parameters δVi , δ
H
i , and σ
P
i were set at 1, i = m, f1, f2. For the purposes
of this sensitivity analysis we only varied the infectivity enhancement of co-infected
individuals when transmitting HIV, δPi , and made it equal for i = m, f1, f2, hence
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only including δPm in the sensitivity analysis (more information in Appendix E). Fur-
thermore, the HSV-2 infection-age structure of our model allows a great flexibility
in choosing the shape of βVi,k(a), i, k = m, f1, f2, i 6= k to model the interchanging
acute and latent stages of HSV-2. Also, since we derived analytically the infection-




V , it is possible to study the effect
of infection-age dependent parameters on these outcomes. In this study we chose
for simplicity the HSV-2 infectivity probabilities βVi,k(a), i, k = m, f1, f2, i 6= k to be
step functions (Appendix E contains more information on the function itself). βVi,k
in Figs. 4.7 and 4.8 refers to the height of the step function. We plan to extend this
study in future work to include different shapes for βVi,k(a), i, k = m, f1, f2, i 6= k using
the extensive preliminary work presented in this chapter that makes such a study
possible. All other time-since-infection variables were here chosen to be constant.
In the Latin Hypercube Sampling, we chose either a uniform (U) or triangular
(T) pdf with peak at the fixed ODE parameter value (see Tables 4.5 and 4.6). The
Latin Hypercube is then created by sampling equally probable regions exactly once
for each simulation [155,158,188]. A total of 3,000 simulations, and hence 3,000 sets
of parameter values were obtained and consistently produced the results.
Using these sets of parameter values, we calculated PRCC indices by a method
that determines the effect of varying each parameter individually on the reproduction
numbers [155, 158, 188]. The PRCC indices that are obtained have a value between
-1 and 1, with a positive (negative) PRCC value signifying the relationship between
the parameter and reproduction number as a positive (negative) relationship. PRCC
indices may also indicate which parameters have the most influence on the reproduc-
tion numbers, with indices of magnitude closer to 1 having the most influence and
closer to 0 having almost no influence [155,188].
Fig. 4.7 gives the PRCC indices for the basic reproduction numbers, RH0 and R
V
0 .
The corresponding values for the indices can be found in Table 4.7. RH0 seems sig-
nificantly dependent on several factors: the length of the sexual activity period of




Parameter Lower Bound Upper Bound Distribution
c .7 1 U
µm 1/480 1/240 T
µf1 1/480 1/240 T
µf2 1/120 1/36 T
bm 5 · µm 12 · µm T
bf2 5 · bf1 10 · bf1 U
Nm .5 · 105 1.5 · 105 T
ρH .001 .002 T
r 1 3 U
ρVf .03 .12 T
ρVm .07 .24 T
δPm 1.0 1.3 T
T indicates a triangular distribution, with peak at the fixed value from Table 4.5.
U indicates a uniform distribution.
males’ sexual partnerships per month (bm), and the transmission probability between
a male and a general population female, βHm,f1 , and to a lesser extent between a male
and a FSW, βHf2,m. The length of sexual activity reflects that once an individual has
a disease, the longer they are sexually active, the more individuals they will infect.
It is interesting to note that the majority of the influential parameters for the HIV
basic reproduction number are all related to the male population, with the probabil-
ity of men infecting women with HIV being more important than the probabilities
of women infecting men. c1, the preference of men for women from the general pop-
ulation, seems to be another important factor in the value of RH0 , which may be












c 0.22301403 0.10190679 0.2602452853 0.098150824
bm 0.28370741 0.10612063 0.2680427498 0.085017149
bf1 0.10567752 0.02932268 0.0995221633 0.004226425
bf2 0.08588136 0.12217032 0.0889434116 0.121739335
µm -0.72321671 -0.32687223 -0.7110994875 -0.316704407
µf1 -0.80320335 -0.39569917 -0.8073834092 -0.401428781
µf2 -0.01708556 -0.04316572 -0.0248582479 -0.036844353
βHm,f1 0.31556204 NA 0.2625038294 0.012115165
βHf1,m 0.09022262 NA 0.1110768711 -0.017815740
βHf2,m 0.16093696 NA 0.1513616342 -0.012076605
βVm,f1 NA 0.66185297 0.2436370753 0.660516281
βVf1,m NA 0.13333530 -0.0000301969 0.135995528
βVf2,m NA 0.11782067 0.0719251663 0.117135153
δPm NA NA 0.3808355572 0.004695554
sexual active time for m and f1, whose importance was discussed above, R
V
0 seems to
have only one significant factor: βVm,f1 , the probability of men infecting women with
HSV-2, during their acute disease stage. This is not surprising, considering men are
almost twice as infectious.
As evident from Fig. 4.8, the same parameters are most influential for the invasion
reproduction numbers with one notable addition: δPm, the enhancement co-infected
individuals get when transmitting HIV, has a strong effect on RHV . This signifies the
importance of HSV-2, and specifically the effect of co-infection, on the HIV endemic.

















































(b)   R0V
Figure 4.7. Effect of model parameters on the basic reproduction numbers,
based on PRCC.
bilities, βV s, influence RHV but, on the contrary, the transmission of HIV probabilities,
βHs, do not have a significant effect on RVH . Also the transmission from FSW to a
male, βVf2,m has a greater impact on R
H
V than the transmission probability from gen-
eral population female to male, βf1,m. The implications of these results are discussed























































(b)   RHV
Figure 4.8. Effect of model parameters on the invasion reproduction num-
bers, based on PRCC.
4.6 Discussion
We present a model of the co-infection between HIV and HSV-2, prompted by the
reported influence HSV-2 has on the HIV epidemic, and without considering methods
of prevention or treatment. The model has several goals. One is to evaluate the effect
of the co-infection of HIV and HSV-2 on HIV prevalence. The second is to explore the
role of female sex workers on the HIV epidemic. The third goal is the introduction
of a infection-age temporal variable that allows for more flexibility in modeling the
interchanging acute and latent stages of HSV-2 and more flexibility when considering
treatment and control of the disease. We calculate the basic and invasion reproduction
numbers and perform sensitivity analysis (Figs. 4.7 and 4.8). We also plot the total
population dynamics based on a simplified version of our model, reducing our original
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system of partial differential equations to a system of ordinary differential equations
by integrating over the infection-age variable a (Fig. 4.4).
Consider the reproduction numbers’ sensitivity analysis in Figs. 4.7 and 4.8. The
following observations and implications are based on the given parameter values and
ranges. It is possible that different outcomes may result for different parameter ranges
and hence that different strategies would be more effective under other conditions. We
observe the very important role that co-infection plays on disease dynamics. This can
be seen by the effect of the enhancement δP on the HIV invasion reproduction number,
indicating that the increased infectivity of co-infected individuals when transmitting
HIV has a strong influence on RHV (see Fig. 4.8). Thus, introducing a control measure
on the HSV-2 populations, which would also affect the co-infected individuals, may
be beneficial for reducing HIV prevalence. To support this hypothesis, we see that
the transmission of HSV-2 probability βV has a positive impact on RHV , while the
transmission of HIV probability βH has almost no influence on RVH . This suggests
that treating individuals with HSV-2 could be effective in lowering HIV prevalence.




are more influential than those of the other two groups, suggests that treatment and
control should be focused on the male population. This would prompt us to investi-
gate the effect of condoms, circumcision, and viral treatment for HSV-2, among other
strategies.
The parameters that inversely influence the reproduction numbers are the mor-
tality rates, µ. Therefore, the length of the period of sexual activity seems to have a
strong positive correlation with the spread of either disease. This parameter is only
important for the general populations, m and f1, while the high turnover of FSWs
seems to have no influence. Hence, education and early detection for STDs in the
general population may be useful strategies for reducing the spread of both HIV and
HSV-2.
The effect of female sex workers on the reproduction numbers is smaller than
expected or often believed. There may be several reasons for this: high turnover
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(reflected in high µf2), the tendency for men to choose women from the general popu-
lation as sexual partners (reflected in high c1 to c2 ratio), the low infectious probability
per partnership (because of the relatively infrequent encounters with the same part-
ner), and the fact that the model does not consider what happens to these women
after they leave the class. Improvements upon the model to consider the effect of
these aspects will be explored in future work. However, this does not suggest that
looking at FSWs as a separate population is not useful. Based on the sensitivity
analysis, there are different modes through which the two female groups influence the
reproduction numbers. The HSV-2 transmission probability from FSW to male per
partnership, βVf2,m, is more influential on R
H
V than the transmission probability from
general population female to male, βVf1,m. This suggests that strategies for reducing
HSV-2 in the FSWs may be an effective control measure against the spread of HIV.
On the other hand, since the general population female exit rate, µf1 , has so much
more influence than the FSW exit rate, µf2 , early detection would be a more appro-
priate tactic when considering non-sex workers. These different strategies are to be
explored.
There are several shortcomings of the model that would have to be discussed.
The exclusion of homosexual encounters may be a factor in its validity. Further, the
model does not include other modes of transmitting HIV, more importantly vertical
transmission and drug use. Also, we do not track the fate of women who leave the
FSW group. These remain topics for future work.
Our model can be used to further include several more realistic characteristics
concerning the two diseases. First, in this work the transmission probabilities for
HSV-2 are only modeled using a step function. In future work several functions that
can model transition between latent and acute stages will be explored. Such a study
is only possible base on the difficult and extensive analytic work presented in this
chapter. These functions would include more aspects of the disease progression: dif-
ferent acute and latent periods, different levels of infectivity, depending on the time
since infection, and the effect of symptomatic versus asymptomatic breakouts on an
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individual’s infectiousness and prevention strategy. Second, the sensitivity analysis
results can be used to study how implementing different control strategies, perturb-
ing in our model the parameters affected by the control measure, may affect the
disease prevalence. And third, including time-since-infection dependent enhancement
parameters, may give insight into the importance of infectivity and/or susceptibility
enhancement as a topic of future biological research, since as of now the direct influ-
ence of these enhancements is uncertain.
However, the model does well in estimating trends in disease progression assuming
lack of treatment. Furthermore, it gives an expression and a biological interpretation
for the infection-age dependent invasion reproduction numbers, adding an interesting
aspect - the importance of the class from which the initial patient arises as well as
a clear interpretation involving infection-age. Therefore, where the disease originates
within the population, which group of people is more susceptible to this disease and
infection-age dependency of parameters have an important role in reproduction num-
ber calculations. Hence, our work has set an important framework that allows to
study the dynamics of the two diseases under different layers of information in order
to successfully implement control measures.
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5. SUMMARY
In this thesis we presented three modeling studies on structured deterministic models
for the dynamics of infectious diseases, particularly malaria, a vector-borne disease,
and STDs including HIV and HSV-2. These are compartmental models, which divide
the total population into multiple epidemiological classes. The types of components
included in the models are determined by the biological questions the models are
intended to study that are of interests to epidemiologists and public health decision
makers. The questions considered in this thesis can be better studied by using models
structured by a continuous age including chronological-age, infection-age, or vaccine-
age. The incorporation of such an age-structure leads to a system of partial differential
equations or differential-integral equations. For each of the models considered, we
performed both, analytical and numerical analyses. We computed the basic and
control reproduction numbers for a specific disease as well as the invasion reproduction
numbers when the joint dynamics of two diseases were considered. These reproduction
numbers are shown to determine the long-term disease outcome via the existence and
stability of equilibria given by the corresponding models. Numerical simulations were
used to confirm or extend the analytical results, and to examine how disease outcomes
may change with varying model parameters, some of which represent control measures
such as drug-treatment and vaccination.
In Chapter 2 we presented and analyzed a malaria model structured by chronological-
age of humans. The model is used to study the population dynamics for endemic
malaria. We divided the infected human population into symptomatic infectious,
asymptomatic infectious and asymptomatic chronic infected individuals, of which only
people in the “infectious” compartments can transmit the parasites to mosquitoes.
The model also includes the mosquito population, which is divided into suscepti-
bles and infectious classes. The equations for the human hosts are PDEs and are
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ODEs for mosquitoes. The formulation of the model was motivated by biological
assumptions on age-dependent human immune response, which requires the inclusion
of multiple types of age-dependent immunity in humans, each represented by a spe-
cific age-dependent parameter. The model also takes into consideration hypotheses
regarding the parasite adaptation to mosquito presence responsible to trigger human
infectiousness. Hence, individuals in the asymptomatic chronic infected class can
become infectious by relapsing due to a process triggered by bites from susceptible
mosquitoes. For the analysis of the existence and stability of the disease free equi-
librium, we considered the human population to be at a stable age distribution in
the absence of disease. Using a characteristic equation for eigenvalues of the linear
operator we obtained an expression for the basic reproduction number R0. We illus-
trate that R0 depends on parameters representing several key biological factors that
have not been modeled previously. We showed that the basic reproduction number
determines the local stability of the disease free equilibrium.
Additional analyses of the PDE system were carried out by applying the approach
of reducing it to an ODE system consisting of n ≥ 1 age groups with the transition
term from one age group to the next due to aging. This can be done when the age-
dependent parameters are approximated by constants, which actually makes it easier
to connect the model parameters to available disease data. We derived R0 for the
ODE system using the next generation matrix approach. The biological interpretation
of R0 was challenging because of the relapse of chronic infected individuals and the
chronological-age structure. Nevertheless, we managed to provide a detail biological
interpretation of the components in the expression of R0.
We conducted numerical simulations for n = 2 age groups (children and adults),
but our model and its analytic study provides the framework that allows to analyze
the effect of any number of age-groups. A sensitivity analysis was conducted to inves-
tigate how the model outcomes may depend on the uncertainty of model parameters.
Our model was capable of generating important insight into the observed patterns
of malaria dynamics. First, it showed that asymptomatic individuals contribute 2-3
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times more than symptomatic individuals and produced a general decrease in preva-
lence with age. It showed that at least 60% of the population is asymptomatic chronic
infected, with twice as many adults than children, and hence that, by relapsing, this
portion of the population may be an important contribution to the infectious pool for
mosquitoes. We observed from numerical simulations a slight increase in symptomatic
adult prevalence when lowering R0. This is due to the age-dependent parameters de-
scribing immunity that our model considers and may have to be accounted for when
implementing control measures. Second, our model suggested, as expected, that con-
trol measures that aim to reduce the biting rate of mosquitoes can have the most
effective impact on the reduction of R0 and prevalence. Third, when implementing a
pre-erythrocytic vaccine our model suggests that children should be targeted to lower
R0 as well as the overall prevalence most effectively. On the contrary, adults should
be targeted in the case of introducing a transmission-blocking vaccine, which would
reduce R0 and symptomatic prevalence. We can also conclude that diagnosis and
treatment should be especially thorough for children in order to reduce symptomatic
malaria prevalence efficiently.
We presented in Chapter 3 another model for malaria to study the effects of
vaccination on malaria prevalence and control. These malaria vaccines provide an
imminent important addition to existing control measures. The human population is
divided into four groups of individuals: susceptible, infectious, vaccinated with initial
dose, and vaccinated with the booster dose. Vaccinated individuals in both vacci-
nated compartments are structured by vaccine-age (time that elapsed after the initial
dose) and the model includes partial differential equations. The vaccine-age depen-
dent transition from the first vaccinated class (initial dose) to the second vaccinated
class (booster dose) makes it possible to model a minimum vaccine-age required for
receiving the booster vaccination. The analysis of the model is based on an equiva-
lent system of integro-differential equations obtained by solving the PDE equations
along the characteristic line. By studying the stability of the disease-free equilibrium
of the linearized system, we derived the control reproduction number R. We also
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proved the global stability of the disease free equilibrium when R < 1 for the case
of no disease-induced death and complete protection from vaccination. This stability
result was extended numerically to the case when disease-induced death is included.
It is also shown that there is exactly one endemic equilibrium when R > 1. An
interesting results is that the model may have a backward bifurcation, i.e., a stable
endemic equilibrium may exist even when R < 1. Although we were unable to prove
analytically the existence of a lower bound Rb < R for the threshold condition with
respect to the existence of a positive equilibrium, we managed to prove a sufficient
condition for the non-existence of an endemic equilibrium when R < 1, and a lower
bound was demonstrated numerically.
The new findings from our model studies include the following. First, by in-
corporating two vaccinated classes our model can provide the threshold vaccination
coverage needed for a vaccine that increases the efficacy after each dose, starting with
a low efficacy. In models with only one vaccinated class, such a threshold may exists
only if the efficacy is high. Second, recall that to consider a minimum vaccine-age
τ0 means the following: individuals that received the initial dose(s) are eligible to
receive the booster dose only if their vaccine-age is at least the minimum vaccine-
age τ0. Hence, when the model considered a minimum vaccine-age persistence of the
disease was predicted in cases which, with no minimum vaccine-age (τ0 = 0), would
have predicted eradication. It also predicted that a booster dose campaign would not
give an added benefit in cases of high minimum vaccine-age, and hence all the efforts
(financial and administrative) should be put on initial dose(s) vaccination campaigns.
When this is the case, the disease prevalence approaches a level that would have been
persistent if the booster dose’s efficacy would have been equal to the initial dose(s)
efficacy, i.e. if the booster dose would not give additional protection. We observed
that to achieve extinction when a minimum vaccine-age is required to be included,
a booster dose with a high efficacy and/or high initial dose(s) coverage is needed for
disease eradication. Third, we demonstrated that an eradication threshold based on
R alone might be biased in some cases, especially when the proportion of reduction
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in R by a vaccination strategy is not a direct indicator of the corresponding reduction
in prevalence. Similarly, the minimum vaccine-age required to start a booster cam-
paign alone plays an important role in decision making. In addition, the value R = 1
may no longer provide a threshold condition for disease extinction since backward
bifrucations are possible. Fifth, the model results demonstrated the importance of
accurate knowledge of the vaccine efficacy and its influence in the success of a malaria
vaccination campaign.
Finally, in Chapter 4 we presented a model for the joint dynamics of HIV and
HSV-2, which is used to study the effect that the presence of HSV-2 may have on
the prevalence of HIV. Based on the epidemiological characteristic of HSV-2 that
an infected individual may change between two disease stages, acute and latent, an
infection-age temporal variable was used to incorporate this feature. We considered
only heterosexual relationships in a population distinguished by males, general pop-
ulation females and female sex workers. Individuals in each group were divided into
susceptibles, HIV infected, HSV-2 infected and co-infected individuals with HIV and
HSV-2. The system consists of integro-differential equations and partial differential
equations (for the HSV-2 infected classes) that are coupled via the force of trans-
mission terms. Using similar techniques as in Chapter 3, in addition to the basic
reproduction number for each disease, the invasion reproduction numbers were also
derived. These help obtain conditions under which one disease (e.g. HIV) can invade
a population in which the other disease (e.g. HSV-2) is at an endemic equilibrium.
The infection-age dependency of parameters and the many possibilities of interaction
between classes added great complexity to the model. Hence, it is very challenging
both, the derivation of the expressions for their invasion reproduction numbers as
well as to provide their biological interpretations. This is one of the novel aspects
this study provided. We gave a biological interpretation of the invasion reproduction
numbers that required a detailed understanding of the origin of the “initial infected”,
difficulty that arises specifically when co-infection and the fact that one disease is at
an endemic state is considered.
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Numerical simulations were performed for a reduced ODE system, which helped
confirm the analytical results. A sensitivity analysis was also conducted to examine
the role of model parameters in influencing the model outcomes. We discussed several
results: First, we observed that co-infection is a key aspect to be considered. In fact,
reducing co-infection and hence reducing the number of HIV infected individuals with
enhanced HIV infectivity due to co-infection with HSV-2, may lower HIV prevalence.
In general we could concluded that, HSV-2 treatment may be much more effective
in lowering HIV prevalence than HIV control measures targeting infectivity may be
in lowering HSV-2 prevalence. We also observed that infections from male to female
for both diseases are more influential than vice versa. Second, our simulation results
suggested that strategies for reducing HSV-2 in female sex workers may help reducing
the HIV prevalence in an HSV-2 endemic population. Third, as pointed out previ-
ously, the inclusion of infection-age dependent parameters added a great difficulty in
deriving and understanding the expressions for the invasive reproduction numbers.
In our work these expressions are presented in great detail and can be used,to the
extend of their complexity, once biological clarity has been achieved in understand-
ing the shape of HSV-2 infection-age dependent parameters, such as probabilities of
HSV-2 transmission, enhanced infectivity when transmitting HIV and/or HSV-2, and
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A. R0 DERIVATION FOR ONE AND TWO AGE GROUPS
In this appendix, we include the details for the derivation of the reproduction number
R0 for the cases of one and two age groups.
A.1 The case of n = 1 age group
Noticing that α1 = 0 the matrices F and V reduce to:
F=

0 0 0 kβ d1
N¯h
N¯1
0 0 0 (1− k)β d1
N¯h
N¯1








 , V =

γ¯1 0 0 0
0 γ¯A1 −pβdA1 N¯vN¯h 0
0 −γA1 pβdA1 N¯vN¯h + µ1 0
0 0 0 µv

(A.1)
from which we get
V −1 =









































0 0 0 kβd1
N¯h
N¯1Tv
0 0 0 (1−k)βd1
N¯h
N¯1Tv






























which is the same as the FV −1 matrix in (2.71).
For the explanation of P
IA1
IA1
we let q1 = γA1/(γA1 + µ1) = γA1/γ¯A1 denote the
probability that a person in IA1 moves to JA1 , let q2 = ρ1/(ρ1 + µ1) denote the
probability that a person in JA1 moves back to IA1 , where ρ1 = pβdA1N¯v/N¯h, and
let q3 = µ1/γ¯A1 denote the probability that once in IA a person does not return to
JA. Then, the probability that a person who starts in IA1 and returns to IA1 after
visiting JA1 exactly one time is q1q2q3, exactly twice is (q1q2)
2q3, and exactly k times
is (q1q2)
kq3, k = 1, 2, · · · . Then, the probability that a person is in IA1 , given that






















A.2 The case of n = 2 age groups
In this case α2 = 0, and the F and V matrices are given by:
F =

0 0 0 0 kβ d1
N¯h
N¯1
0 0 0 0 ~hA1
0 0 0 0 kβ d2
N¯h
N¯2











γ¯1 0 0 0 0
0 AA1 0 0 0
−α1 0 γ¯2 0 0
0 −C1 0 AA2 0







 , ~hA2 =




















 γ¯A1 −pβdA1 N¯vN¯h
−γA1 pβdA1 N¯vN¯h + µ1 + α1
 , AA2 =
 γ¯A2 −pβdA2 N¯vN¯h









T1 0 0 0 0
0 A−1A1 0 0 0
θ1
γ2





























































Thus, FV −1 =




0 0 0 0 (1− k)hA1Tv





























which is the same as (2.74). It follows that





















vA1 · A−1A1 + vA2 · A−1A2 C1A−1A1
)
hA1Tv + vA2 · A−1A2 hA2Tv.
(A.14)
This leads to the formula for R0 =
√−E2(FV −1) given in (2.75).
The following shows the explanation of the expressions in (2.76), (2.77) and (2.78).
For the explanation of P
IAk
IAk
in (2.76) (k = 1, 2), we let q1k = γAk/γ¯Ak denote
the probability that a person in IAk moves to JAk and q2k = ρk/(ρk + µk + αk) the
probability that a person in JAk moves back to IAk . Let q3k = (µk +αk)/(γ¯Ak) denote
the probability that once in IAk a person does not return to JAk . Then, the derivation
of the expression in (2.76) for P
IAk
IAk
is equivalent as explained in the case for n = 1
age groups.
For the explanation of P
JA1
IA1
in (2.77), we let q1 = γA1/γ¯A1 denote the probability
that a person in IA1 moves to JA1 and q2 = ρ1/(ρ1 + µ1 + α1) the probability that
a person in JA1 moves back to IA1 . Let p3 = (µ1 + α1)/(ρ1 + µ1 + α1) denote the
probability that once in JA1 a person does not return to IA1 . Then the probability
that a person is in JA1 , given that the person entered the IA1  JA1 loop through

















ρ1 + µ1 + α1
γA1
γ¯A1
γ¯A1(ρ1 + µ1 + α1)





For the explanation of P
IA2
JA2
in (2.78), we let q1 = γA2/γ¯A2 denote now the proba-
bility that a person in IA2 moves to JA2 and q2 = ρ2/(ρ2 + µ2) the probability that a
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person in JA2 moves back to IA2 . Let p3 = µ2/(γA2 + µ2) denote the probability that
once in IA2 a person does not return to JA2 . Then the probability that a person is in



























B. INVASION HIV REPRODUCTION NUMBER (RHV )
In this section the invasion reproduction number for HIV, RHV from Section 4.4.1, will
be calculated. We assume the HIV disease invades an endemic HSV-2 population.
We will analyze system (4.1), where the variables Hi, Pi will be assumed to be disease
variables and Si, Vi non-disease variables. We then linearize system (4.1) around the
HIV disease free and HSV-2 endemic equilibrium (S0i , 0, V
0
i (a), 0), look for eigenvalues
for the linear operator and derive a characteristic equation,in order to define RHV .































(a)Pfj(t, a)da, j = 1, 2.
(B.3)















































, j = 1, 2.
(B.5)
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We will use (B.1) and (B.2) extensively in our calculations. Since we will linearize












m(a)da, for j = 1, 2.
When linearizing system (4.1) around the HIV DFE (S0i , 0, V
0
i (a), 0) and consid-
ering only the equations for the disease variables Hi and Pi, we obtain the following
linear system equivalent to the linear system of equations with the disease variables






























































[Hfj(x+ t− a) + γfk(x+ t− a)]dx

















[Hm(x+ t− a) + γm(x+ t− a)]dx,
j = 1, 2.
In the next step we look for eigenvalues for the linear operator, i.e. for solutions of
the form Hi(t) = H¯ie
ωt, λi(t) = λ¯ie






















(H¯m + γ¯m)− δHfjbmcj
φ0m,fj
N0fj







K2,fj ,m(ω)(H¯fj + γ¯fj),








































































































































+ µHfj . (B.9)










































K1,fj ,m) =: G
H
V (w). (B.10)
We can then define the invasion HIV reproduction number as RHV :=
√
GHV (0). This

























































































































are the rates at which male m and female fj, j = 1, 2 individuals exit the Hm and Hfj
classes respectively, either because of acquiring HSV-2 or because of ceasing sexual
activity. A detailed biological interpretation can be found in Section 4.4.1.
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C. INVASION HSV-2 REPRODUCTION NUMBER (RVH)
In this section we will show the derivation of the HSV-2 invasion reproduction number
RVH from Section 4.4.2. We will proceed in a similar way as we did in order to find the
HIV invasion reproduction number (see Appendix B). In this case we will consider
that in system (4.1), the HSV-2 variables Vi, Pi are disease variables and Si, Hi are
non-disease variables. We will then linearize system (4.1) around the HSV-2 disease




i , 0, 0), and then derive a characteristic
equation in order to define RVH .







































































(− p˙Vfj(x))LPfj(a)LPfj(x)dx e−ωada, (C.4)
where
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LVi (a) := e
− ∫ a0 µVi (τ)dτ , i = m, f1, f2,
pVm(a) := e











− ∫ a0 FVfj (τ)dτ (with FVfj (τ) := δVfj(τ)bfjβHm,fjH0mN0m
)
,
−p˙Vfj(x) = FVfj (x)pVfj(x), j = 1, 2.
In the following, consider λVi (t), i = m, f1, f2, ηm,fj(t), ηfj ,m(t), j = 1, 2, as defined in
(B.3).
After linearizing system (4.1) around the HSV-2 DFE (S0i , H
0
i , 0, 0), i = m, f1, f2,
reducing the system to only consider the HSV-2 disease variables, Vi and Pi, and
substituting into the linear system solutions of the form
λVi (t) = λ¯
V
i e
ωt, ηm,fj(t) = η¯m,fje
ωt, ηfj ,m(t) = η¯fj ,me
ωt
in order to find the eigenvalues of the linear operator, the linearized system can be





















η¯fj ,m = Fˆfj ,m(ω)λ¯
V
fj
, j = 1, 2.
(C.5)
Let us define




Eˆm,fj(ω) := Dˆm,fj(ω) +
bmcj
N0fj
Fˆm,fj(ω), j = 1, 2.











m, j = 1, 2,
(C.6)






 = 0. (C.7)
Computing the determinant, (C.7) is equivalent to the following equation
GVH(ω) := Eˆf1,m(ω)Eˆm,f1(ω) + Eˆf2,m(ω)Eˆm,f2(ω) = 1. (C.8)
We then can define the HSV-2 invasion reproduction number as RVH :=
√
GVH(0). For
a biological interpretation refer to Section 4.4.2.
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D. BIOLOGICAL INTERPRETATION OF THE TERMS
OF RHV
This appendix describes biologically the remaining terms in equation (4.22) of Section
4.4.1. The first term was explained in Section 4.4.1.











where [Pm(Hm)](a) represents the number of co-infected males of time-since-HSV-2-
infection a, that were HIV only males before (see Table 4.3 in Section 4.4.1). This
case represents the path
Sm
initial−−−→ Hm becomes−−−−→ Pm infects−−−−→ Sfj become−−−−→ Hfj infect−−−→ Nm
in Fig. 4.2 in Section 4.4.1. Here the initial HIV infected male becomes co-infected
and is still sexually active at time-since-co-infection a, ([Pm(Hm)](a)). Then, at time-




as Hfj , j = 1, 2 females infect males at a rate pi
H
fj ,m
, throughout their permanence in
the HIV class THfj . We integrate to consider all individuals in Pm, of all times-since-
HSV-2-infection, that infected susceptible females.











where HHmfj (S0fj) is as in the first term. The path
Sm
initial−−−→ Hm infects−−−−→ Sfj become−−−−→ Hfj become−−−−→ Pfj infect−−−→ Nm
in Fig. 4.2 represents this scenario. This case is explained in the following way: the
initial HIV-positive male is in Hm, infects susceptible females, who as Hfj females,
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with probability qVmHfj ,Pfj
, get infected with HSV-2 and are still sexually active at
time-since-co-infection a with probability LPfj(a). These co-infected females then in-
fect males at time-since-infection a, at a rate δPfj(a)pi
H
fj ,m
. Finally, by integrating we
consider infections due to co-infected females with all possible times-since-HSV-2-
infection.











where (HPm(Hm)fj (S0fj))(a) is the number of HIV females, who initially were in the
susceptible class, got infected with HIV by a co-infected male who was initially an
Hm male (see Table 4.3). The path corresponding to this term is
Sm
initial−−−→ Hm becomes−−−−→ Pm infects−−−−→ Sfj become−−−−→ Hfj become−−−−→ Pfj infect−−−→ Nm
in Fig. 4.2. The interpretation is as in the previous case, only that the initial HIV
male individual becomes co-infected before infecting susceptible females.
The fifth term is ∫ ∞
0




where [PHmfj (V 0fj)](a) represents the number of co-infected females (with time-since-
infection a) who got infected with HIV while being in the HSV-2 only class, by the
initial HIV male (who is in Hm) (see Table 4.3). This case follows the path
Sm
initial−−−→ Hm infects−−−−→ Vfj become−−−−→ Pfj infect−−−→ Nm.
The situation is as follows, the first HIV male case infects V 0fj(x) females during his
sexual lifetime, who as Pfj females remain sexually active at time-since-infection a(
[PHmfj (V 0fj)](a)
)




. We integrate to consider infection by females with co-infection of all
possible times-since-infection.








where [PPm(Hm)fj (V 0fj)](a) is similar to [PHmfj (V 0fj)](a), with the only difference being
that the females got the infection from the initial HIV male after he was co-infected
with HSV-2 (see Table 4.3). This case follows the path
Sm
initial−−−→ Hm becomes−−−−→ Pm infects−−−−→ Vfj become−−−−→ Pfj infect−−−→ Nm.
The interpretation is as in term five, only that, as stated above, the initial HIV male
individual becomes co-infected before infecting HSV-2 only females with HIV.
The last three terms correspond to the case when the initial HIV case is a male who
was already infected with HSV-2.





where HPmfj (S0fj) corresponds to the number of HIV females that acquired HIV, while
susceptible, by the initial co-infected HIV male (see Table 4.3). These females then




Observe that this term follows the path
Vm
initial−−−→ Pm infects−−−−→ Sfj become−−−−→ Hfj infect−−−→ Nm.











where HPmfj (S0fj) is as in the previous case. This case describes the path
Vm
initial−−−→ Pm infects−−−−→ Sfj become−−−−→ Hfj become−−−−→ Pfj infect−−−→ Nm
in Fig. 4.2. The interpretation is similar to the previous case, only that the females in-
fected by the initial male, before infecting males, become co-infected with probability
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qVmHfj ,Pfj
, and then infect males when their time-since-HSV-2-infection is a. We inte-
grate to account for male infections from all times-since-infection of those co-infected
females.
The last term reads
∫ ∞
0




where [PPmfj (V 0fj)](a) is as in the previous case, with the only difference being that
now V 0fj females are being infected by Pm males, instead of susceptible females. The
path followed by this term is the following,
Vm
initial−−−→ Pm infects−−−−→ Vfj become−−−−→ Pfj infect−−−→ Nm.
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E. CHOOSING PARAMETERS
This section justifies our choices for mean values of the parameters. For a full list of
parameters and their explanations, consult Table 4.2 in Section 4.2. In what follows,
i = m, f1, f2.
E.1 µi
Recall that the analysis required a constant population size for each population
group (m, f1, f2). Therefore, we considered the same exiting parameter µi for each
class (S,H, V, P ). This is not simply the mortality rate, it is the rate at which individ-
uals cease sexual activity. We assume that the average sexual lifespan for individuals
from the general population is 30 years. For high-risk women, class f2, we assumed 4
years. It is hard to determine how long FSWs work on average - migration to different
place of work, periods of working in and out of the sex industry, and disparity within
the type of partners (client, relationship, etc.) make such a calculation unreliable.
Furthermore, in our model we do not consider movement between groups. Still, the
length of working in the sexual industry can be approximated to be around 4 years,
considering the high turn over [189]. Therefore, our mean value for µm and µf1 is
1/360 and for µf2 is 1/48 per month.
E.2 bi, Ni
Several of these parameters were found in the literature, while others were calcu-
lated using the balance equations (4.2).
Studies on African men agree that the average number of lifetime sexual partner-
ships for men are 8-10 [190], therefore, we chose 9 as our mean. Then, bm is 9/360
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partnerships per month.
The number of lifetime sexual partnerships for the general female population is not
that concrete: [190] estimates this number to be around 2 for South Africa, while [191]
estimates them at 6.8. The reasons for the vast disparities between female numbers
in different areas and especially between male and female numbers that are often
discussed are: overreporting in males, underreporting in females, low reliability of
recollection, matters of how the questions on the survey are worded, and sampling
bias that leaves sex workers out of the surveys [190–193]. The average number of
sexual partners for FSWs also varies: [189] estimates it at 22 per week, [193] gives a
range of 13-22 per week, depending on how they are reported, and according to [194],
it varies between 60 and 160 partners per year.
Given the great disparity between the data, we calculated bf1 and bf2 from bm and
our assumptions for the ratio between bf2 and bf1 and the preference men give to f1
women when choosing a sexual partner, c1. bf2/bf1 was estimated at 10. The ratio
may seem small considering the numbers above, however beyond the unreliability
of the data discussed above, another cultural issue would have to be considered. In
South Africa for example, it is common for individuals to enter casual relationships in
exchange for money or gifts [195–198]. We believe women with that behavior would
have to be considered in the f2 category. If they are, this would add another level of
uncertainty about the parameters. Hence our estimation is conservative.
The proportion of partners of males who are f1, c1, was chosen to be 0.9. Adding
to the discussion about difficulty in estimating parameters, [199] gives an overview
of global studies that calculate the percentage of men who paid for sexual services.
The figures differ greatly, depending on how the surveys were conducted. However, if
“paying” for sex is considered exchanging money, gifts, or favors in return for sexual
favors, then around 10% of men have engaged in such activity. Hence our assumption.
c2 = 1− c1. Nm is chosen at 107. We further assumed that
Nm = Nf1 +Nf2 . Therefore, given bm, c1, Nm, and bf2/bf1 , we calculate bf1 , bf2 , c2, Nf1 ,
and Nf2 using the balance equation 4.2.
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E.3 βH
Note that the units of our values are probability of transmission per partnership.
Therefore, if an individual has a lot of partnerships, the average transmission is low
for each partnership. If a person has only a few partnerships, the average probability
of transmission is high because a lot of time is spent per partnership. We assume that
there is no difference between male and female transmissions per act. No significant
difference has been found in lower income countries, while the usual assumption that
men as inserters are more infectious has been shown for higher income countries [200].
The average infectivity is reported per coital act. In Africa the average probability per
act varies greatly, depending on region, way of approximation, viral load, circumcision
of males, and HIV stage [200–205]. The mean values of probabilities of transmission
per act range between 0.0007 and 0.0082 [201]. HIV-positive individuals spend most
of their time in the latent stage, so we assumed a more conservative 0.0017 per coital
act. Therefore, in Table 4.5, ρH is the probability of HIV transmission per act and is
set at 0.0017. Average acts per month vary [206]. However, we believe that 2.5 acts
per month is within the average per lifetime [207]. For sex workers, we assumed the
number of acts per partnership per year to be 2 because of the relatively high turnover
of clients. Therefore, in Table 4.5, r is the number of sexual acts per partnership per
year for FSWs and is estimated at 2. βHm,f1 , β
H
m,f2






We decided to use a simple step function describing βVi,k, k = m, f1, f2,
k 6= i for this paper. The step functions alternates periods of infectivity (nonzero
value) and latency (zero). Different studies find different rates of transmission. [208]
gives a great disparity between ethnicities for transmission rates. The average is
6.8% per year of male-to-female transmission risk (5.8 for white women, 11.2 for
black women) and 4.4% per year risk for female-to-male contacts (2.6 for white, 8.1
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for black males). The participants were instructed in safe sexual practices but the role
of different sexual behaviors is not mentioned in the results. In [209] male-to-female
probability of transmission is 16.9% (9.1% to 31%, depending on whether women had
HSV-1 antibodies) and female-to-male is 3.8% per 11 months. 9 of the infections were
asymptomatic, 4 were in early symptoms, which leads us to suspect that either the
participants were instructed not to have sex during outbreaks or were aware of the
risks before entering the survey. Based on these data, we assumed 8% male-to-female
risk per year and 4% female-to-male. Therefore, in Table 4.5, ρVm is the probability
of transmission of HSV-2 by a male individual per year, and is set at 0.08. ρVf is the
probability of transmission of HSV-2 by a female individual, and is set at 0.04.
For the reproduction numbers sensitivity analysis, using some available data about
the periods of latency, we constructed a step function for βVm,f1(a) by alternating
periods of infectiousness of length two weeks with periods of latency (no infectivity)
of 2.5 months [100, 100, 210, 211]. The value of the step function at the non-zero
intervals was constructed, so the average of βVm,f1(a) matched the 8% male-to-female
infectious probability per year, converting it to probability per partnership. The other
βV s were calculated similarly. The parameter βVi,k, i, k = m, f1, f2, i 6= k used in the
sensitivity analysis, figures 4.7 and 4.8 refers to the height of the step function.
E.5 δV and δP
In [107], the authors claim that the increased susceptibility of an individual with
HSV-2 to HIV is 2-4 times higher than that of a healthy person. According to [114],
the risk of acquisition of HIV if one already has HSV-2 is increased 3-fold. In [204],
it was found that the probability per act of someone with both HSV-2 and HIV
to transmit HIV increases 4-fold in comparison with an individual who only has
HIV. However, our parameters are in probabilities per partnership. Therefore, an
enhancement of 2 to 4 would make our probabilities greater than 1, which is not
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realistic. Therefore, we were conservative in our assumption that δP = 1.1 and
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